1
|
Matsui H, Ohta T, Nakamura T, Uruga T, Tada M. In situ 3D X-ray imaging of water distribution in each layer of a membrane electrode assembly of a polymer electrolyte fuel cell. Phys Chem Chem Phys 2024. [PMID: 38592673 DOI: 10.1039/d4cp00728j] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/10/2024]
Abstract
In situ 3D computed tomography imaging with statistical analysis successfully revealed the water accumulation and drainage characteristics in the stacked gas diffusion layers (GDLs) and membrane electrode assembly (MEA) of a polymer electrolyte fuel cell. Efficient water drainage at the interface between the cathode GDL and MEA was confirmed upon supplying oxygen to the cathode.
Collapse
Affiliation(s)
- Hirosuke Matsui
- Department of Chemistry, Graduate School of Science & Research Center for Materials Science (RCMS) & Integrated Research Consortium on Chemical Science (IRCCS) & Reaction Infography (R-ing) World Research Unit, Nagoya University, Furo, Chikusa, Nagoya, Aichi 464-8602, Japan.
- RIKEN SPring-8 Center, SPring-8, Koto, Sayo, Hyogo 679-5198, Japan
| | - Tomoro Ohta
- Department of Chemistry, Graduate School of Science & Research Center for Materials Science (RCMS) & Integrated Research Consortium on Chemical Science (IRCCS) & Reaction Infography (R-ing) World Research Unit, Nagoya University, Furo, Chikusa, Nagoya, Aichi 464-8602, Japan.
- RIKEN SPring-8 Center, SPring-8, Koto, Sayo, Hyogo 679-5198, Japan
| | - Takahiro Nakamura
- Department of Chemistry, Graduate School of Science & Research Center for Materials Science (RCMS) & Integrated Research Consortium on Chemical Science (IRCCS) & Reaction Infography (R-ing) World Research Unit, Nagoya University, Furo, Chikusa, Nagoya, Aichi 464-8602, Japan.
| | - Tomoya Uruga
- Japan Synchrotron Radiation Research Center, SPring-8, Koto, Sayo, Hyogo 679-5198, Japan
| | - Mizuki Tada
- Department of Chemistry, Graduate School of Science & Research Center for Materials Science (RCMS) & Integrated Research Consortium on Chemical Science (IRCCS) & Reaction Infography (R-ing) World Research Unit, Nagoya University, Furo, Chikusa, Nagoya, Aichi 464-8602, Japan.
- RIKEN SPring-8 Center, SPring-8, Koto, Sayo, Hyogo 679-5198, Japan
| |
Collapse
|
2
|
Yamada E, Sakamoto H, Matsui H, Uruga T, Sugimoto K, Ha MQ, Dam HC, Matsuda R, Tada M. Three-Dimensional Visualization of Adsorption Distribution in a Single Crystalline Particle of a Metal-Organic Framework. J Am Chem Soc 2024; 146:9181-9190. [PMID: 38528433 DOI: 10.1021/jacs.3c14778] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/27/2024]
Abstract
Many unique adsorption properties of metal-organic frameworks (MOFs) have been revealed by diffraction crystallography, visualizing their vacant and guest-loaded crystal structures at the molecular scale. However, it has been challenging to see the spatial distribution of the adsorption behaviors throughout a single MOF particle in a transient equilibrium state. Here, we report three-dimensional (3D) visualization of molecular adsorption behaviors in a single crystalline particle of a MOF by in situ X-ray absorption fine structure spectroscopy combined with computed tomography for the first time. The 3D maps of water-coordinated Co sites in a 100 μm-scale MOF-74-Co crystal were obtained with 1 μm spatial resolution under several water vapor pressures. Through the visualization of the water vapor adsorption process, 3D spectroimaging revealed the mechanism and spatial heterogeneity of guest adsorption inside a single particle of a crystalline MOF.
Collapse
Affiliation(s)
- Emina Yamada
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa, Nagoya, Aichi 464-8602, Japan
- RIKEN SPring-8 Center, Sayo, Hyogo, 679-5198, Japan
| | - Hirotoshi Sakamoto
- RIKEN SPring-8 Center, Sayo, Hyogo, 679-5198, Japan
- Research Center for Materials Science, Nagoya University, Furo-cho, Chikusa, Nagoya, Aichi 464-8602, Japan
| | - Hirosuke Matsui
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa, Nagoya, Aichi 464-8602, Japan
- RIKEN SPring-8 Center, Sayo, Hyogo, 679-5198, Japan
| | - Tomoya Uruga
- Japan Synchrotron Radiation Research Center (JASRI)/SPring-8, Koto, Sayo, Hyogo 679-5198, Japan
| | - Kunihisa Sugimoto
- Japan Synchrotron Radiation Research Center (JASRI)/SPring-8, Koto, Sayo, Hyogo 679-5198, Japan
- Faculty of Science and Engineering, Graduate School of Science and Engineering, Kindai University, Kowakae. Higashiosaka, Osaka 577-8502, Japan
| | - Minh-Quyet Ha
- School of Knowledge Science, Japan Advanced Institute of Science and Technology, Asahidai, Nomi, Ishikawa 923-1292, Japan
| | - Hieu-Chi Dam
- School of Knowledge Science, Japan Advanced Institute of Science and Technology, Asahidai, Nomi, Ishikawa 923-1292, Japan
| | - Ryotaro Matsuda
- Department of Chemistry and Biotechnology, Graduate School of Engineering, Nagoya University, Furo-cho, Chikusa, Nagoya, Aichi 464-8603, Japan
- Institute for Advanced Study, Nagoya University, Furo-cho, Chikusa, Nagoya, Aichi 464-8601, Japan
| | - Mizuki Tada
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa, Nagoya, Aichi 464-8602, Japan
- RIKEN SPring-8 Center, Sayo, Hyogo, 679-5198, Japan
- Research Center for Materials Science, Nagoya University, Furo-cho, Chikusa, Nagoya, Aichi 464-8602, Japan
- Institute for Advanced Study, Nagoya University, Furo-cho, Chikusa, Nagoya, Aichi 464-8601, Japan
| |
Collapse
|
3
|
Muratsugu S, Sawaguchi K, Shiraogawa T, Chiba S, Sakata Y, Shirai S, Baba H, Ehara M, Akine S, Tada M. Induced chirality at the surface: fixation of a dynamic M/ P invertible helical Co 3 complex on SiO 2. Chem Commun (Camb) 2024; 60:2094-2097. [PMID: 38294205 DOI: 10.1039/d3cc05534e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2024]
Abstract
Dynamic M/P invertible helicity was successfully induced at a SiO2 surface immobilized with a dynamic helical trinuclear cobalt complex, [LCo3(NHMe2)6](OTf)3, using chiral ((R) or (S))-1-phenylethylamine. Solid-state CD spectra and theoretical calculations suggested that the fixation of the M/P helical complex on the surface via coordination interactions was the key factor of the induced chirality at the surface.
Collapse
Affiliation(s)
- Satoshi Muratsugu
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8602 Aichi, Japan.
- Integrated Research Consortium on Chemical Science (IRCCS), Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8602 Aichi, Japan
| | - Kana Sawaguchi
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8602 Aichi, Japan.
- Research Center for Materials Science (RCMS), Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8602 Aichi, Japan
| | - Takafumi Shiraogawa
- Institute for Molecular Science/School of Physical Sciences, Graduate University for Advanced Studies, Myodaiji, Okazaki, 444-8585 Aichi, Japan.
| | - Shunsuke Chiba
- Graduate School of Natural Science and Technology, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192 Ishikawa, Japan.
| | - Yoko Sakata
- Graduate School of Natural Science and Technology, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192 Ishikawa, Japan.
- Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, Kakuma-machi, Kanazawa, 920-1192 Ishikawa, Japan
| | - Sora Shirai
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8602 Aichi, Japan.
| | - Hiroshi Baba
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8602 Aichi, Japan.
| | - Masahiro Ehara
- Institute for Molecular Science/School of Physical Sciences, Graduate University for Advanced Studies, Myodaiji, Okazaki, 444-8585 Aichi, Japan.
| | - Shigehisa Akine
- Graduate School of Natural Science and Technology, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192 Ishikawa, Japan.
- Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, Kakuma-machi, Kanazawa, 920-1192 Ishikawa, Japan
| | - Mizuki Tada
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8602 Aichi, Japan.
- Integrated Research Consortium on Chemical Science (IRCCS), Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8602 Aichi, Japan
- Research Center for Materials Science (RCMS), Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8602 Aichi, Japan
| |
Collapse
|
4
|
Zatsepin P, Moriyama T, Chen C, Muratsugu S, Tada M, Yamashita M. Vanadium Alumanyl Complex: Synthesis, Characterization, Reactivity, and Application as a Catalyst for C-H Alumanylation of Alkenes. J Am Chem Soc 2024; 146:3492-3497. [PMID: 38279921 DOI: 10.1021/jacs.3c13418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2024]
Abstract
A complex containing a V-Al bond is described. This species can be prepared by either transmetalation of a previously disclosed alumanylpotassium with Cp2VCl or photolytic oxidative alumination of Cp2V using the corresponding dialumane. Reaction of the resulting V-Al complex with H2 gave a Cp2V-dihydridoaluminate complex. These complexes were studied with X-ray crystallography, vanadium K-edge XANES spectroscopy, and DFT calculations. Finally, the reactivity of these molecules was studied opening the way to a catalytic C-H alumanylation of alkenes.
Collapse
Affiliation(s)
- Pavel Zatsepin
- Department of Molecular and Macromolecular Chemistry, Graduate School of Engineering, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8603, Aichi, Japan
| | - Takumi Moriyama
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8602, Aichi, Japan
| | - Chaoqi Chen
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8602, Aichi, Japan
| | - Satoshi Muratsugu
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8602, Aichi, Japan
- Integrated Research Consortium on Chemical Science (IRCCS), Nagoya University, Tokai National Higher Education and Research System, Furo-cho, Chikusa-ku, Nagoya 464-8602, Japan
| | - Mizuki Tada
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8602, Aichi, Japan
- Integrated Research Consortium on Chemical Science (IRCCS), Nagoya University, Tokai National Higher Education and Research System, Furo-cho, Chikusa-ku, Nagoya 464-8602, Japan
- Research Center for Materials Science (RCMS), Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8602, Aichi, Japan
| | - Makoto Yamashita
- Department of Molecular and Macromolecular Chemistry, Graduate School of Engineering, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8603, Aichi, Japan
- Integrated Research Consortium on Chemical Science (IRCCS), Nagoya University, Tokai National Higher Education and Research System, Furo-cho, Chikusa-ku, Nagoya 464-8602, Japan
| |
Collapse
|
5
|
Kurumada S, Yamanashi R, Sugita K, Kubota K, Ito H, Ikemoto S, Chen C, Moriyama T, Muratsugu S, Tada M, Koitaya T, Ozaki T, Yamashita M. Mechanochemical Synthesis of Non-Solvated Dialkylalumanyl Anion and XPS Characterization of Al(I) and Al(II) Species. Chemistry 2024; 30:e202303073. [PMID: 38018466 DOI: 10.1002/chem.202303073] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2023] [Revised: 11/28/2023] [Accepted: 11/29/2023] [Indexed: 11/30/2023]
Abstract
A non-solvated alkyl-substituted Al(I) anion dimer was synthesized by a reduction of haloalumane precursor using a mechanochemical method. The crystallographic and theoretical analysis revealed its structure and electronic properties. Experimental XPS analysis of the Al(I) anions with reference compounds revealed the lower Al 2p binding energy corresponds to the lower oxidation state of Al species. It should be emphasized that the experimentally obtained XPS binding energies were reproduced by delta SCF calculations and were linearly correlated with NPA charges and 2p orbital energies.
Collapse
Grants
- 21H01915 Ministry of Education, Culture, Sports, Science and Technology
- 22H00335 Ministry of Education, Culture, Sports, Science and Technology
- 20H04808 Ministry of Education, Culture, Sports, Science and Technology
- 23H01973 Ministry of Education, Culture, Sports, Science and Technology
- JPMJCR19R1 Japan Science and Technology Corporation
- JPMJFR201I Japan Science and Technology Corporation
- 202115731 Japan Society for the Promotion of Science London
- 22J23885 Japan Society for the Promotion of Science London
Collapse
Affiliation(s)
- Satoshi Kurumada
- Department of Molecular and Macromolecular Chemistry, Graduate School of Engineering, Nagoya University, Furo-cho, Chikusa-ku, 464-8603, Nagoya, Aichi, Japan
| | - Ryotaro Yamanashi
- Department of Molecular and Macromolecular Chemistry, Graduate School of Engineering, Nagoya University, Furo-cho, Chikusa-ku, 464-8603, Nagoya, Aichi, Japan
| | - Kengo Sugita
- Department of Molecular and Macromolecular Chemistry, Graduate School of Engineering, Nagoya University, Furo-cho, Chikusa-ku, 464-8603, Nagoya, Aichi, Japan
| | - Koji Kubota
- Division of Applied Chemistry, Graduate School of Engineering, Hokkaido University, 060-8628, Sapporo, Hokkaido, Japan
- Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, 060-8628, Sapporo, Hokkaido, Japan
| | - Hajime Ito
- Division of Applied Chemistry, Graduate School of Engineering, Hokkaido University, 060-8628, Sapporo, Hokkaido, Japan
- Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, 060-8628, Sapporo, Hokkaido, Japan
| | - Satoru Ikemoto
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, 464-8603, Nagoya, Aichi, Japan
| | - Chaoqi Chen
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, 464-8603, Nagoya, Aichi, Japan
| | - Takumi Moriyama
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, 464-8603, Nagoya, Aichi, Japan
| | - Satoshi Muratsugu
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, 464-8603, Nagoya, Aichi, Japan
- Integrated Research Consortium on Chemical Science (IRCCS), Nagoya University, Furo-cho, Chikusa-ku, 464-8602, Nagoya, Aichi, Japan
| | - Mizuki Tada
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, 464-8603, Nagoya, Aichi, Japan
- Integrated Research Consortium on Chemical Science (IRCCS), Nagoya University, Furo-cho, Chikusa-ku, 464-8602, Nagoya, Aichi, Japan
- Research Center for Materials Science (RCMS), Nagoya University, Furo-cho, Chikusa-ku, 464-8602, Nagoya, Aichi, Japan
| | - Takanori Koitaya
- Department of Chemistry, Graduate School of Science, Kyoto University, Kitashirakawa-Oiwake-cho, Sakyo-ku, 606-8502, Kyoto, Japan
| | - Taisuke Ozaki
- The Institute for Solid State Physics, The University of Tokyo, 5-1-5 Kashiwanoha, 277-8581, Kashiwa, Chiba, Japan
| | - Makoto Yamashita
- Department of Molecular and Macromolecular Chemistry, Graduate School of Engineering, Nagoya University, Furo-cho, Chikusa-ku, 464-8603, Nagoya, Aichi, Japan
- Integrated Research Consortium on Chemical Science (IRCCS), Nagoya University, Furo-cho, Chikusa-ku, 464-8602, Nagoya, Aichi, Japan
| |
Collapse
|
6
|
Kimura Y, Huang S, Nakamura T, Ishiguro N, Sekizawa O, Nitta K, Uruga T, Takeuchi T, Okumura T, Tada M, Uchimoto Y, Amezawa K. 5D Analysis of Capacity Degradation in Battery Electrodes Enabled by Operando CT-XANES. Small Methods 2023; 7:e2300310. [PMID: 37452269 DOI: 10.1002/smtd.202300310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/09/2023] [Revised: 06/29/2023] [Indexed: 07/18/2023]
Abstract
For devices encountering long-term stability challenges, a precise evaluation of degradation is of paramount importance. However, methods for comprehensively elucidating the degradation mechanisms in devices, particularly those undergoing dynamic chemical and mechanical changes during operation, such as batteries, are limited. Here, a method is presented using operando computed tomography combined with X-ray absorption near-edge structure spectroscopy (CT-XANES) that can directly track the evolution of the 3D distribution of the local capacity loss in battery electrodes during (dis)charge cycles, thereby enabling a five-dimensional (the 3D spatial coordinates, time, and chemical state) analysis of the degradation. This paper demonstrates that the method can quantify the spatiotemporal dynamics of the local capacity degradation within an electrode during cycling, which has been truncated by existing bulk techniques, and correlate it with the overall electrode performance degradation. Furthermore, the method demonstrates its capability to uncover the correlation among observed local capacity degradation within electrodes, reaction history during past (dis)charge cycles, and electrode microstructure. The method thus provides critical insights into the identification of degradation factors that are not available through existing methods, and therefore, will contribute to the development of batteries with long-term stability.
Collapse
Affiliation(s)
- Yuta Kimura
- Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Katahira, Sendai, Miyagi, 980-8579, Japan
| | - Su Huang
- Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Katahira, Sendai, Miyagi, 980-8579, Japan
| | - Takashi Nakamura
- Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Katahira, Sendai, Miyagi, 980-8579, Japan
| | - Nozomu Ishiguro
- Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Katahira, Sendai, Miyagi, 980-8579, Japan
| | - Oki Sekizawa
- Japan Synchrotron Radiation Research Institute, SPring-8, Koto, Sayo-cho, Sayo-gun, Hyogo, 679-5198, Japan
| | - Kiyofumi Nitta
- Japan Synchrotron Radiation Research Institute, SPring-8, Koto, Sayo-cho, Sayo-gun, Hyogo, 679-5198, Japan
| | - Tomoya Uruga
- Japan Synchrotron Radiation Research Institute, SPring-8, Koto, Sayo-cho, Sayo-gun, Hyogo, 679-5198, Japan
| | - Tomonari Takeuchi
- Research Institute of Electrochemical Energy, National Institute of Advanced Industrial Science and Technology, 1-8-31 Midorigaoka, Ikeda, Osaka, 563-8577, Japan
| | - Toyoki Okumura
- Research Institute of Electrochemical Energy, National Institute of Advanced Industrial Science and Technology, 1-8-31 Midorigaoka, Ikeda, Osaka, 563-8577, Japan
| | - Mizuki Tada
- Research Center for Materials Science/Graduate School of Science/Institute for Advanced Science, Nagoya University, Furo, Nagoya, Aichi, 464-8602, Japan
- RIKEN SPring-8 Center, RIKEN, Koto, Sayo-cho, Sayo-gun, Hyogo, 679-5148, Japan
| | - Yoshiharu Uchimoto
- Graduate School of Human and Environmental Studies, Kyoto University, Nihonmatsu-cho Yoshida, Sakyo-ku, Kyoto, 606-8501, Japan
| | - Koji Amezawa
- Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Katahira, Sendai, Miyagi, 980-8579, Japan
| |
Collapse
|
7
|
Abe K, Akhlaq N, Akutsu R, Ali A, Alonso Monsalve S, Alt C, Andreopoulos C, Antonova M, Aoki S, Arihara T, Asada Y, Ashida Y, Atkin ET, Barbi M, Barker GJ, Barr G, Barrow D, Batkiewicz-Kwasniak M, Bench F, Berardi V, Berns L, Bhadra S, Blanchet A, Blondel A, Bolognesi S, Bonus T, Bordoni S, Boyd SB, Bravar A, Bronner C, Bron S, Bubak A, Buizza Avanzini M, Caballero JA, Calabria NF, Cao S, Carabadjac D, Carter AJ, Cartwright SL, Catanesi MG, Cervera A, Chakrani J, Cherdack D, Chong PS, Christodoulou G, Chvirova A, Cicerchia M, Coleman J, Collazuol G, Cook L, Cudd A, Dalmazzone C, Daret T, Davydov YI, De Roeck A, De Rosa G, Dealtry T, Delogu CC, Densham C, Dergacheva A, Di Lodovico F, Dolan S, Douqa D, Doyle TA, Drapier O, Dumarchez J, Dunne P, Dygnarowicz K, Eguchi A, Emery-Schrenk S, Erofeev G, Ershova A, Eurin G, Fedorova D, Fedotov S, Feltre M, Finch AJ, Fiorentini Aguirre GA, Fiorillo G, Fitton MD, Franco Patiño JM, Friend M, Fujii Y, Fukuda Y, Fusshoeller K, Giannessi L, Giganti C, Glagolev V, Gonin M, González Rosa J, Goodman EAG, Gorin A, Grassi M, Guigue M, Hadley DR, Haigh JT, Hamacher-Baumann P, Harris DA, Hartz M, Hasegawa T, Hassani S, Hastings NC, Hayato Y, Henaff D, Hiramoto A, Hogan M, Holeczek J, Holin A, Holvey T, Hong Van NT, Honjo T, Iacob F, Ichikawa AK, Ikeda M, Ishida T, Ishitsuka M, Israel HT, Iwamoto K, Izmaylov A, Izumi N, Jakkapu M, Jamieson B, Jenkins SJ, Jesús-Valls C, Jiang JJ, Jonsson P, Joshi S, Jung CK, Jurj PB, Kabirnezhad M, Kaboth AC, Kajita T, Kakuno H, Kameda J, Kasetti SP, Kataoka Y, Katayama Y, Katori T, Kawaue M, Kearns E, Khabibullin M, Khotjantsev A, Kikawa T, Kikutani H, King S, Kiseeva V, Kisiel J, Kobata T, Kobayashi H, Kobayashi T, Koch L, Kodama S, Konaka A, Kormos LL, Koshio Y, Kostin A, Koto T, Kowalik K, Kudenko Y, Kudo Y, Kuribayashi S, Kurjata R, Kutter T, Kuze M, La Commara M, Labarga L, Lachner K, Lagoda J, Lakshmi SM, Lamers James M, Lamoureux M, Langella A, Laporte JF, Last D, Latham N, Laveder M, Lavitola L, Lawe M, Lee Y, Lin C, Lin SK, Litchfield RP, Liu SL, Li W, Longhin A, Long KR, Lopez Moreno A, Ludovici L, Lu X, Lux T, Machado LN, Magaletti L, Mahn K, Malek M, Mandal M, Manly S, Marino AD, Marti-Magro L, Martin DGR, Martini M, Martin JF, Maruyama T, Matsubara T, Matveev V, Mauger C, Mavrokoridis K, Mazzucato E, McCauley N, McElwee J, McFarland KS, McGrew C, McKean J, Mefodiev A, Megias GD, Mehta P, Mellet L, Metelko C, Mezzetto M, Miller E, Minamino A, Mineev O, Mine S, Miura M, Molina Bueno L, Moriyama S, Moriyama S, Morrison P, Mueller TA, Munford D, Munteanu L, Nagai K, Nagai Y, Nakadaira T, Nakagiri K, Nakahata M, Nakajima Y, Nakamura A, Nakamura H, Nakamura K, Nakamura KD, Nakano Y, Nakayama S, Nakaya T, Nakayoshi K, Naseby CER, Ngoc TV, Nguyen VQ, Niewczas K, Nishimori S, Nishimura Y, Nishizaki K, Nosek T, Nova F, Novella P, Nugent JC, O’Keeffe HM, O’Sullivan L, Odagawa T, Ogawa T, Okada R, Okinaga W, Okumura K, Okusawa T, Ospina N, Owen RA, Oyama Y, Palladino V, Paolone V, Pari M, Parlone J, Parsa S, Pasternak J, Pavin M, Payne D, Penn GC, Pershey D, Pickering L, Pidcott C, Pintaudi G, Pistillo C, Popov B, Porwit K, Posiadala-Zezula M, Prabhu YS, Pupilli F, Quilain B, Radermacher T, Radicioni E, Radics B, Ramírez MA, Ratoff PN, Reh M, Riccio C, Rondio E, Roth S, Roy N, Rubbia A, Ruggeri AC, Ruggles CA, Rychter A, Sakashita K, Sánchez F, Santucci G, Schloesser CM, Scholberg K, Scott M, Seiya Y, Sekiguchi T, Sekiya H, Sgalaberna D, Shaikhiev A, Shaker F, Shaykina A, Shiozawa M, Shorrock W, Shvartsman A, Skrobova N, Skwarczynski K, Smyczek D, Smy M, Sobczyk JT, Sobel H, Soler FJP, Sonoda Y, Speers AJ, Spina R, Suslov IA, Suvorov S, Suzuki A, Suzuki SY, Suzuki Y, Sztuc AA, Tada M, Tairafune S, Takayasu S, Takeda A, Takeuchi Y, Takifuji K, Tanaka HK, Tanihara Y, Tani M, Teklu A, Tereshchenko VV, Teshima N, Thamm N, Thompson LF, Toki W, Touramanis C, Towstego T, Tsui KM, Tsukamoto T, Tzanov M, Uchida Y, Vagins M, Vargas D, Varghese M, Vasseur G, Vilela C, Villa E, Vinning WGS, Virginet U, Vladisavljevic T, Wachala T, Walsh JG, Wang Y, Wan L, Wark D, Wascko MO, Weber A, Wendell R, Wilking MJ, Wilkinson C, Wilson JR, Wood K, Wret C, Xia J, Xu YH, Yamamoto K, Yamamoto T, Yanagisawa C, Yang G, Yano T, Yasutome K, Yershov N, Yevarouskaya U, Yokoyama M, Yoshimoto Y, Yoshimura N, Yu M, Zaki R, Zalewska A, Zalipska J, Zaremba K, Zarnecki G, Zhao X, Zhu T, Ziembicki M, Zimmerman ED, Zito M, Zsoldos S. Measurements of neutrino oscillation parameters from the T2K experiment using 3.6×1021 protons on target. Eur Phys J C Part Fields 2023; 83:782. [PMID: 37680254 PMCID: PMC10480298 DOI: 10.1140/epjc/s10052-023-11819-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/07/2023] [Accepted: 07/10/2023] [Indexed: 09/09/2023]
Abstract
The T2K experiment presents new measurements of neutrino oscillation parameters using 19.7 ( 16.3 ) × 10 20 protons on target (POT) in (anti-)neutrino mode at the far detector (FD). Compared to the previous analysis, an additional 4.7 × 10 20 POT neutrino data was collected at the FD. Significant improvements were made to the analysis methodology, with the near-detector analysis introducing new selections and using more than double the data. Additionally, this is the first T2K oscillation analysis to use NA61/SHINE data on a replica of the T2K target to tune the neutrino flux model, and the neutrino interaction model was improved to include new nuclear effects and calculations. Frequentist and Bayesian analyses are presented, including results on sin 2 θ 13 and the impact of priors on the δ CP measurement. Both analyses prefer the normal mass ordering and upper octant of sin 2 θ 23 with a nearly maximally CP-violating phase. Assuming the normal ordering and using the constraint on sin 2 θ 13 from reactors, sin 2 θ 23 = 0 . 561 - 0.032 + 0.021 using Feldman-Cousins corrected intervals, and Δ m 32 2 = 2 . 494 - 0.058 + 0.041 × 10 - 3 eV 2 using constant Δ χ 2 intervals. The CP-violating phase is constrained to δ CP = - 1 . 97 - 0.70 + 0.97 using Feldman-Cousins corrected intervals, and δ CP = 0 , π is excluded at more than 90% confidence level. A Jarlskog invariant of zero is excluded at more than 2 σ credible level using a flat prior in δ CP , and just below 2 σ using a flat prior in sin δ CP . When the external constraint on sin 2 θ 13 is removed, sin 2 θ 13 = 28 . 0 - 6.5 + 2.8 × 10 - 3 , in agreement with measurements from reactor experiments. These results are consistent with previous T2K analyses.
Collapse
Affiliation(s)
- K. Abe
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
| | - N. Akhlaq
- School of Physics and Astronomy, Queen Mary University of London, London, UK
| | - R. Akutsu
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
| | - A. Ali
- TRIUMF, Vancouver, BC Canada
- Department of Physics, University of Winnipeg, Winnipeg, MB Canada
| | - S. Alonso Monsalve
- Institute for Particle Physics and Astrophysics, ETH Zurich, Zurich, Switzerland
| | - C. Alt
- Institute for Particle Physics and Astrophysics, ETH Zurich, Zurich, Switzerland
| | - C. Andreopoulos
- Department of Physics, University of Liverpool, Liverpool, UK
| | - M. Antonova
- IFIC (CSIC and University of Valencia), Valencia, Spain
| | - S. Aoki
- Kobe University, Kobe, Japan
| | - T. Arihara
- Department of Physics, Tokyo Metropolitan University, Tokyo, Japan
| | - Y. Asada
- Department of Physics, Yokohama National University, Yokohama, Japan
| | - Y. Ashida
- Department of Physics, Kyoto University, Kyoto, Japan
| | - E. T. Atkin
- Department of Physics, Imperial College London, London, UK
| | - M. Barbi
- Department of Physics, University of Regina, Regina, Saskatchewan Canada
| | - G. J. Barker
- Department of Physics, University of Warwick, Coventry, UK
| | - G. Barr
- Department of Physics, Oxford University, Oxford, UK
| | - D. Barrow
- Department of Physics, Oxford University, Oxford, UK
| | | | - F. Bench
- Department of Physics, University of Liverpool, Liverpool, UK
| | - V. Berardi
- Dipartimento Interuniversitario di Fisica, INFN Sezione di Bari and Università e Politecnico di Bari, Bari, Italy
| | - L. Berns
- Department of Physics, Faculty of Science, Tohoku University, Sendai, Miyagi Japan
| | - S. Bhadra
- Department of Physics and Astronomy, York University, Toronto, ON Canada
| | - A. Blanchet
- Section de Physique, DPNC, University of Geneva, Geneva, Switzerland
| | - A. Blondel
- Section de Physique, DPNC, University of Geneva, Geneva, Switzerland
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - S. Bolognesi
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - T. Bonus
- Faculty of Physics and Astronomy, Wroclaw University, Wrocław, Poland
| | - S. Bordoni
- Section de Physique, DPNC, University of Geneva, Geneva, Switzerland
| | - S. B. Boyd
- Department of Physics, University of Warwick, Coventry, UK
| | - A. Bravar
- Section de Physique, DPNC, University of Geneva, Geneva, Switzerland
| | - C. Bronner
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
| | - S. Bron
- TRIUMF, Vancouver, BC Canada
| | - A. Bubak
- Institute of Physics, University of Silesia, Katowice, Poland
| | - M. Buizza Avanzini
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, IN2P3-CNRS, Palaiseau, France
| | - J. A. Caballero
- Departamento de Física Atómica, Molecular y Nuclear, Universidad de Sevilla, 41080 Sevilla, Spain
| | - N. F. Calabria
- Dipartimento Interuniversitario di Fisica, INFN Sezione di Bari and Università e Politecnico di Bari, Bari, Italy
| | - S. Cao
- Institute For Interdisciplinary Research in Science and Education (IFIRSE), ICISE, Quy Nhon, Vietnam
| | - D. Carabadjac
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, IN2P3-CNRS, Palaiseau, France
- Université Paris-Saclay, Gif-sur-Yvette, France
| | - A. J. Carter
- Department of Physics, Royal Holloway University of London, Egham, Surrey UK
| | - S. L. Cartwright
- Department of Physics and Astronomy, University of Sheffield, Sheffield, UK
| | - M. G. Catanesi
- Dipartimento Interuniversitario di Fisica, INFN Sezione di Bari and Università e Politecnico di Bari, Bari, Italy
| | - A. Cervera
- IFIC (CSIC and University of Valencia), Valencia, Spain
| | - J. Chakrani
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, IN2P3-CNRS, Palaiseau, France
| | - D. Cherdack
- Department of Physics, University of Houston, Houston, TX USA
| | - P. S. Chong
- Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, PA 19104 USA
| | - G. Christodoulou
- CERN European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
| | - A. Chvirova
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M. Cicerchia
- Dipartimento di Fisica, INFN Sezione di Padova and Università di Padova, Padua, Italy
- INFN-Laboratori Nazionali di Legnaro, Legnaro, Italy
| | - J. Coleman
- Department of Physics, University of Liverpool, Liverpool, UK
| | - G. Collazuol
- Dipartimento di Fisica, INFN Sezione di Padova and Università di Padova, Padua, Italy
| | - L. Cook
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
- Department of Physics, Oxford University, Oxford, UK
| | - A. Cudd
- Department of Physics, University of Colorado at Boulder, Boulder, CO USA
| | - C. Dalmazzone
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - T. Daret
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - Yu. I. Davydov
- Joint Institute for Nuclear Research, Dubna, Moscow Region Russia
| | - A. De Roeck
- CERN European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
| | - G. De Rosa
- Dipartimento di Fisica, INFN Sezione di Napoli and Università di Napoli, Naples, Italy
| | - T. Dealtry
- Physics Department, Lancaster University, Lancaster, UK
| | - C. C. Delogu
- Dipartimento di Fisica, INFN Sezione di Padova and Università di Padova, Padua, Italy
| | - C. Densham
- Rutherford Appleton Laboratory, STFC, Harwell, Oxford, UK
- Department of Physics, University of Tokyo, Tokyo, Japan
| | - A. Dergacheva
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - F. Di Lodovico
- Department of Physics, King’s College London, Strand, London, WC2R 2LS UK
| | - S. Dolan
- CERN European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
| | - D. Douqa
- Section de Physique, DPNC, University of Geneva, Geneva, Switzerland
| | - T. A. Doyle
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, NY USA
| | - O. Drapier
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, IN2P3-CNRS, Palaiseau, France
| | - J. Dumarchez
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - P. Dunne
- Department of Physics, Imperial College London, London, UK
| | - K. Dygnarowicz
- Institute of Radioelectronics and Multimedia Technology, Warsaw University of Technology, Warsaw, Poland
| | - A. Eguchi
- Department of Physics, University of Tokyo, Tokyo, Japan
| | - S. Emery-Schrenk
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - G. Erofeev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - A. Ershova
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - G. Eurin
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - D. Fedorova
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - S. Fedotov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M. Feltre
- Dipartimento di Fisica, INFN Sezione di Padova and Università di Padova, Padua, Italy
| | - A. J. Finch
- Physics Department, Lancaster University, Lancaster, UK
| | | | - G. Fiorillo
- Dipartimento di Fisica, INFN Sezione di Napoli and Università di Napoli, Naples, Italy
| | - M. D. Fitton
- Rutherford Appleton Laboratory, STFC, Harwell, Oxford, UK
| | - J. M. Franco Patiño
- Departamento de Física Atómica, Molecular y Nuclear, Universidad de Sevilla, 41080 Sevilla, Spain
| | - M. Friend
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- J-PARC, Tokai, Japan
| | - Y. Fujii
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- J-PARC, Tokai, Japan
| | - Y. Fukuda
- Department of Physics, Miyagi University of Education, Sendai, Japan
| | - K. Fusshoeller
- Institute for Particle Physics and Astrophysics, ETH Zurich, Zurich, Switzerland
| | - L. Giannessi
- Section de Physique, DPNC, University of Geneva, Geneva, Switzerland
| | - C. Giganti
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - V. Glagolev
- Joint Institute for Nuclear Research, Dubna, Moscow Region Russia
| | - M. Gonin
- ILANCE, CNRS-University of Tokyo International Research Laboratory, Kashiwa, Chiba 277-8582 Japan
| | - J. González Rosa
- Departamento de Física Atómica, Molecular y Nuclear, Universidad de Sevilla, 41080 Sevilla, Spain
| | - E. A. G. Goodman
- School of Physics and Astronomy, University of Glasgow, Glasgow, UK
| | - A. Gorin
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M. Grassi
- Dipartimento di Fisica, INFN Sezione di Padova and Università di Padova, Padua, Italy
| | - M. Guigue
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - D. R. Hadley
- Department of Physics, University of Warwick, Coventry, UK
| | - J. T. Haigh
- Department of Physics, University of Warwick, Coventry, UK
| | | | - D. A. Harris
- Department of Physics and Astronomy, York University, Toronto, ON Canada
| | - M. Hartz
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
- TRIUMF, Vancouver, BC Canada
| | - T. Hasegawa
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- J-PARC, Tokai, Japan
| | - S. Hassani
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - N. C. Hastings
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
| | - Y. Hayato
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
| | - D. Henaff
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - A. Hiramoto
- Department of Physics, Kyoto University, Kyoto, Japan
| | - M. Hogan
- Department of Physics, Colorado State University, Fort Collins, Colorado USA
| | - J. Holeczek
- Institute of Physics, University of Silesia, Katowice, Poland
| | - A. Holin
- Rutherford Appleton Laboratory, STFC, Harwell, Oxford, UK
| | - T. Holvey
- Department of Physics, Oxford University, Oxford, UK
| | - N. T. Hong Van
- International Centre of Physics, Institute of Physics (IOP), Vietnam Academy of Science and Technology (VAST), 10 Dao Tan, Ba Dinh, Hanoi, Vietnam
| | - T. Honjo
- Department of Physics, Osaka Metropolitan University, Osaka, Japan
| | - F. Iacob
- Dipartimento di Fisica, INFN Sezione di Padova and Università di Padova, Padua, Italy
| | - A. K. Ichikawa
- Department of Physics, Faculty of Science, Tohoku University, Sendai, Miyagi Japan
| | - M. Ikeda
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
| | - T. Ishida
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- J-PARC, Tokai, Japan
| | - M. Ishitsuka
- Department of Physics, Faculty of Science and Technology, Tokyo University of Science, Noda, Chiba Japan
| | - H. T. Israel
- Department of Physics and Astronomy, University of Sheffield, Sheffield, UK
| | - K. Iwamoto
- Department of Physics, University of Tokyo, Tokyo, Japan
| | - A. Izmaylov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - N. Izumi
- Department of Physics, Faculty of Science and Technology, Tokyo University of Science, Noda, Chiba Japan
| | - M. Jakkapu
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
| | - B. Jamieson
- Department of Physics, University of Winnipeg, Winnipeg, MB Canada
| | - S. J. Jenkins
- Department of Physics, University of Liverpool, Liverpool, UK
| | - C. Jesús-Valls
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
| | - J. J. Jiang
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, NY USA
| | - P. Jonsson
- Department of Physics, Imperial College London, London, UK
| | - S. Joshi
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - C. K. Jung
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, NY USA
- Kavli IPMU (WPI), The University of Tokyo, Tokyo, Japan
| | - P. B. Jurj
- Department of Physics, Imperial College London, London, UK
| | - M. Kabirnezhad
- Department of Physics, Imperial College London, London, UK
| | - A. C. Kaboth
- Department of Physics, Royal Holloway University of London, Egham, Surrey UK
- Rutherford Appleton Laboratory, STFC, Harwell, Oxford, UK
| | - T. Kajita
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Japan
- Kavli IPMU (WPI), The University of Tokyo, Tokyo, Japan
| | - H. Kakuno
- Department of Physics, Tokyo Metropolitan University, Tokyo, Japan
| | - J. Kameda
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
| | - S. P. Kasetti
- Department of Physics and Astronomy, Louisiana State University, Baton Rouge, LA USA
| | - Y. Kataoka
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
| | - Y. Katayama
- Department of Physics, Yokohama National University, Yokohama, Japan
| | - T. Katori
- Department of Physics, King’s College London, Strand, London, WC2R 2LS UK
| | - M. Kawaue
- Department of Physics, Kyoto University, Kyoto, Japan
| | - E. Kearns
- Department of Physics, Boston University, Boston, MA USA
- Kavli IPMU (WPI), The University of Tokyo, Tokyo, Japan
| | - M. Khabibullin
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - A. Khotjantsev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - T. Kikawa
- Department of Physics, Kyoto University, Kyoto, Japan
| | - H. Kikutani
- Department of Physics, University of Tokyo, Tokyo, Japan
| | - S. King
- Department of Physics, King’s College London, Strand, London, WC2R 2LS UK
| | - V. Kiseeva
- Joint Institute for Nuclear Research, Dubna, Moscow Region Russia
| | - J. Kisiel
- Institute of Physics, University of Silesia, Katowice, Poland
| | - T. Kobata
- Department of Physics, Osaka Metropolitan University, Osaka, Japan
| | - H. Kobayashi
- Department of Physics, University of Tokyo, Tokyo, Japan
| | - T. Kobayashi
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- J-PARC, Tokai, Japan
| | - L. Koch
- Institut für Physik, Johannes Gutenberg-Universität Mainz, Staudingerweg 7, 55128 Mainz, Germany
| | - S. Kodama
- Department of Physics, University of Tokyo, Tokyo, Japan
| | | | - L. L. Kormos
- Physics Department, Lancaster University, Lancaster, UK
| | - Y. Koshio
- Department of Physics, Okayama University, Okayama, Japan
- Kavli IPMU (WPI), The University of Tokyo, Tokyo, Japan
| | - A. Kostin
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - T. Koto
- Department of Physics, Tokyo Metropolitan University, Tokyo, Japan
| | - K. Kowalik
- National Centre for Nuclear Research, Warsaw, Poland
| | - Y. Kudenko
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
- Moscow Institute of Physics and Technology (MIPT), Moscow Region, Russia and National Research Nuclear University “MEPhI”, Moscow, Russia
| | - Y. Kudo
- Department of Physics, Yokohama National University, Yokohama, Japan
| | | | - R. Kurjata
- Institute of Radioelectronics and Multimedia Technology, Warsaw University of Technology, Warsaw, Poland
| | - T. Kutter
- Department of Physics and Astronomy, Louisiana State University, Baton Rouge, LA USA
| | - M. Kuze
- Department of Physics, Tokyo Institute of Technology, Tokyo, Japan
| | - M. La Commara
- Dipartimento di Fisica, INFN Sezione di Napoli and Università di Napoli, Naples, Italy
| | - L. Labarga
- Department of Theoretical Physics, University Autonoma Madrid, 28049 Madrid, Spain
| | - K. Lachner
- Department of Physics, University of Warwick, Coventry, UK
| | - J. Lagoda
- National Centre for Nuclear Research, Warsaw, Poland
| | - S. M. Lakshmi
- National Centre for Nuclear Research, Warsaw, Poland
| | - M. Lamers James
- Physics Department, Lancaster University, Lancaster, UK
- Rutherford Appleton Laboratory, STFC, Harwell, Oxford, UK
| | - M. Lamoureux
- Dipartimento di Fisica, INFN Sezione di Padova and Università di Padova, Padua, Italy
| | - A. Langella
- Dipartimento di Fisica, INFN Sezione di Napoli and Università di Napoli, Naples, Italy
| | - J.-F. Laporte
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - D. Last
- Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, PA 19104 USA
| | - N. Latham
- Department of Physics, University of Warwick, Coventry, UK
| | - M. Laveder
- Dipartimento di Fisica, INFN Sezione di Padova and Università di Padova, Padua, Italy
| | - L. Lavitola
- Dipartimento di Fisica, INFN Sezione di Napoli and Università di Napoli, Naples, Italy
| | - M. Lawe
- Physics Department, Lancaster University, Lancaster, UK
| | - Y. Lee
- Department of Physics, Kyoto University, Kyoto, Japan
| | - C. Lin
- Department of Physics, Imperial College London, London, UK
| | - S.-K. Lin
- Department of Physics and Astronomy, Louisiana State University, Baton Rouge, LA USA
| | - R. P. Litchfield
- School of Physics and Astronomy, University of Glasgow, Glasgow, UK
| | - S. L. Liu
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, NY USA
| | - W. Li
- Department of Physics, Oxford University, Oxford, UK
| | - A. Longhin
- Dipartimento di Fisica, INFN Sezione di Padova and Università di Padova, Padua, Italy
| | - K. R. Long
- Department of Physics, Imperial College London, London, UK
- Rutherford Appleton Laboratory, STFC, Harwell, Oxford, UK
| | - A. Lopez Moreno
- Department of Physics, King’s College London, Strand, London, WC2R 2LS UK
| | - L. Ludovici
- INFN Sezione di Roma and Università di Roma “La Sapienza”, Rome, Italy
| | - X. Lu
- Department of Physics, University of Warwick, Coventry, UK
| | - T. Lux
- Institut de Fisica d’Altes Energies (IFAE)-The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra, Barcelona Spain
| | - L. N. Machado
- School of Physics and Astronomy, University of Glasgow, Glasgow, UK
| | - L. Magaletti
- Dipartimento Interuniversitario di Fisica, INFN Sezione di Bari and Università e Politecnico di Bari, Bari, Italy
| | - K. Mahn
- Department of Physics and Astronomy, Michigan State University, East Lansing, MI USA
| | - M. Malek
- Department of Physics and Astronomy, University of Sheffield, Sheffield, UK
| | - M. Mandal
- National Centre for Nuclear Research, Warsaw, Poland
| | - S. Manly
- Department of Physics and Astronomy, University of Rochester, Rochester, NY USA
| | - A. D. Marino
- Department of Physics, University of Colorado at Boulder, Boulder, CO USA
| | - L. Marti-Magro
- Department of Physics, Yokohama National University, Yokohama, Japan
| | | | - M. Martini
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Paris, France
- IPSA-DRII, Ivry-sur-Seine, France
| | - J. F. Martin
- Department of Physics, University of Toronto, Toronto, ON Canada
| | - T. Maruyama
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- J-PARC, Tokai, Japan
| | - T. Matsubara
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
| | - V. Matveev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - C. Mauger
- Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, PA 19104 USA
| | - K. Mavrokoridis
- Department of Physics, University of Liverpool, Liverpool, UK
| | - E. Mazzucato
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - N. McCauley
- Department of Physics, University of Liverpool, Liverpool, UK
| | - J. McElwee
- Department of Physics and Astronomy, University of Sheffield, Sheffield, UK
| | - K. S. McFarland
- Department of Physics and Astronomy, University of Rochester, Rochester, NY USA
| | - C. McGrew
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, NY USA
| | - J. McKean
- Department of Physics, Imperial College London, London, UK
| | - A. Mefodiev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - G. D. Megias
- Departamento de Física Atómica, Molecular y Nuclear, Universidad de Sevilla, 41080 Sevilla, Spain
| | - P. Mehta
- Department of Physics, University of Liverpool, Liverpool, UK
| | - L. Mellet
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - C. Metelko
- Department of Physics, University of Liverpool, Liverpool, UK
| | - M. Mezzetto
- Dipartimento di Fisica, INFN Sezione di Padova and Università di Padova, Padua, Italy
| | - E. Miller
- Department of Physics, King’s College London, Strand, London, WC2R 2LS UK
| | - A. Minamino
- Department of Physics, Yokohama National University, Yokohama, Japan
| | - O. Mineev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - S. Mine
- Department of Physics and Astronomy, University of California, Irvine, Irvine, CA USA
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
| | - M. Miura
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
- Kavli IPMU (WPI), The University of Tokyo, Tokyo, Japan
| | | | - S. Moriyama
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
- Kavli IPMU (WPI), The University of Tokyo, Tokyo, Japan
| | - S. Moriyama
- Department of Physics, Yokohama National University, Yokohama, Japan
- Kavli IPMU (WPI), The University of Tokyo, Tokyo, Japan
| | - P. Morrison
- School of Physics and Astronomy, University of Glasgow, Glasgow, UK
| | - Th. A. Mueller
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, IN2P3-CNRS, Palaiseau, France
| | - D. Munford
- Department of Physics, University of Houston, Houston, TX USA
| | - L. Munteanu
- CERN European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
| | - K. Nagai
- Department of Physics, Yokohama National University, Yokohama, Japan
| | - Y. Nagai
- Department of Atomic Physics, Eötvös Loránd University, Budapest, Hungary
| | - T. Nakadaira
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- J-PARC, Tokai, Japan
| | - K. Nakagiri
- Department of Physics, University of Tokyo, Tokyo, Japan
| | - M. Nakahata
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
| | - Y. Nakajima
- Department of Physics, University of Tokyo, Tokyo, Japan
| | - A. Nakamura
- Department of Physics, Okayama University, Okayama, Japan
| | - H. Nakamura
- Department of Physics, Faculty of Science and Technology, Tokyo University of Science, Noda, Chiba Japan
| | - K. Nakamura
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
- J-PARC, Tokai, Japan
| | - K. D. Nakamura
- Department of Physics, Faculty of Science, Tohoku University, Sendai, Miyagi Japan
| | - Y. Nakano
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
| | - S. Nakayama
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
| | - T. Nakaya
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
- Department of Physics, Kyoto University, Kyoto, Japan
| | - K. Nakayoshi
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- J-PARC, Tokai, Japan
| | | | - T. V. Ngoc
- Institute For Interdisciplinary Research in Science and Education (IFIRSE), ICISE, Quy Nhon, Vietnam
- The Graduate University of Science and Technology, Vietnam Academy of Science and Technology, Ho Chi Minh City, Vietnam
| | - V. Q. Nguyen
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, IN2P3-CNRS, Palaiseau, France
| | - K. Niewczas
- Faculty of Physics and Astronomy, Wroclaw University, Wrocław, Poland
| | - S. Nishimori
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
| | - Y. Nishimura
- Department of Physics, Keio University, Yokohama, Kanagawa Japan
| | - K. Nishizaki
- Department of Physics, Osaka Metropolitan University, Osaka, Japan
| | - T. Nosek
- National Centre for Nuclear Research, Warsaw, Poland
| | - F. Nova
- Rutherford Appleton Laboratory, STFC, Harwell, Oxford, UK
| | - P. Novella
- IFIC (CSIC and University of Valencia), Valencia, Spain
| | - J. C. Nugent
- Department of Physics, Faculty of Science, Tohoku University, Sendai, Miyagi Japan
| | | | - L. O’Sullivan
- Institut für Physik, Johannes Gutenberg-Universität Mainz, Staudingerweg 7, 55128 Mainz, Germany
| | - T. Odagawa
- Department of Physics, Kyoto University, Kyoto, Japan
| | - T. Ogawa
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
| | - R. Okada
- Department of Physics, Okayama University, Okayama, Japan
| | - W. Okinaga
- Department of Physics, University of Tokyo, Tokyo, Japan
| | - K. Okumura
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Japan
| | - T. Okusawa
- Department of Physics, Osaka Metropolitan University, Osaka, Japan
| | - N. Ospina
- Department of Theoretical Physics, University Autonoma Madrid, 28049 Madrid, Spain
| | - R. A. Owen
- School of Physics and Astronomy, Queen Mary University of London, London, UK
| | - Y. Oyama
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- J-PARC, Tokai, Japan
| | - V. Palladino
- Dipartimento di Fisica, INFN Sezione di Napoli and Università di Napoli, Naples, Italy
| | - V. Paolone
- Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, PA USA
| | - M. Pari
- Dipartimento di Fisica, INFN Sezione di Padova and Università di Padova, Padua, Italy
| | - J. Parlone
- Department of Physics, University of Liverpool, Liverpool, UK
| | - S. Parsa
- Section de Physique, DPNC, University of Geneva, Geneva, Switzerland
| | - J. Pasternak
- Department of Physics, Imperial College London, London, UK
| | | | - D. Payne
- Department of Physics, University of Liverpool, Liverpool, UK
| | - G. C. Penn
- Department of Physics, University of Liverpool, Liverpool, UK
| | - D. Pershey
- Department of Physics, Duke University, Durham, NC USA
| | - L. Pickering
- Department of Physics, Royal Holloway University of London, Egham, Surrey UK
| | - C. Pidcott
- Department of Physics and Astronomy, University of Sheffield, Sheffield, UK
| | - G. Pintaudi
- Department of Physics, Yokohama National University, Yokohama, Japan
| | - C. Pistillo
- Laboratory for High Energy Physics (LHEP), Albert Einstein Center for Fundamental Physics, University of Bern, Bern, Switzerland
| | - B. Popov
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Paris, France
- JINR, Dubna, Russia
| | - K. Porwit
- Institute of Physics, University of Silesia, Katowice, Poland
| | | | - Y. S. Prabhu
- National Centre for Nuclear Research, Warsaw, Poland
| | - F. Pupilli
- Dipartimento di Fisica, INFN Sezione di Padova and Università di Padova, Padua, Italy
| | - B. Quilain
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, IN2P3-CNRS, Palaiseau, France
| | - T. Radermacher
- III. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
| | - E. Radicioni
- Dipartimento Interuniversitario di Fisica, INFN Sezione di Bari and Università e Politecnico di Bari, Bari, Italy
| | - B. Radics
- Department of Physics and Astronomy, York University, Toronto, ON Canada
| | - M. A. Ramírez
- Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, PA 19104 USA
| | - P. N. Ratoff
- Physics Department, Lancaster University, Lancaster, UK
| | - M. Reh
- Department of Physics, University of Colorado at Boulder, Boulder, CO USA
| | - C. Riccio
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, NY USA
| | - E. Rondio
- National Centre for Nuclear Research, Warsaw, Poland
| | - S. Roth
- III. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
| | - N. Roy
- Department of Physics and Astronomy, York University, Toronto, ON Canada
| | - A. Rubbia
- Institute for Particle Physics and Astrophysics, ETH Zurich, Zurich, Switzerland
| | - A. C. Ruggeri
- Dipartimento di Fisica, INFN Sezione di Napoli and Università di Napoli, Naples, Italy
| | - C. A. Ruggles
- School of Physics and Astronomy, University of Glasgow, Glasgow, UK
| | - A. Rychter
- Institute of Radioelectronics and Multimedia Technology, Warsaw University of Technology, Warsaw, Poland
| | - K. Sakashita
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- J-PARC, Tokai, Japan
| | - F. Sánchez
- Section de Physique, DPNC, University of Geneva, Geneva, Switzerland
| | - G. Santucci
- Department of Physics and Astronomy, York University, Toronto, ON Canada
| | - C. M. Schloesser
- Section de Physique, DPNC, University of Geneva, Geneva, Switzerland
| | - K. Scholberg
- Department of Physics, Duke University, Durham, NC USA
- Kavli IPMU (WPI), The University of Tokyo, Tokyo, Japan
| | - M. Scott
- Department of Physics, Imperial College London, London, UK
| | - Y. Seiya
- Department of Physics, Osaka Metropolitan University, Osaka, Japan
- Science Department, BMCC/CUNY, New York, NY USA
| | - T. Sekiguchi
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- J-PARC, Tokai, Japan
| | - H. Sekiya
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
- Kavli IPMU (WPI), The University of Tokyo, Tokyo, Japan
| | - D. Sgalaberna
- Institute for Particle Physics and Astrophysics, ETH Zurich, Zurich, Switzerland
| | - A. Shaikhiev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - F. Shaker
- Department of Physics and Astronomy, York University, Toronto, ON Canada
| | - A. Shaykina
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M. Shiozawa
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
| | - W. Shorrock
- Department of Physics, Imperial College London, London, UK
| | - A. Shvartsman
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - N. Skrobova
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | | | - D. Smyczek
- III. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
| | - M. Smy
- Department of Physics and Astronomy, University of California, Irvine, Irvine, CA USA
| | - J. T. Sobczyk
- Faculty of Physics and Astronomy, Wroclaw University, Wrocław, Poland
| | - H. Sobel
- Department of Physics and Astronomy, University of California, Irvine, Irvine, CA USA
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
| | - F. J. P. Soler
- School of Physics and Astronomy, University of Glasgow, Glasgow, UK
| | - Y. Sonoda
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
| | - A. J. Speers
- Physics Department, Lancaster University, Lancaster, UK
| | - R. Spina
- Dipartimento Interuniversitario di Fisica, INFN Sezione di Bari and Università e Politecnico di Bari, Bari, Italy
| | - I. A. Suslov
- Joint Institute for Nuclear Research, Dubna, Moscow Region Russia
| | - S. Suvorov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | | | - S. Y. Suzuki
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- J-PARC, Tokai, Japan
| | - Y. Suzuki
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
| | - A. A. Sztuc
- Department of Physics, Imperial College London, London, UK
| | - M. Tada
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- J-PARC, Tokai, Japan
| | - S. Tairafune
- Department of Physics, Faculty of Science, Tohoku University, Sendai, Miyagi Japan
| | - S. Takayasu
- Department of Physics, Osaka Metropolitan University, Osaka, Japan
| | - A. Takeda
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
| | - Y. Takeuchi
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
- Kobe University, Kobe, Japan
| | - K. Takifuji
- Department of Physics, Faculty of Science, Tohoku University, Sendai, Miyagi Japan
| | - H. K. Tanaka
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
- Kavli IPMU (WPI), The University of Tokyo, Tokyo, Japan
| | - Y. Tanihara
- Department of Physics, Yokohama National University, Yokohama, Japan
| | - M. Tani
- Department of Physics, Kyoto University, Kyoto, Japan
| | - A. Teklu
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, NY USA
| | | | - N. Teshima
- Department of Physics, Osaka Metropolitan University, Osaka, Japan
| | - N. Thamm
- III. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
| | - L. F. Thompson
- Department of Physics and Astronomy, University of Sheffield, Sheffield, UK
| | - W. Toki
- Department of Physics, Colorado State University, Fort Collins, Colorado USA
| | - C. Touramanis
- Department of Physics, University of Liverpool, Liverpool, UK
| | - T. Towstego
- Department of Physics, University of Toronto, Toronto, ON Canada
| | - K. M. Tsui
- Department of Physics, University of Liverpool, Liverpool, UK
| | - T. Tsukamoto
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- J-PARC, Tokai, Japan
| | - M. Tzanov
- Department of Physics and Astronomy, Louisiana State University, Baton Rouge, LA USA
| | - Y. Uchida
- Department of Physics, Imperial College London, London, UK
| | - M. Vagins
- Department of Physics and Astronomy, University of California, Irvine, Irvine, CA USA
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
| | - D. Vargas
- Institut de Fisica d’Altes Energies (IFAE)-The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra, Barcelona Spain
| | - M. Varghese
- Institut de Fisica d’Altes Energies (IFAE)-The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra, Barcelona Spain
| | - G. Vasseur
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - C. Vilela
- CERN European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
| | - E. Villa
- CERN European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
- Section de Physique, DPNC, University of Geneva, Geneva, Switzerland
| | | | - U. Virginet
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | | | - T. Wachala
- H. Niewodniczanski Institute of Nuclear Physics PAN, Cracow, Poland
| | - J. G. Walsh
- Department of Physics and Astronomy, Michigan State University, East Lansing, MI USA
| | - Y. Wang
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, NY USA
| | - L. Wan
- Department of Physics, Boston University, Boston, MA USA
| | - D. Wark
- Department of Physics, Oxford University, Oxford, UK
- Rutherford Appleton Laboratory, STFC, Harwell, Oxford, UK
| | - M. O. Wascko
- Department of Physics, Imperial College London, London, UK
| | - A. Weber
- Institut für Physik, Johannes Gutenberg-Universität Mainz, Staudingerweg 7, 55128 Mainz, Germany
| | - R. Wendell
- Department of Physics, Kyoto University, Kyoto, Japan
- Kavli IPMU (WPI), The University of Tokyo, Tokyo, Japan
| | - M. J. Wilking
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, NY USA
| | - C. Wilkinson
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - J. R. Wilson
- Department of Physics, King’s College London, Strand, London, WC2R 2LS UK
| | - K. Wood
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - C. Wret
- Department of Physics, Oxford University, Oxford, UK
| | - J. Xia
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
| | - Y.-H. Xu
- Physics Department, Lancaster University, Lancaster, UK
| | - K. Yamamoto
- Department of Physics, Osaka Metropolitan University, Osaka, Japan
- Nambu Yoichiro Institute of Theoretical and Experimental Physics (NITEP), Osaka, Japan
| | - T. Yamamoto
- Department of Physics, Osaka Metropolitan University, Osaka, Japan
| | - C. Yanagisawa
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, NY USA
- Science Department, BMCC/CUNY, New York, NY USA
| | - G. Yang
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, NY USA
| | - T. Yano
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
| | - K. Yasutome
- Department of Physics, Kyoto University, Kyoto, Japan
| | - N. Yershov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - U. Yevarouskaya
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - M. Yokoyama
- Department of Physics, University of Tokyo, Tokyo, Japan
- Kavli IPMU (WPI), The University of Tokyo, Tokyo, Japan
| | - Y. Yoshimoto
- Department of Physics, University of Tokyo, Tokyo, Japan
| | - N. Yoshimura
- Department of Physics, Kyoto University, Kyoto, Japan
| | - M. Yu
- Department of Physics, Yokohama National University, Yokohama, Japan
| | - R. Zaki
- Department of Physics and Astronomy, York University, Toronto, ON Canada
| | - A. Zalewska
- H. Niewodniczanski Institute of Nuclear Physics PAN, Cracow, Poland
| | - J. Zalipska
- National Centre for Nuclear Research, Warsaw, Poland
| | - K. Zaremba
- Institute of Radioelectronics and Multimedia Technology, Warsaw University of Technology, Warsaw, Poland
| | - G. Zarnecki
- H. Niewodniczanski Institute of Nuclear Physics PAN, Cracow, Poland
| | - X. Zhao
- Institute for Particle Physics and Astrophysics, ETH Zurich, Zurich, Switzerland
| | - T. Zhu
- Department of Physics, Imperial College London, London, UK
| | - M. Ziembicki
- Institute of Radioelectronics and Multimedia Technology, Warsaw University of Technology, Warsaw, Poland
| | - E. D. Zimmerman
- Department of Physics, University of Colorado at Boulder, Boulder, CO USA
| | - M. Zito
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Paris, France
| | - S. Zsoldos
- Department of Physics, King’s College London, Strand, London, WC2R 2LS UK
| | - T2K Collaboration
- Department of Theoretical Physics, University Autonoma Madrid, 28049 Madrid, Spain
- Laboratory for High Energy Physics (LHEP), Albert Einstein Center for Fundamental Physics, University of Bern, Bern, Switzerland
- Department of Physics, Boston University, Boston, MA USA
- Department of Physics and Astronomy, University of California, Irvine, Irvine, CA USA
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
- Department of Physics, University of Colorado at Boulder, Boulder, CO USA
- Department of Physics, Colorado State University, Fort Collins, Colorado USA
- Department of Physics, Duke University, Durham, NC USA
- Department of Atomic Physics, Eötvös Loránd University, Budapest, Hungary
- Institute for Particle Physics and Astrophysics, ETH Zurich, Zurich, Switzerland
- CERN European Organization for Nuclear Research, 1211 Geneva 23, Switzerland
- Section de Physique, DPNC, University of Geneva, Geneva, Switzerland
- School of Physics and Astronomy, University of Glasgow, Glasgow, UK
- H. Niewodniczanski Institute of Nuclear Physics PAN, Cracow, Poland
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki Japan
- Department of Physics, University of Houston, Houston, TX USA
- Institut de Fisica d’Altes Energies (IFAE)-The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra, Barcelona Spain
- Institut für Physik, Johannes Gutenberg-Universität Mainz, Staudingerweg 7, 55128 Mainz, Germany
- IFIC (CSIC and University of Valencia), Valencia, Spain
- Institute For Interdisciplinary Research in Science and Education (IFIRSE), ICISE, Quy Nhon, Vietnam
- Department of Physics, Imperial College London, London, UK
- Dipartimento Interuniversitario di Fisica, INFN Sezione di Bari and Università e Politecnico di Bari, Bari, Italy
- Dipartimento di Fisica, INFN Sezione di Napoli and Università di Napoli, Naples, Italy
- Dipartimento di Fisica, INFN Sezione di Padova and Università di Padova, Padua, Italy
- INFN Sezione di Roma and Università di Roma “La Sapienza”, Rome, Italy
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
- International Centre of Physics, Institute of Physics (IOP), Vietnam Academy of Science and Technology (VAST), 10 Dao Tan, Ba Dinh, Hanoi, Vietnam
- ILANCE, CNRS-University of Tokyo International Research Laboratory, Kashiwa, Chiba 277-8582 Japan
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba Japan
- Department of Physics, Keio University, Yokohama, Kanagawa Japan
- Department of Physics, King’s College London, Strand, London, WC2R 2LS UK
- Kobe University, Kobe, Japan
- Department of Physics, Kyoto University, Kyoto, Japan
- Physics Department, Lancaster University, Lancaster, UK
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, IN2P3-CNRS, Palaiseau, France
- Department of Physics, University of Liverpool, Liverpool, UK
- Department of Physics and Astronomy, Louisiana State University, Baton Rouge, LA USA
- Joint Institute for Nuclear Research, Dubna, Moscow Region Russia
- Department of Physics and Astronomy, Michigan State University, East Lansing, MI USA
- Department of Physics, Miyagi University of Education, Sendai, Japan
- National Centre for Nuclear Research, Warsaw, Poland
- Department of Physics and Astronomy, State University of New York at Stony Brook, Stony Brook, NY USA
- Department of Physics, Okayama University, Okayama, Japan
- Department of Physics, Osaka Metropolitan University, Osaka, Japan
- Department of Physics, Oxford University, Oxford, UK
- Department of Physics and Astronomy, University of Pennsylvania, Philadelphia, PA 19104 USA
- Department of Physics and Astronomy, University of Pittsburgh, Pittsburgh, PA USA
- School of Physics and Astronomy, Queen Mary University of London, London, UK
- Department of Physics, University of Regina, Regina, Saskatchewan Canada
- Department of Physics and Astronomy, University of Rochester, Rochester, NY USA
- Department of Physics, Royal Holloway University of London, Egham, Surrey UK
- III. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
- Departamento de Física Atómica, Molecular y Nuclear, Universidad de Sevilla, 41080 Sevilla, Spain
- Department of Physics and Astronomy, University of Sheffield, Sheffield, UK
- Institute of Physics, University of Silesia, Katowice, Poland
- Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Paris, France
- Rutherford Appleton Laboratory, STFC, Harwell, Oxford, UK
- Department of Physics, University of Tokyo, Tokyo, Japan
- Kamioka Observatory, Institute for Cosmic Ray Research, University of Tokyo, Kamioka, Japan
- Research Center for Cosmic Neutrinos, Institute for Cosmic Ray Research, University of Tokyo, Kashiwa, Japan
- Department of Physics, Tokyo Institute of Technology, Tokyo, Japan
- Department of Physics, Tokyo Metropolitan University, Tokyo, Japan
- Department of Physics, Faculty of Science and Technology, Tokyo University of Science, Noda, Chiba Japan
- Department of Physics, University of Toronto, Toronto, ON Canada
- TRIUMF, Vancouver, BC Canada
- Faculty of Physics, University of Warsaw, Warsaw, Poland
- Institute of Radioelectronics and Multimedia Technology, Warsaw University of Technology, Warsaw, Poland
- Department of Physics, Faculty of Science, Tohoku University, Sendai, Miyagi Japan
- Department of Physics, University of Warwick, Coventry, UK
- Department of Physics, University of Winnipeg, Winnipeg, MB Canada
- Faculty of Physics and Astronomy, Wroclaw University, Wrocław, Poland
- Department of Physics, Yokohama National University, Yokohama, Japan
- Department of Physics and Astronomy, York University, Toronto, ON Canada
- Université Paris-Saclay, Gif-sur-Yvette, France
- INFN-Laboratori Nazionali di Legnaro, Legnaro, Italy
- J-PARC, Tokai, Japan
- Kavli IPMU (WPI), The University of Tokyo, Tokyo, Japan
- Moscow Institute of Physics and Technology (MIPT), Moscow Region, Russia and National Research Nuclear University “MEPhI”, Moscow, Russia
- IPSA-DRII, Ivry-sur-Seine, France
- The Graduate University of Science and Technology, Vietnam Academy of Science and Technology, Ho Chi Minh City, Vietnam
- JINR, Dubna, Russia
- Nambu Yoichiro Institute of Theoretical and Experimental Physics (NITEP), Osaka, Japan
- Science Department, BMCC/CUNY, New York, NY USA
| |
Collapse
|
8
|
Ishiguro N, Matsui H, Wakamatsu K, Suzuki Y, Sekizawa O, Nitta K, Terada Y, Uruga T, Tada M. Oxidation and phase transfer of individual Cr-doped dendritic FeO x particles visualized by full-field nano-XAFS spectroimaging. Phys Chem Chem Phys 2023. [PMID: 37345959 DOI: 10.1039/d3cp00907f] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/23/2023]
Abstract
Iron oxides with various compositions and polymorphs have been widely used as compounds that require reversible redox properties, such as catalysts. However, partial decomposition during phase transitions often causes irreversible degradation of the redox properties of iron oxides. Cr doping into the crystalline framework of iron oxide dendrites improves the stability of the structural transformation of iron oxides. We spatially visualized the FeOx-dendrite phase distribution during oxidation in crystalline dendritic FeOx and Cr-FeOx particles by full-field nano-X-ray absorption fine structure spectroimaging. The spectroimaging visualized propagation in the phase transitions in the individual FeOx particles and changes in the phase transition behaviors of the Cr-FeOx particles. The statistical analysis of the spectroimaging data revealed the phase transition trends in parts of the FeOx and Cr-FeOx particles in three Fe density zones (particle thicknesses) and the probability densities of the phase proportions in the dendrites.
Collapse
Affiliation(s)
- Nozomu Ishiguro
- Element Visualization Team, Materials Visualization Photon Science Group, RIKEN SPring-8 Center, 1-1-1 Kouto, Sayo, Hyogo 679-5148, Japan
- International Center for Synchrotron Radiation Innovation Smart (SRIS)/Institute of Multidisciplinary Research for Advanced Materials (IMRAM), Tohoku University, Katahira 2-1-1, Aoba-ku, Sendai 980-8577, Japan.
- Department of Chemistry, Graduate School of Science/Research Center for Materials Science (RCMS)/Integrated Research Consortium on Chemical Sciences (IRCCS)/Institute for Advanced Study, Nagoya University, Furuuchi, Chikusa-ku, Nagoya, Aichi 464-8602, Japan.
| | - Hirosuke Matsui
- Department of Chemistry, Graduate School of Science/Research Center for Materials Science (RCMS)/Integrated Research Consortium on Chemical Sciences (IRCCS)/Institute for Advanced Study, Nagoya University, Furuuchi, Chikusa-ku, Nagoya, Aichi 464-8602, Japan.
| | - Kohei Wakamatsu
- Department of Chemistry, Graduate School of Science/Research Center for Materials Science (RCMS)/Integrated Research Consortium on Chemical Sciences (IRCCS)/Institute for Advanced Study, Nagoya University, Furuuchi, Chikusa-ku, Nagoya, Aichi 464-8602, Japan.
| | - Yoya Suzuki
- Department of Chemistry, Graduate School of Science/Research Center for Materials Science (RCMS)/Integrated Research Consortium on Chemical Sciences (IRCCS)/Institute for Advanced Study, Nagoya University, Furuuchi, Chikusa-ku, Nagoya, Aichi 464-8602, Japan.
| | - Oki Sekizawa
- Japan Synchrotron Radiation Research Institute, SPring-8, 1-1-1 Kouto, Sayo, Hyogo 679-5198, Japan
| | - Kiyofumi Nitta
- Japan Synchrotron Radiation Research Institute, SPring-8, 1-1-1 Kouto, Sayo, Hyogo 679-5198, Japan
| | - Yasuko Terada
- Japan Synchrotron Radiation Research Institute, SPring-8, 1-1-1 Kouto, Sayo, Hyogo 679-5198, Japan
| | - Tomoya Uruga
- Japan Synchrotron Radiation Research Institute, SPring-8, 1-1-1 Kouto, Sayo, Hyogo 679-5198, Japan
| | - Mizuki Tada
- Element Visualization Team, Materials Visualization Photon Science Group, RIKEN SPring-8 Center, 1-1-1 Kouto, Sayo, Hyogo 679-5148, Japan
- Department of Chemistry, Graduate School of Science/Research Center for Materials Science (RCMS)/Integrated Research Consortium on Chemical Sciences (IRCCS)/Institute for Advanced Study, Nagoya University, Furuuchi, Chikusa-ku, Nagoya, Aichi 464-8602, Japan.
| |
Collapse
|
9
|
Inagaki M, Abe N, Li Z, Nakashima Y, Acharyya S, Ogawa K, Kawaguchi D, Hiraoka H, Banno A, Meng Z, Tada M, Ishida T, Lyu P, Kokubo K, Murase H, Hashiya F, Kimura Y, Uchida S, Abe H. Cap analogs with a hydrophobic photocleavable tag enable facile purification of fully capped mRNA with various cap structures. Nat Commun 2023; 14:2657. [PMID: 37169757 PMCID: PMC10175277 DOI: 10.1038/s41467-023-38244-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2022] [Accepted: 04/21/2023] [Indexed: 05/13/2023] Open
Abstract
Starting with the clinical application of two vaccines in 2020, mRNA therapeutics are currently being investigated for a variety of applications. Removing immunogenic uncapped mRNA from transcribed mRNA is critical in mRNA research and clinical applications. Commonly used capping methods provide maximum capping efficiency of around 80-90% for widely used Cap-0- and Cap-1-type mRNAs. However, uncapped and capped mRNA possesses almost identical physicochemical properties, posing challenges to their physical separation. In this work, we develop hydrophobic photocaged tag-modified cap analogs, which separate capped mRNA from uncapped mRNA by reversed-phase high-performance liquid chromatography. Subsequent photo-irradiation recovers footprint-free native capped mRNA. This approach provides 100% capping efficiency even in Cap-2-type mRNA with versatility applicable to 650 nt and 4,247 nt mRNA. We find that the Cap-2-type mRNA shows up to 3- to 4-fold higher translation activity in cultured cells and animals than the Cap-1-type mRNA prepared by the standard capping method.
Collapse
Affiliation(s)
- Masahito Inagaki
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, 464-8602, Japan
| | - Naoko Abe
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, 464-8602, Japan
| | - Zhenmin Li
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, 464-8602, Japan
| | - Yuko Nakashima
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, 464-8602, Japan
- Research Center for Materials Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, 464-8602, Japan
| | - Susit Acharyya
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, 464-8602, Japan
| | - Kazuya Ogawa
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, 464-8602, Japan
| | - Daisuke Kawaguchi
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, 464-8602, Japan
| | - Haruka Hiraoka
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, 464-8602, Japan
| | - Ayaka Banno
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, 464-8602, Japan
| | - Zheyu Meng
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, 464-8602, Japan
| | - Mizuki Tada
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, 464-8602, Japan
| | - Tatsuma Ishida
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, 464-8602, Japan
| | - Pingxue Lyu
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, 464-8602, Japan
| | - Kengo Kokubo
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, 464-8602, Japan
| | - Hirotaka Murase
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, 464-8602, Japan
| | - Fumitaka Hashiya
- Research Center for Materials Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, 464-8602, Japan
| | - Yasuaki Kimura
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, 464-8602, Japan
| | - Satoshi Uchida
- Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 1-5 Shimogamohangi-cho, Sakyo-ku, Kyoto, 606-0823, Japan
- Innovation Center of NanoMedicine (iCONM), Kawasaki Institute of Industrial Promotion, 3-25-14 Tonomachi, Kawasaki-ku, Kawasaki, 210-0821, Japan
- Medical Research Institute, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan
| | - Hiroshi Abe
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, 464-8602, Japan.
- Research Center for Materials Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, 464-8602, Japan.
- CREST, Japan Science and Technology Agency, 7, Gobancho, Chiyoda-ku, Tokyo, 102-0076, Japan.
- Institute for Glyco-core Research (iGCORE), Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, 464-8601, Japan.
| |
Collapse
|
10
|
Ikemoto S, Muratsugu S, Koitaya T, Tsuji Y, Das M, Yoshizawa K, Glorius F, Tada M. Coordination-Induced Trigger for Activity: N-Heterocyclic Carbene-Decorated Ceria Catalysts Incorporating Cr and Rh with Activity Induction by Surface Adsorption Site Control. J Am Chem Soc 2023; 145:1497-1504. [PMID: 36511728 DOI: 10.1021/jacs.2c07290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
A coordination-induced trigger for catalytic activity is proposed on an N-heterocyclic carbene (NHC)-decorated ceria catalyst incorporating Cr and Rh (ICy-r-Cr0.19Rh0.06CeOz). ICy-r-Cr0.19Rh0.06CeOz was prepared by grafting 1,3-dicyclohexylimidazol-2-ylidene (ICy) onto H2-reduced Cr0.19Rh0.06CeOz (r-Cr0.19Rh0.06CeOz) surfaces, which went on to exhibit substantial catalytic activity for the 1,4-arylation of cyclohexenone with phenylboronic acid, whereas r-Cr0.19Rh0.06CeOz without ICy was inactive. FT-IR, Rh K-edge XAFS, XPS, and photoluminescence spectroscopy showed that the ICy carbene-coordinated Rh nanoclusters were the key active species. The coordination-induced trigger for catalytic activity on the ICy-bearing Rh nanoclusters could not be attributed to electronic donation from ICy to the Rh nanoclusters. DFT calculations suggested that ICy controlled the adsorption sites of the phenyl group on the Rh nanocluster to promote the C-C bond formation of the phenyl group and cyclohexenone.
Collapse
Affiliation(s)
- Satoru Ikemoto
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - Satoshi Muratsugu
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - Takanori Koitaya
- Department of Materials Molecular Science, Institute for Molecular Science, Myodaiji-cho, Okazaki, Aichi 444-8585, Japan
| | - Yuta Tsuji
- Institute for Materials Chemistry and Engineering and International Research Center for Molecular Systems, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan.,Faculty of Engineering Sciences, Kyushu University, 6-1 Kasuga-koen, Kasuga, Fukuoka 816-8580, Japan
| | - Mowpriya Das
- Westfälische Wilhelms-Universität Münster, Organisch-Chemisches Institut, Corrensstrasse 40, 48149 Münster, Germany
| | - Kazunari Yoshizawa
- Institute for Materials Chemistry and Engineering and International Research Center for Molecular Systems, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka 819-0395, Japan
| | - Frank Glorius
- Westfälische Wilhelms-Universität Münster, Organisch-Chemisches Institut, Corrensstrasse 40, 48149 Münster, Germany
| | - Mizuki Tada
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan.,Research Center for Materials Science (RCMS), Integrated Research Consortium on Chemical Sciences (IRCCS), and Institute for Advanced Study, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| |
Collapse
|
11
|
Tanifuji K, Sakai Y, Matsuoka Y, Tada M, Sameera WMC, Ohki Y. CO Binding onto Heterometals of [Mo 3S 4M] (M = Fe, Co, Ni) Cubes. BCSJ 2022. [DOI: 10.1246/bcsj.20220143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Kazuki Tanifuji
- Institute for Chemical Research, Kyoto-University, Gokasho, Uji 611-0011, Japan
| | - Yuta Sakai
- Institute for Chemical Research, Kyoto-University, Gokasho, Uji 611-0011, Japan
- Department of Chemistry, Graduate School of Science and Research Center for Materials Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8602, Japan
| | - Yuto Matsuoka
- Institute for Chemical Research, Kyoto-University, Gokasho, Uji 611-0011, Japan
| | - Mizuki Tada
- Department of Chemistry, Graduate School of Science and Research Center for Materials Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8602, Japan
| | - W. M. C. Sameera
- Institute for Low Temperature Science, Hokkaido University, Sapporo 060-0819, Japan
- Department of Chemistry, University of Colombo, Colombo 00300, Sri Lanka
| | - Yasuhiro Ohki
- Institute for Chemical Research, Kyoto-University, Gokasho, Uji 611-0011, Japan
| |
Collapse
|
12
|
Anno S, Okano T, Mandai K, Orita K, Yamada Y, Mamoto K, Iida T, Tada M, Inui K, Koike T, Nakamura H. POS0681 DRUG RETENTION RATE AND EFFECTIVENESS OF JAK INHIBITOR IN PATIENTS WITH DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1746] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundRecently, the disease activity of rheumatoid arthritis (RA) was improved due to the ‘treat-to-target’ strategy. However, some patients remain various symptoms despite recommended treatment was performed. Then, the term of ‘difficult-to-treat RA (D2TRA)’ is widely recognized. Janus kinase inhibitor (JAKi) might be effective for D2TRA patients, because JAKi can simultaneously block the function of multiple cytokines.ObjectivesThe aim of this study was to evaluate drug retention rate and effectiveness of JAKi in patients with D2TRA.MethodsThis study included 220 RA patients (tofacitinib 101, baricitinib 83, upadacitinib 20, peficitinib 14, filgotinib 2) treated with JAKi. Sixty-two patients were treated as first line bDMARDs/JAKi (1st group), 57 patients were treated as second line bDMARDs/ JAKi (2nd group), 101 patients were treated as third and more bDMARDs/ JAKi. In these 101 patients, 25 patients did not met D2TRA criteria (non-D2TRA group) and 76 patients met D2TRA criteria (D2TRA group). Drug retention rate and effectiveness of JAKi were evaluated during 24 weeks in each group.ResultsUsage rate of methotrexate was lower and dosage of glucocorticoid was higher in D2TRA group than in other groups (Table 1). Drug retention rate at 24 weeks was 87.1% (54/62) in 1st group, 80.1% (46/57) in 2nd group, 88% (22/25) in non-D2TRA group, 61.8% (47/76) in D2TRA group. Drug retention rate was lower in D2TRA group compared to 1st group, 2nd group and non-DT2RA group (p<0.01, p=0.03, p=0.01). DAS28-CRP was 4.4, 4.0, 3.9, 4.4 at baseline, 3.0, 3.0, 3.3, 3.5 at 4 weeks, 2.5, 2.9, 2.7, 3.3 at 12 weeks, 2.5, 3.0, 2.9, 3.2 at 24 weeks in 1st group, 2nd group, non-D2TRA group and D2TRA group, respectively. Improvement ratio of DAS28-CRP was 32.9, 27.6, 20.4, 19.3 % at 4 weeks, 40.8, 26.5, 28.1, 19.5 % at 12 weeks, 40.8, 24.6, 18.7, 24.7 % at 24 weeks. DAS28-CRP was improved in all groups. Altough 1st group showed higher improvement ratio of DAS28-CRP at 24 weeks compared to 2nd group, non-DT2RA group and D2TRA group (p<0.01, p<0.01, p<0.01), there was no differences between DT2RA group and 2nd group or non-D2TRA group (p=0.95, p=0.48). SDAI was 22.9, 19.9, 18.3, 23.9 at baseline, 11.8, 11.9, 13.3, 14.4 at 4 weeks, 7.9, 11.3, 8.4, 13.3 at 12 weeks, 8.5, 11.5, 9.7, 12.6 at 24 weeks. CDAI was 21.3, 18.8, 17.6, 21.8 at baseline, 11.3, 11.2, 12.5, 13.9 at 4 weeks, 7.5, 10.9, 8.0, 12.3 at 12 weeks, 8.1, 10.7, 8.6, 12.1 at 24 weeks. HAQ was 1.15, 0.99, 0.89, 1.39 at baseline, 0.84, 0.76, 0.93, 1.22 at 4 weeks, 0.79, 0.84, 0.77, 1.17 at 12 weeks, 0.76, 0.79, 0.76, 1.14 at 24 weeks. Improvement rate of HAQ at 24 weeks were 44.3%, 23.9%, 21.2%, 8.1%.Table 1.Baseline characteristics of RA patients1st group (n=62)2nd group (n=57)non-D2TRA group (n=25)D2TRA group (n=76)Age (years)64.9 ± 14.866.1 ± 11.564.6 ± 16.163.0 ± 15.0Female (%)75.879.096.080.3Disease durations (years)10.4 ± 11.717.6 ± 17.622.6 ± 22.416.3 ± 15.7RF (IU/ml)296.3 ± 1153.8314.9 ± 1037.7262.4 ± 375.9305.9 ± 819.6RF positive ratio (%)81.878.479.275.7Anti CCP antibody (U/ml)221.8 ± 327.2157.8 ± 258.795.9 ± 101.6191.8 ± 250.6Anti CCP antibody positive ratio (%)79.679.672.283.3CRP (U/ml)1.5 ± 2.11.1 ± 2.01.6 ± 1.61.8 ± 2.9MMP-3 (ng/ml)185.7 ± 167.6146.7 ± 122.1190.1 ± 152.6268.0 ± 451.2DAS28-CRP4.3 ± 1.24.1 ± 1.33.9 ± 1.44.4 ± 1.3SDAI21.8 ± 12.221.7 ± 13.118.4 ± 13.023.9 ± 12.8CDAI20.3 ± 11.320.7 ± 12.717.6 ± 12.822.1 ± 12.2HAQ1.1 ± 0.81.2 ± 1.00.9 ± 0.81.4 ± 1.1MTX use (%)69.463.25647.4MTX (mg/day)10.7 ± 3.410.4 ± 3.58.8 ± 3.59.0 ± 4.3Glucocorticoid use (%)29.136.81646.1Glucocorticoid dose (mg/day)3.3 ± 2.13.0 ± 1.53.5 ± 1.95.1 ± 2.8ConclusionDrug retention rate of JAKi in treatment of D2TRA group were lower than that of 1st group, 2nd group, and non-D2TRA group. Clinical efficacy of JAKi in D2TRA group were not significantly different to 2nd group and non-D2TRA group. However, HAQ improvement was weak in D2TRA group.Disclosure of InterestsNone declared
Collapse
|
13
|
Okano T, Mamoto K, Yamada Y, Mandai K, Anno S, Tada M, Inui K, Koike T, Nakamura H. AB0188 ULTRASONOGRAPHIC RESIDUAL INTRA-ARTICULAR SYNOVITIS IS MORE SEVERE IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH PREDNISOLONE. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundThe treatment option including biological DMARDs (BIO) and JAK inhibitor (JAK) was expanded, and the number of patients reached to the treatment target are increasing in rheumatoid arthritis (RA). On the other hand, it is also true that some patients are still using prednisolone (PSL). Recently, ultrasound has played a role of sensitive imaging modality in the diagnosis and follow-up of patients with RA. It is known that residual synovitis was found in ultrasound even in patients with clinical remission.ObjectivesWe investigated the differences of ultrasonographic intra-articular synovitis findings between treatment drugs in patients with RA.MethodsFrom January 2017 to August 2020, 750 RA patients who underwent ultrasound examination were included. A US examination was performed at the bilateral first to fifth metacarpophalangeal (MCP) joints, first interphalangeal (IP) and second to fifth proximal interphalangeal (PIP) joints, wrist joints (three part of radial, medial and ulnar) and first to fifth metatarsophalangeal (MTP) joints, by using HI VISION Ascendus (Hitachi Medical Corporation, Japan) with a multifrequency linear transducer (18-6 MHz). The gray scale and power Doppler findings were assessed by the semi-quantitative method (0-3). All patients were divided into with or without BIO / JAK, methotrexate (MTX) and PSL. Then, patients were matched using the propensity score adjusted for gender, age, RA disease duration, disease activity, CRP value, and MMP-3 value. The total gray scale and power Doppler score (GSUS / PDUS) were compared between treatment drugs of RA by using propensity score matching methods.ResultsThe average age of 750 RA patients were 64.5 years and an average disease duration of RA was 13.9 years and females were 581 (77.5%). There were 517 patients (68.9%) treated with BIO/JAK and 233 patients treated without BIO/JAK. The 205 patients in each group were matched. GSUS were 10.6±11.1 vs 9.2±10.4 (p=0.218) and PDUS 7.4±9.2 vs 6.5±9.0 (p=0.328). Ultrasound residual synovitis was not different between with or without BIO/JAK in matched patients. There were 525 patients (70.0%) treated MTX, the average MTX dose was 9.3 mg, and 225 patients treated without MTX. The 203 patients with or without MTX in each group were matched. GSUS were 9.7±10.6 vs 11.4±12.0 (p=0.119) and PDUS 6.6±8.8 vs 8.1±10.1 (p=0.117). Ultrasound residual synovitis was not different between with or without MTX in matched patients. There were 111 patients (14.8%) treated PSL, the average dose was 4.0mg, and 639 patients treated without PSL. The 105 patients with or without PSL in each group were matched. GSUS were 15.7±13.9 vs 11.6±10.6 (p=0.018) and PDUS 11.5±11.4 vs 8.1±9.6 (p=0.021). Ultrasound residual synovitis was more severe treated with PSL than without PSL in matched patients.ConclusionIn a comparison between RA patients matched backgrounds such as disease activity, there was no difference in ultrasound residual synovitis between patients with or without BIO/JAK and MTX. However, there was significant difference in patients with or without PSL. This suggests that PSL use suppresses clinical symptoms but does not improve synovitis. Thus, it should be noted that joint destruction may progress in patients treating with PSL.References[1]Grassi W, Okano T, Di Geso L, Filippucci E. Imaging in rheumatoid arthritis: options, uses and optimization. Expert Rev Clin Immunol. 2015;11:1131-46.[2]Nguyen H, Ruyssen-Witrand A, Gandjbakhch F, Constantin A, Foltz V, Cantagrel A. Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: a systematic review and meta-analysis. Rheumatology (Oxford). 2014;53:2110-8.AcknowledgementsWe wish to thank Atsuko Kamiyama, Tomoko Nishimura for clinical assistant, Setsuko Takeda, Emi Yamashita, Yuko Yoshida, Emi Ohtani, Yuka Domae, Asami Yagami, Shingo Washida for their special efforts as a sonographer and collecting data.Disclosure of InterestsTadashi Okano Speakers bureau: Asahi Kasei, Astellas, Abbvie, Amgen, Ayumi, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead Sciences, Janssen, Kyowa Kirin, Mitsubishi Tanabe, Novartis, Ono, Pfizer, Sanofi, Takeda, UCB, Grant/research support from: Asahi Kasei, Abbvie, Chugai, Eisai, Mitsubishi Tanabe, Kenji Mamoto: None declared, Yutaro Yamada: None declared, Koji Mandai: None declared, Shohei Anno: None declared, Masahiro Tada: None declared, Kentaro Inui Speakers bureau: Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma, Janssen Pharmaceutical K.K., Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Abbvie GK, Pfizer Inc., Eisai Co.,Ltd., Chugai Pharmaceutical Co., Ltd., Grant/research support from: Janssen Pharmaceutical K.K., Astellas Pharma Inc., Sanofi K.K., Abbvie GK, Takeda Pharmaceutical Co. Ltd., QOL RD Co. Ltd., Mitsubishi Tanabe Pharma, Ono Pharmaceutical Co. Ltd., Eisai Co.,Ltd.,, Tatsuya Koike Speakers bureau: Takeda Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical, Eisai, Abbott Japan, Teijin Pharma, Banyu Pharmaceutical and Ono Pharmaceutical, Hiroaki Nakamura: None declared
Collapse
|
14
|
Mamoto K, Koike T, Okano T, Sugioka Y, Tada M, Inui K, Nakamura H. AB0229 ACHIEVING GLUCOCORTICOID FREE MIGHT DECREASE RISK FOR CLINICAL FRACTURES IN PATIENTS WITH RHEUMATOID ARTHRITIS - TEN-YEAR FINDINGS FROM THE TOMORROW STUDY. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4682] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundPatients with rheumatoid arthritis (RA) who have muscle weakness and stiff or painful joints might be at increased risk of falls and fractures.ObjectivesThe present study prospectively investigates correlations between decreasing doses of glucocorticoid (GC) and the incidence of clinical fractures in patients with RA based on the ten-year findings of the TOMORROW study (UMIN000003876) that started in 2010.MethodsWe evaluated anthropometric parameters, bone mineral density, disease activity, RA medication, and the incidence of clinical fractures over a period of ten years in 202 patients with RA (mean age, 58.6 years; mean disease duration, 14.0 years). We also investigated the effects of GC doses on the incidence of clinical fractures over the same period in patients with RA using multivariate regression analysis.ResultsThe incidence of clinical fractures for ten years in patients with RA was 0.036/person-year. There were 89 patients (44.1%) treated with GC at least once during ten years. The incidences of clinical fractures in patients with RA treated with and without GC during ten years were 0.052 and 0.026/person-year, respectively. After adjusting for fracture risk factors including age, sex, smoking, and body mass index, cox proportional hazard model revealed that GC dose of ≥ 2 mg/day at baseline was a significant risk factor for clinical fractures (Hazard ratio [HR]:2.430; 95%CI, 1.040-5.675, p=0.040). Although the risk for clinical fractures did not decrease by just reducing the dose of GC (HR:4.505; 95%CI, 0.589-34.457, p=0.147), it was significantly lower if the dose of GC could be reduced to zero during ten years (HR:0.407; 95%CI, 0.194-0.857, p=0.018).ConclusionMedication with even low dose of GC are apparently significantly associated with an increased frequency of clinical fractures among patients with RA. However, if the dose of GC was reduced to free during ten years, the clinical fracture risk could become lower. We concluded that we should decrease the dose of GC to free after controlling disease activity of RA.Disclosure of InterestsNone declared
Collapse
|
15
|
Tada M, Yamada Y, Mandai K, Matsumoto Y, Hidaka N. AB1096 THE INFLUENCE OF THE BEHAVIORAL RESTRICTION OF COVID-19 PANDEMIC FOR THE FRAILTY OF PATIENTS WITH RHEUMATOID ARTHRITIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.907] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundWe previously reported the prevalence of frailty and relation of disease activity at patients with rheumatoid arthritis (RA)1. The behavioral restriction of COVID-19 pandemic influenced for the lifestyle of people included patients with RA.ObjectivesThe relationship between the behavioral restriction of COVID-19 pandemic and frailty was investigated.MethodsWe used the date from prospective observational study (CHIKARA study: UMIN000023744). 70 from 100 patients with RA were followed-up and evaluated the frailty and subcategories (social, physical, mental, nutrition, and cognitive) by frailty checklist. The prevalence of frailty and the change of exercise and daily life activities by visual analog scale were investigated at pre- and post-behavioral restriction. The correlation of frailty and change of amount of exercise and daily life activity examined by univariate analysis.ResultsMean age was 69.7 years (women n=57, men n=13). The prevalence of frailty at post-behavioral restriction increased compared that at pre-behavioral restriction (post:35.8% vs pre:30.0%). Especially, cognitive and total score at post-behavioral restriction increased significantly. The rate of decrease of exercise by <25%, 26~50%, and 51%< were 70%, 21%, and 9%, respectively (mean:20% decrease). Whereas, the rate of decrease of daily life activities by <25%, 26~50%, and 51%< were 37%, 27%, and 36%, respectively (mean:44% decrease). The change of exercise was significantly negatively correlated with the change of nutrition (R=-0.245, P=0.041) at Table 1. There was no correlation between the change of daily life activities and subcategories.Table 1.Univariate analysis of the changes in daily living activities or exercise and those in frailty and subcategoriesChange of daily living activitiesChange of exerciseR valueP valueR valueP valueΔ Social0.0990.417-0.0060.962Δ Physical0.1820.130-0.0050.965Δ Mental-0.2000.097-0.2340.051Δ Nutrition-0.2040.091-0.2450.041Δ Cognitive-0.0870.476-0.0340.778Δ Total-0.0910.454-0.1780.140Δ, change from pre- to post-behavioral restriction.Analyzed by Spearman’s rank correlation coefficientConclusionThe exercise slightly decreased and the daily life activities decreased almost 50% by the behavioral restriction of COVID-19 pandemic. The prevalence of frailty increased 5.8%, and cognitive and total score were significantly high at post-behavioral restriction of COVID-19 pandemic. The decrease of exercise correlated with the worse of nutrition.References[1]Tada M, Yamada Y, Mandai K, Hidaka N. Correlation between frailty and disease activity in patients with rheumatoid arthritis: Data from the CHIKARA study. Geriatr Gerontol Int 2019; 19:1220-5.Disclosure of InterestsNone declared
Collapse
|
16
|
Anno S, Okano T, Mandai K, Orita K, Yamada Y, Mamoto K, Iida T, Tada M, Inui K, Koike T, Nakamura H. POS0290 THE EFFECTS OF TREATMENT RESPONSE AND RISK FACTOR TO INHIBIT THE CLINICAL RESPONSE IN PATIENTS WITH DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS TREATED WITH IL-6 RECEPTOR INHIBITOR, ABATACEPT AND JAK INHIBITOR. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1772] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundRecently, the disease activity of rheumatoid arthritis (RA) was improved due to the ‘treat-to-target’ strategy. However, some patients remain various symptoms despite recommended treatment was performed. Then, the term of ‘difficult-to-treat RA (D2TRA)’ is widely recognized. It is unknown how the difference of type of biological disease-modifying anti rheumatic dugs (bDMARDs)/Janus kinase inhibitor (JAKi) will affect clinical efficacy in patients with D2TRA. Moreover, the risk factor to inhibit the clinical response in patients with D2TRA is unknown.ObjectivesThe aim of this study was to evaluate the treatment response in patients with D2TRA who were treated with interleukin 6 receptor inhibitor (IL-6Ri), abatacept and JAKi.MethodsThis study used the multicenter database included 673 RA patients treated with bDMARDs/JAKi (tocilizumab 240, sarilumab 67, abatacept 146, tofacitinib 101, baricitinib 83, upadacitinib 20, peficitinib 14, filgotinib 2). Two hundred forty-two patients were treated as first line bDMARDs/JAKi (IL-6Ri 117, abatacept 63, JAKi 62), 211 patients were treated as second line bDMARDs/JAKi (IL-6Ri 117, abatacept 37, JAKi 57), 220 patients were treated as third and more bDMARDs/JAKi. In these 220 patients, 82 patients did not meet D2TRA criteria (IL-6Ri 42, abatacept 15, JAKi 25) and 138 patients met D2TRA criteria (IL-6Ri 31, abatacept 31, JAKi 76). In all patients, we analyzed 138 patients with D2TRA (113 female, mean age was 63.1 ± 13.7 years). Drug retention rate and effectiveness of bDMARDs/JAKi in patients with D2TRA were evaluated for 24 weeks. Multivariate linear regression analysis was performed to clarify the risk factors to inhibit the clinical response.ResultsDrug retention rate of patients with D2TRA at 24 weeks was 67.7% in IL-6Ri group, 74.2% in abatacept group, 61.8% in JAKi group. Drug retention rate in patients with D2TRA was not different between groups (IL-6Ri vs abatacept: p=0.86, IL-6Ri vs JAKi group: p=0.39, abatacept vs JAKi group: p=0.33). DAS28-CRP at 4, 12, 24 weeks decreased in all group (Figure 1). Abatacept showed lower improvement ratio of DAS28-CRP at 24 weeks compared to IL-6Ri group (IL-6Ri vs abatacept: p<0.01, IL-6Ri vs JAKi: p=0.1, abatacept vs JAKi: p=0.07). Good responder (defined as decrease in DAS28-CRP score > 1.2 with a score < 3.2) was 52.4% patients in IL-6Ri, 17.4% patients in abatacept, 29.8% patients in JAKi. SDAI and CDAI at 4, 12, 24 weeks decreased in all group (Figure 1). There were no diferences between the groups in improvement ratio of SDAI (IL-6Ri vs abatacept: p=0.11, IL-6Ri vs JAKi: p=0.81, abatacept vs JAKi: p=0.08) and CDAI (IL-6Ri vs abatacept: p=0.31, IL-6Ri vs JAKi: p=0.82, abatacept vs JAKi: p=0.13) at 24 weeks. HAQ was 1.42, 1.15, 1.39 at baseline, 1.27, 1.07, 1.22 at 4 weeks, 1.17, 1.07, 1.17 at 12 weeks, 1.26, 1.06, 1.14 at 24 weeks in IL-6Ri group, abatacept and JAKi, respectively. Multivariate linear regression analysis revealed that high HAQ (β=0.28, p=0.02) and high dosage of glucocorticoid (β=0.67, p<0.01) inhibited the improvement of DAS28-CRP. Type of bDMARDs/JAKi (β=-0.09, p=0.36) did not affect the DAS28-CRP improvement for 24 weeks.Table 1.Multivariate linear regression analysis of risk factor to inhibit the clinical response in patients with D2TRA.β95% CIpAge (years)-0.037-0.025, 0.0170.74male-0.047-0.788, 0.4860.64Disease durations (years)-0.048-0.028, 0.0170.63RF (IU/ml)-0.082-0.0004, 0.00020.41Anti CCP antibody (U/ml)0.111-0.0005, 0.0020.26DAS28-CRP-0.063-0.265, 0.1420.55HAQ0.2790.059, 0.7170.02MTX (mg/day)0.136-0.018, 0.0810.21Glucocorticoid dose (mg/day)0.6690.174, 0.324< 0.01Type of bDMARDs/JAKi-0.088-0.415, 0.1510.36ConclusionDrug retention rate and clinical efficacy of D2TRA patients were not different among IL-6Ri, abatacept and JAKi. DT2RA patient with functional disorder and high dosage of glucocorticoid were risk factor to inhibit the clinical response.Disclosure of InterestsNone declared
Collapse
|
17
|
Tada M, Yamada Y, Mandai K, Matsumoto Y, Hidaka N. OP0133 THE DECREASE OF MUSCLE MASS BY THE BEHAVIORAL RESTRICTION OF COVID-19 PANDEMIC IN PATIENTS WITH RHEUMATOID ARTHRITIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.553] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundWe previously reported the prevalence of sarcopenia and body compositions at patients with rheumatoid arthritis (RA)1. The behavioral restriction of COVID-19 pandemic influenced for the lifestyle of people included patients with RA.ObjectivesThe change of exercise and daily life activity of patients with RA were investigated and body composition and muscle function were compared pre- and post-behavioral restriction.MethodsWe used the date from prospective observational study (CHIKARA study: UMIN000023744). 70 from 100 patients with RA were followed-up and evaluated the change of exercise and daily life activity by visual analog scale. They were measured the muscle mass, fat mass, basal metabolic rate by body composition analyzer and grip strength as muscle function. The relationship between the change of exercise and daily life activity and body composition was investigated by univariate analysis.ResultsMean age was 69.7 years (women n=57, men n=13). The rate of decrease of exercise by <25%, 26~50%, and 51%< were 70%, 21%, and 9%, respectively (mean:20% decrease). Whereas, the rate of decrease of daily life activities by <25%, 26~50%, and 51%< were 37%, 27%, and 36%, respectively (mean:44% decrease). Muscle mass at post-behavioral restriction decrease significantly compared that at pre-behavioral restriction activities (34.0kg vs 34.7kg, P<0.001). Fat mass at post-behavioral restriction increase significantly compared that at pre-behavioral restriction (16.2kg vs 15.5kg, P=0.014). Grip strength at post-behavioral restriction decrease significantly compared that at pre-behavioral restriction (16.2kg vs 17.2kg, P=0.026). The change of exercise was significantly positively correlated with the change of muscle mass and basal metabolic rate (R=0.273, P=0.021 and R=0.256, P=0.033, relatively) at Table 1. Whereas, the change of daily living activities was not significantly correlated with the change of muscle mass and muscle function.Table 1.Univariate analysis of the changes in daily living activities or exercise and those in body composition or muscle functionChange of daily living activitiesChange of exerciseR valueP valueR valueP valueΔ Weight (kg)-0.1230.311-0.1310.279Δ BMI (kg/m2)-0.1080.397-0.1130.345Δ Muscle mass (kg)0.1400.3110.2730.021Δ Fat mass (kg)-0.0610.614-0.0750.539Δ Fat percentage (%)-0.0030.982-0.0180.884Δ Basal metabolic rate (kcal)0.2010.0950.2560.033Δ Grip strength (kg)0.1170.3360.0370.762Δ Walk speed (m/s)0.1690.1610.1390.250Δ, change from pre- to post-behavioral restriction; BMI, body mass indexAnalyzed by Spearman’s rank correlation coefficientConclusionMuscle mass and grip strength decrease and fat mass increase in patients with RA by the behavioral restriction of COVID-19 pandemic. Muscle mass and basal metabolic rate decrease in patients without exercise habits. Maintenance of muscle mass might be important during the COVID-19 pandemic.References[1]Tada, M., Yamada, Y., Mandai, K. & Hidaka, N. Matrix metalloprotease 3 is associated with sarcopenia in rheumatoid arthritis - results from the CHIKARA study. Int J Rheum Dis 21, 1962-1969, doi:10.1111/1756-185X.13335 (2018).Disclosure of InterestsNone declared
Collapse
|
18
|
Mamoto K, Koike T, Okano T, Sugioka Y, Tada M, Inui K, Nakamura H. AB0225 FRAX ASSESSMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS PREDICTED THE REAL INCIDENCE OF CLINICAL FRACTURES FOR 10 YEARS FROM THE RESULTS OF THE 10-YEAR TOMORROW STUDY. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundTo investigate if FRAX in patients with RA can predict the incidence of new clinical fractures for 10 years by using the 10-year data of the TOMORROW study (UMIN000003876) which is a prospective cohort study.ObjectivesTo investigate if FRAX in patients with RA can predict the incidence of new clinical fractures for 10 years by using the 10-year data of the TOMORROW study (UMIN000003876) which is a prospective cohort study.MethodsWe calculated ten-year probability of major osteoporotic fracture (FRAX) in 208 RA patients and 205 sex- and age-matched volunteers (Vo), and compared FRAX with the incidence of clinical fractures for 10 years.ResultsThe mean FRAX were 14.5 and 8.8% in 175 RA patients and 168 Vo, respectively, in whom we could calculate FRAX at baseline and complete to investigate the incidence of clinical fractures for 10 years from baseline. The mean FRAX in RA patients was significantly higher than that in Vo (P<0.001). The actual incidence of clinical fractures for 10 years in RA patients was significantly higher than that in Vo (33.9 vs 22.9%, P=0.031). In both groups, the actual incidence of clinical fractures was higher than FRAX prediction. Logistic regression analysis revealed that FRAX and FRAX≧15% were the significant risk factors for clinical fractures for 10 years in both groups (Odds ratio (OR), 1.055, P<0.001, 2.943, P=0.043, respectively). The mean FRAX in RA patients with and without clinical fractures for 10 years were 18.5 and 12.5%, respectively (P=0.002). In RA patients, FRAX was also the significant risk factor for clinical fractures (OR, 1.046, P=0.004).ConclusionFRAX and the incidence of clinical fractures for 10 years were significantly higher in RA patients than them of Vo. We confirmed that FRAX was the risk factor for clinical fractures in actual clinical practice.Disclosure of InterestsNone declared
Collapse
|
19
|
Okano T, Koike T, Inui K, Tada M, Mamoto K, Yamada Y, Orita K, Mandai K, Anno S, Iida T, Nakamura H. AB0405 JAK INHIBITORS IMPROVE PATIENT-REPORTED OUTCOMES SUCH AS PAIN AND HAQ EARLIER THAN ANTI-IL-6 INHIBITORS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundClinical feature of Janus kinase (JAK) inhibitor is recognized as not only suppress inflammation but also improve patient-reported outcomes (PRO) such as pain and health assessment questioner (HAQ) in patients with rheumatoid arthritis (RA). This representative clinical feature was known as a results of phase 3 trial compared to TNF inhibitor. One of the mechanisms of JAK in RA is to suppresses interleikin-6 (IL-6). However, the effect for PRO in JAK inhibitor compared to IL-6 inhibitor have not been known.ObjectivesWe investigated the effect for patient-reported outcomes such as pain and HAQ in patients with RA treated with JAK inhibitor compared to IL-6 inhibitor.MethodsThis study was analysed a multicenter database included RA patients treated with biological disease-modifying anti rheumatic dugs (bDMARDs) and JAK inhibitors. In 307 patients treated with IL-6 inhibitor (tocilizumab 240 and sarilumab 67) and 220 patients with JAK inhibitor (tofacitinib 101, baricitinib 83, upadacitinib 20, peficitinib 14 and filgotinib 2), 155 patients were treated as first-line bDMARDs/JAK inhibitor (IL-6R inhibitor 104 and JAK inhibitor 51). In this first-line patients, patients treated with IL-6R inhibitor and JAK inhibitor were matched using the propensity score adjusted for gender, age, RA disease duration, baseline charactristics of disease activity, CRP level, and MMP-3 level. The beaseline data and the change of clinical and laboratory data at 4, 12 and 24 weeks were compared between IL-6 inhibitor and JAK inhibitor.ResultsThirty-six patients in each group were matched and analyzed. The average age was 62.4 and 62.6 years and the average disease duration of RA was 13.2 and 10.1 years in IL-6 inhibitor and JAK inhibitor. The baseline characteristics were not significantly different in both groups. At week 4, tender joint count (TJC) was significantly improved in JAK inhibitor than IL-6 (IL-6: -1.86 vs JAK: -4.12, p= 0.036) and HAQ was significantly improved in JAK inhibitor than IL-6 (IL-6: -0.04 vs JAK: -0.27, p= 0.041). Moreover, Clinical Disease Activity Index (CDAI) was also improved in JAK inhibitor than IL-6 (IL-6: -6.6 vs JAK: -10.9, p= 0.026) at week 4. However, pain VAS and patient global VAS were not significantly different in each group in week4. TJC, HAQ and CDAI was not different in both groups at week 12 and week 24. On the other hand, ESR was significantly decreased in IL-6 inhibitor than JAK inhibitor at week 4, 12 and 24 (IL-6: -26.6 vs JAK: -14.1, p=0.018 at week 4, IL-6: -32.7 vs JAK: -16.5 p=0.004 at week 12, IL-6: -31.3vs JAK: -17.7 p=0.014 at week 24).ConclusionIn a comparison between IL-6 inhibitor and JAK inhibitor as a first-line molecular-targeted drug matched baseline charactristics of disease activity, TJC and HAQ was improved in JAK inhibitor earlier than IL-6 inhibitors. JAK inhibitor suppress multi cytokine that might be the reason why JAK inhibitor improve pain. Improvement of patient reported outcome in JAK inhibitor was found also in comparison with IL-6 inhibitor.References[1]Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017;376:652-62.[2]Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib Versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. Arthritis Rheumatol. 2019;71:1788-1800.AcknowledgementsWe wish to thank Atsuko Kamiyama and Tomoko Nishimura for clinical assistant, and all member of Team RA.Disclosure of InterestsTadashi Okano Speakers bureau: Asahi Kasei, Astellas, Abbvie, Amgen, Ayumi, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead Sciences, Janssen, Kyowa Kirin, Mitsubishi Tanabe, Novartis, Ono, Pfizer, Sanofi, Takeda, UCB, Grant/research support from: Asahi Kasei, Abbvie, Chugai, Eisai, Mitsubishi Tanabe, Tatsuya Koike Speakers bureau: Takeda Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical, Eisai, Abbott Japan, Teijin Pharma, Banyu Pharmaceutical and Ono Pharmaceutical, Kentaro Inui Speakers bureau: Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma, Janssen Pharmaceutical K.K., Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Abbvie GK, Pfizer Inc., Eisai Co.,Ltd., Chugai Pharmaceutical Co., Ltd., Grant/research support from: Janssen Pharmaceutical K.K., Astellas Pharma Inc., Sanofi K.K., Abbvie GK, Takeda Pharmaceutical Co. Ltd., QOL RD Co. Ltd., Mitsubishi Tanabe Pharma, Ono Pharmaceutical Co. Ltd., Eisai Co.,Ltd., Masahiro Tada: None declared, Kenji Mamoto: None declared, Yutaro Yamada: None declared, kazuki Orita: None declared, Koji Mandai: None declared, Shohei Anno: None declared, Takahiro Iida: None declared, Hiroaki Nakamura: None declared
Collapse
|
20
|
Yamada Y, Tada M, Mandai K, Hidaka N, Nakamura H. AB0262 PATIENTS WITH RHEUMATOID ARTHRITIS WHO DEVELOP SARCOPENIA FALL FREQUENTLY: 5-YEAR DATA FROM THE CHIKARA STUDY. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1686] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundPatients with rheumatoid arthritis (RA) are likely to have sarcopenia due to decreased muscle mass and physical function. Some patients develop sarcopenia even if disease activity is well-controlled. We previously reported that 13.2% of RA patients without sarcopenia at baseline developed sarcopenia over a year1.ObjectivesThe aim was to longitudinally investigate sarcopenia status and the characteristics of RA patients using data from the prospective, observational CHIKARA study.MethodsBody composition, laboratory data, disease activity, physical function (HAQ), treatment, and history of falls and fractures were investigated in 100 RA patients who participated in the CHIKARA study at baseline and at 5 years. They were divided into 4 groups depending on their sarcopenia status: no sarcopenia developed (N group; sarcopenia absent at baseline and 5 years); sarcopenia developed (S group; sarcopenia absent at baseline, but present at 5 years); cured (C group; sarcopenia present at baseline, but absent at 5 years); and persistent (P group; sarcopenia present at baseline and at 5 years).ResultsSeventy RA patients completed the survey. There were no differences among the 4 groups in disease activity, physical function, and treatment. The N group, accounting for 67.1% of all patients, was young and had high body mass index, muscle mass, fat mass, estimated bone mass, and body metabolic rate at baseline. On the other hand, the S group, accounting for 4.3% of all patients, fell significantly more frequently (p=0.035), 3.3 times during 5 years. The P group, accounting for 18.6% of all patients, had significantly higher MMP-3 at baseline (p=0.006). The C group accounted for 10.0% of all patients (Table 1).Table 1.Characteristics of 77 RA patients by sarcopenia status at baseline and at 5-year follow-upno development (n=47)development (n=3)cured (n=7)persisted (n=13)p valueage, years63 (57.5, 70)76 (74.5, 81)66 (54, 70)73 (65, 82)0.006disease duration, years6.5 (1.1, 10.7)15.2 (14.9, 20.7)11.4 (7.2, 14.8)3.5 (1.1, 6.5)0.021MTX dose, mg/day8.1 ± 3.76.0 ± 2.07.4 ± 3.86.2 ± 4.80.406biologics use, %36.266.728.623.10.513GC use, %23.4028.615.40.701average GC dose, mg/day3.5 ± 1.103.7 ± 1.86.3 ± 1.80.833CRP, mg/dl0.1 (0.04, 0.18)0.04 (0.04, 0.23)0.2 (0.12, 0.47)0.19 (0.08,0.82)0.22MMP-3, ng/ml62.2 (50.3, 98.6)58.9 (47.8, 71.3)74.9 (58.3,147.2)160 (90.8,262)0.006DAS28ESR3.34 ± 0.914.11 ± 0.723.36 ± 1.383.79 ± 1.200.355mHAQ0.25 (0, 0.5)0.63 (0.56, 1.25)0.87 (0.25, 1.0)0.25 (0.13, 0.75)0.132BMI, kg/m223.22 ± 3.5121.4 ± 2.2518.69 ± 2.0819.56 ± 2.39<0.001SMI, kg/m26.73 ± 0.76.1 ± 0.25.51 ± 0.145.79 ± 0.6<0.001fat percentage, %30.39 ± 8.7730.03 ± 9.1225.04 ± 6.2323.75 ± 6.560.051estimated bone mass, kg2.2 (2, 2.4)1.9 (1.75, 1.95)1.6 (1.55, 1.9)1.9 (1.7, 2.2)0.001BMR, kcal1101 (1051, 1198)986 (934, 1010)896 (872, 994)978 (902,1107)<0.001ΔDAS28ESR-0.15 ± 0.84-0.43 ± 1.730.04 ± 0.89-0.59 ± 1.330.445ΔSMI, kg/m2-0.06 ± 0.34-0.38 ± 0.570.25 ± 0.220.08 ± 0.420.038fall, times1.63.331.290.380.045Data are shown as mean ± standard deviation (SD) or median (25th, 75th percentile).GC: glucocorticoids, MMP-3: matrix metalloproteinase 3, DAS: disease activity score, HAQ: health assessment questionnaire, BMI: body mass index, SMI: skeletal muscle mass index, BMR: body metabolization rate, Δ:change during 5 years.ConclusionOverall, 4.3% of RA patients developed sarcopenia and fell frequently during 5-year follow-up. Patients who develop sarcopenia require special care because they are at high risk of falls.References[1]Y Yamada, M Tada, K Mandai et al. Glucocorticoid use is an independent risk factor for developing sarcopenia in patients with rheumatoid arthritis: from the CHIKARA study. Clin Rheumatol 2020 Jun;39(6):1757-1764.Disclosure of InterestsNone declared
Collapse
|
21
|
Tada M, Okano T, Mamoto K, Yamada Y, Orita K, Mandai K, Anno S, Iida T, Inui K, Koike T. AB0387 THE RELATIONSHIP BETWEEN JAK INHIBITORS AND CREATINE KINASE ELEVATION IN PATIENTS WITH RHEUMATOID ARTHRITIS: A REAL-WORLD CLINICAL STUDY. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundSome cases of creatine kinase (CK) elevation caused by Janus kinase (JAK) inhibitor treatment for rheumatoid arthritis (RA) have been reported in clinical trials1. However, the frequency and patients’ background characteristics in clinical practice are unknown.ObjectivesThe correlation between JAK inhibitor treatment for RA and changes in CK levels in clinical practice were investigated using a multicenter database.MethodsThe multicenter database of JAK inhibitors was used, and 103 (tofacitinib 46, baricitinib 44, upadacitinib 11, peficitinib 1, filgotinib 1) of 265 RA patients were followed up at 24 weeks, and their CK levels were evaluated. The time-dependent change of CK was evaluated by sex and analyzed by the Wilcoxon signed-rank test. The percentage abnormal from the standard titer was calculated. The factors related to an elevated CK at 24 weeks were investigated using patients’ background characteristics at the time of starting JAK inhibitors by univariate analysis.ResultsWomen accounted for 85.4% of the patients, the median age was 68 years, disease duration was 15 years, and the mean DAS28ESR was 5.00. The CK levels of both men and women were significantly elevated at 4 weeks and maintained until 24 weeks (men, women: 63, 62 (0 weeks), 101, 95 (4 weeks), 119, 96 (12 weeks), 155, 99 (24 weeks), U/L, P<0.001) (Figure 1). The percentage abnormal was also significantly increased at 4 weeks and maintained until 24 weeks (5.8% (0 weeks), 20.7% (4 weeks), 26.3% (12 weeks), 24.3% (24 weeks), P=0.002). The factors significantly positively related to elevated CK levels at 24 weeks were male, CK, creatinine, and lactate dehydrogenase (LDH), and stage, class, modified health assessment questionnaire, estimated glomerular filtration rate (eGFR), and glucocorticoid use were significantly negatively correlated (Table 1). There were no significant differences in CK elevation among the agents.Table 1.Characteristics at the time of starting JAK inhibitors related to elevated creatine kinase levels at 24 weeksUnivariateData at stating JAK inhibitorsR valueP valueCreatine kinase0.653<0.001Gender, men0.2470.012Steinbrocker stage-0.2150.039Steinbrocker class-0.2770.008modified health assessment questionnaire-0.2680.008Creatinine0.2890.003eGFR-0.2310.019LDH0.2010.041Glucocorticoid use-0.4090.008Analyzed by Spearman rank correlation coefficientFigure 1.Time-dependent changes of CK in all RA patientsConclusionCK was significantly elevated at 4 weeks and maintained until 24 weeks. However, no patients complained of muscle pain and stopped JAK inhibitors. Patients with high CK, low eGFR, high LDH, or maintained activities of daily living at the time of starting JAK inhibitors tended to have high CK levels at 24 weeks.References[1]Fleischmann, R. et al. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. Arthritis & rheumatology (Hoboken, N.J.) 71, 1788-1800, doi:10.1002/art.41032 (2019).Disclosure of InterestsNone declared
Collapse
|
22
|
Yoshimura C, Koike T, Mamoto K, Okano T, Sugioka Y, Tada M, Inui K, Nakamura H. POS0631 EVEN LOW-DOSE GLUCOCORTICOID USE IS A RISK FACTOR FOR CLINICAL FRACTURES IN PATIENTS WITH RHEUMATOID ARTHRITIS: TEN-YEAR FINDINGS OF THE TOMORROW STUDY. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundPatients with rheumatoid arthritis (RA) who have sarcopenia and stiff or painful joints might be at increased risk of falls and fractures.ObjectivesThe present study aimed to prospectively identify the incidence of clinical fractures and associated risk factors in patients with RA in a cohort study named the TOMORROW (UMIN000003876) that started in 2010.MethodsWe evaluated anthropometric parameters, bone mineral density (BMD), disease activity, RA medication at entry and observed the incidence of clinical fractures during ten years in 202 patients with RA (mean age, 58.6 y; medication with biological agents, 54.9%) and 202 age- and sex-matched non-RA volunteers (Vo) (mean age, 57.4 y). We compared the incidence of clinical fractures between patients with RA and Vo for ten years, and analyzed the risk factors for clinical fractures using Cox proportional hazard model.ResultsThe incidences of clinical fractures were 0.036 and 0.024/person-year in patients with RA and Vo, respectively. Cox proportional hazard model revealed that low BMD at the thoracic vertebrae (< 0.7 g/cm2) and history of fractures at entry were significantly associated with the incidence of clinical fractures (Hazard ratio [HR]1.737, p=0.020 and HR1.514, p=0.047, respectively) in all participants. RA morbidity, however, was not (HR1.398, p=0.112). In patients with RA, medication with GC at entry was a significant risk factor for clinical fractures (HR1.898, p=0.017). Additionally, a mean GC dose (≥ 2 mg/day) at entry and during the ten-year period increased risk for fractures (HR 2.189, p=0.004, 1.866, p=0.022, respectively).ConclusionRA per se was not a risk factor for clinical fractures in this cohort. Low BMD at the thoracic vertebrae at entry and the use of GC with even low dose at entry and during ten years were significantly associated with an increased frequency of clinical fractures among patients with RA.Disclosure of InterestsNone declared
Collapse
|
23
|
Matsui H, Takao S, Higashi K, Kaneko T, Samjeské G, Uruga T, Tada M, Iwasawa Y. Operando Imaging of Ce Radical Scavengers in a Practical Polymer Electrolyte Fuel Cell by 3D Fluorescence CT-XAFS and Depth-Profiling Nano-XAFS-SEM/EDS Techniques. ACS Appl Mater Interfaces 2022; 14:6762-6776. [PMID: 35077130 DOI: 10.1021/acsami.1c22336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
There is little information on the spatial distribution, migration, and valence of Ce species doped as an efficient radical scavenger in a practical polymer electrolyte fuel cell (PEFC) for commercial fuel cell vehicles (FCVs) closely related to a severe reliability issue for long-term PEFC operation. An in situ three-dimensional fluorescence computed tomography-X-ray absorption fine structure (CT-XAFS) imaging technique and an in situ same-view nano-XAFS-scanning electron microscopy (SEM)/energy-dispersive spectrometry (EDS) combination technique were applied for the first time to perform operando spatial visualization and depth-profiling analysis of Ce radical scavengers in a practical PEFC of Toyota MIRAI FCV under PEFC operating conditions. Using these in situ techniques, we successfully visualized and analyzed the domain, density, valence, and migration of Ce scavengers that were heterogeneously distributed in the components of PEFC, such as anode microporous layer, anode catalyst layer, polymer electrolyte membrane (PEM), cathode catalyst layer, and cathode microporous layer. The average Ce valence states in the whole PEFC and PEM were 3.9+ and 3.4+, respectively, and the Ce3+/Ce4+ ratios in the PEM under H2 (anode)-N2 (cathode) at an open-circuit voltage (OCV), H2-air at 0.2 A cm-2, and H2-air at 0.0 A cm-2 were 70 ± 5:30 ± 5%, as estimated by both in situ fluorescence CT-X-ray absorption near-edge spectroscopy (XANES) and nano-XANES-SEM/EDS techniques. The Ce3+ migration rates in the electrolyte membrane toward the anode and cathode electrodes ranged from 0.3 to 3.8 μm h-1, depending on the PEFC operating conditions. Faster Ce3+ migration was not observed with voltage transient response processes by highly time-resolved (100 ms) and spatially resolved (200 nm) nano-XANES imaging. Ce3+ ions were suggested to be coordinated with both Nafion sulfonate (Nfsul) groups and water to form [Ce(Nfsul)x(H2O)y]3+. The Ce migration behavior may also be affected by the spatial density of Ce, interactions of Ce with Nafion, thickness and states of the PEM, and H2O convection, in addition to the PEFC operating conditions. The unprecedented operando imaging of Ce radical scavengers in the practical PEFCs by both in situ three-dimensional (3D) fluorescence CT-XAFS imaging and in situ depth-profiling nano-XAFS-SEM/EDS techniques yields intriguing insights into the spatial distribution, chemical states, and behavior of Ce scavengers under the working conditions for the development of next-generation PEFCs with high long-term reliability and durability.
Collapse
Affiliation(s)
- Hirosuke Matsui
- Department of Chemistry, Graduate School of Science, Nagoya University, Chikusa, Nagoya, Aichi 464-8602, Japan
| | - Shinobu Takao
- Innovation Research Center for Fuel Cells, The University of Electro-Communications, Chofugaoka, Chofu, Tokyo 182-8585, Japan
| | - Kotaro Higashi
- Innovation Research Center for Fuel Cells, The University of Electro-Communications, Chofugaoka, Chofu, Tokyo 182-8585, Japan
| | - Takuma Kaneko
- Innovation Research Center for Fuel Cells, The University of Electro-Communications, Chofugaoka, Chofu, Tokyo 182-8585, Japan
| | - Gabor Samjeské
- Department of Chemistry, Graduate School of Science, Nagoya University, Chikusa, Nagoya, Aichi 464-8602, Japan
| | - Tomoya Uruga
- Innovation Research Center for Fuel Cells, The University of Electro-Communications, Chofugaoka, Chofu, Tokyo 182-8585, Japan
- Japan Synchrotron Radiation Research Institute, SPring-8, Sayo, Hyogo 679-5198, Japan
| | - Mizuki Tada
- Department of Chemistry, Graduate School of Science, Nagoya University, Chikusa, Nagoya, Aichi 464-8602, Japan
- Research Center for Materials Science, Nagoya University, Furo-cho, Chikusa, Nagoya, Aichi 464-8602, Japan
| | - Yasuhiro Iwasawa
- Innovation Research Center for Fuel Cells, The University of Electro-Communications, Chofugaoka, Chofu, Tokyo 182-8585, Japan
- Department of Engineering Science, Graduate School of Informatics and Engineering, The University of Electro-Communications, Chofugaoka, Chofu, Tokyo 182-8585, Japan
| |
Collapse
|
24
|
Ikemoto S, Muratsugu S, Koitaya T, Tada M. Chromium Oxides as Structural Modulators of Rhodium Dispersion on Ceria to Generate Active Sites for NO Reduction. ACS Catal 2021. [DOI: 10.1021/acscatal.1c03807] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Satoru Ikemoto
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| | - Satoshi Muratsugu
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
- Japan Science and Technology Agency (JST), Precursory Research for Embryonic Science and Technology (PRESTO), 4-1-8 Honcho, Kawaguchi 332-0012, Japan
| | - Takanori Koitaya
- Japan Science and Technology Agency (JST), Precursory Research for Embryonic Science and Technology (PRESTO), 4-1-8 Honcho, Kawaguchi 332-0012, Japan
- Department of Materials Molecular Science, Institute for Molecular Science, Myodaiji-cho, Okazaki, Aichi 444-8585, Japan
| | - Mizuki Tada
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
- Research Center for Materials Science (RCMS), Integrated Research Consortium on Chemical Sciences (IRCCS), and Institute for Advanced Study, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi 464-8602, Japan
| |
Collapse
|
25
|
Matsumoto Y, Sugioka Y, Tada M, Okano T, Mamoto K, Inui K, Habu D, Koike T. POS1456-HPR THE SERUM IRON LEVEL MIGHT BE USEFUL IN DETERMINING THE SEVERITY OF MALNUTRITION IN PATIENTS WITH RHEUMATOID ARTHRITIS. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.947] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:The Global Leadership Initiative on Malnutrition (GLIM) criteria, the first international criteria for diagnosis of malnutrition, was released in 2018 [1]. Patients with rheumatoid arthritis (RA) are thought to be prone to malnutrition due to decreased food intake and increased muscle catabolism caused by chronic inflammation or pain. However, there has been no report to assess the nutritional status of RA patients in accordance with the GLIM criteria. In addition, commonly used blood nutrient indicators such as albumin might not be appropriate as nutritional indicators for RA because these values are affected by inflammation.Objectives:This study aims to examine the rates of malnutrition in RA patients according to GLIM criteria, and the relationship between blood nutrient indicators and the severity of malnutrition.Methods:In this study, we conducted a cross-sectional survey of 135 female RA patients in 2020. According to the GLIM criteria, patients were considered to be malnourished if patients had one of the following phenotypic: (1) low body mass index, (2) non-volitional weight loss, (3) reduced muscle mass, and one of the following etiologic: (1) reduced food intake or assimilation, (2) disease burden/inflammatory condition. Reduced muscle mass was evaluated by measuring calf circumference, and inflammatory condition was evaluated by Disease Activity Score (DAS) 28. In accordance with the GLIM criteria, the severity of malnutrition was judged as three levels: no problem, moderate, and severe malnutrition. Albumin, transthyretin, transferrin, retinol binding protein, zinc, iron, ceruloplasmin, and total cholesterol were assessed as blood nutrition indicators. Also grip strength was assessed. We compared each nutritional indicator among the three groups according to the severity of malnutrition using age-adjusted analysis of covariance, and examined the relationship between each nutritional indicator and the severity of malnutrition using receiver operating characteristic (ROC) analysis.Results:In RA patients, 20% were classified as severe malnutrition, and 40% were moderate or more. Serum iron levels were significantly lower in the severe malnutrition group compared to the no problem group (p = 0.001). In ROC analysis, serum iron, zinc, albumin, and grip strength (area under curve; AUC; 0.680, 0.696, 0.636, 0.790, respectively) were significant parameters for classification of moderate and severe malnutrition. Serum iron and grip strength (AUC for respective parameters were 0.741, 0.747) were significant parameters for classification of severe malnutrition.Conclusion:Evaluation based on the GLIM criteria showed that about 40% of RA patients were under moderate or severe malnutrition. It was suggested that serum iron and grip strength might be useful to predict the severity of malnutrition.References:[1]Cederholm T, Jensen GL, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi T, et al. GLIM criteria for the diagnosis of malnutrition – A consensus report from the global clinical nutrition community. Clinical Nutrition 2019; 38: 1-9.Acknowledgements:We thank to Tomoko Nakatsuka, and the Center for Drug & Food Clinical Evaluation, Osaka City University Hospital, for management and collection of the study data. We also thank to study participants.Disclosure of Interests:Yoshinari Matsumoto Grant/research support from: Yamada Research Grant, Yuko Sugioka: None declared, Masahiro Tada: None declared, Tadasi Okano Speakers bureau: AbbVie, Asahikasei, Astellas Pharma Inc, Ayumi Pharmaceutical, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiich Sankyo, Eisai, Janssen, Lilly, Mitsubishi Tanabe Pharma Corporation, Novartis Pharma, Ono Pharmaceutical, Pfizer, Sanofi, Takeda Pharmaceutical, Teijin Pharma and UCB, Grant/research support from: AbbVie, Eisai, Mitsubishi Tanabe Pharma Corporation and Nipponkayaku, Kenji Mamoto: None declared, Kentaro Inui Speakers bureau: Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma, Janssen Pharmaceutical K.K., Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Abbvie GK, Pfizer Inc., Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd, Grant/research support from: anssen Pharmaceutical K.K., Astellas Pharma Inc., Sanofi K.K., Abbvie GK, Takeda Pharmaceutical Co. Ltd., QOL RD Co. Ltd., Mitsubishi Tanabe Pharma, Ono Pharmaceutical Co. Ltd., Eisai Co., Ltd., Daiki Habu: None declared, Tatsuya Koike Speakers bureau: AbbVie, Astellas Pharma Inc, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Janssen, Lilly, Mitsubishi Tanabe Pharma Corporation, MSD, Ono Pharmaceutical, Pfizer, Roche, Takeda Pharmaceutical, Teijin Pharma, and UCB, Grant/research support from: AbbVie, Astellas Pharma Inc, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Janssen, Lilly, Mitsubishi Tanabe Pharma Corporation, MSD, Ono Pharmaceutical, Pfizer, Roche, Takeda Pharmaceutical, Teijin Pharma, and UCB
Collapse
|
26
|
Yamada Y, Tada M, Mandai K, Hidaka N, Nakamura H. AB0813 DEVELOPING SARCOPENIA IS A RISK FACTOR FOR FRACTURES IN PATIENTS WITH RHEUMATOID ARTHRITIS: 4-YEAR DATA FROM THE CHIKARA STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Patients with rheumatoid arthritis (RA) tend to have sarcopenia due to decreased muscle mass and function. We previously reported that 13.2% of RA patients without sarcopenia at baseline developed sarcopenia over a year using data from the prospective, observational CHIKARA study1.Objectives:The aim was to investigate sarcopenia status and the characteristics of RA patients longitudinally.Methods:Body composition, laboratory data, disease activity, physical function, treatment, and history of falls and fractures were investigated in 100 RA patients who participated in the CHIKARA study at baseline and at 4 years. The patients were divided into 4 groups depending on their sarcopenia status: no sarcopenia development (N group), sarcopenia development (S group), cured (C group), and persisted (P group).Results:Of the 77 RA patients who completed the survey, 48 were in the N group; their body mass index, skeletal muscle mass index, fat percentage, estimated bone mass, and body metabolization rate at baseline were significantly elevated. On the other hand, 6 patients were in the S group; 83.3% of them experienced fractures during the 4 years, significantly more than in the other groups. Ten patients were in the P group, and their baseline MMP-3 was significantly higher than in the other groups. Thirteen patients were in the C group. There were no differences among the 4 groups in disease activity and physical function (Table 1).Table 1.Characteristics of 77 RA patients by sarcopenia status at baseline and at 4-year follow-up.no development(n=48)development(n=6)cured(n=10)persisted(n=13)p valueBaseline age, years64.5 (57.8, 72)70.0 (65.5, 72.3)61.0 (54.5, 68.3)72 (68, 81)0.062 disease duration, years4.6 (1.1, 9.9)11.7 (2.8, 18.9)8.1 (4.2, 14.3)4.0 (2.2, 7.7)0.427 biologics use, %37.516.730.023.10.617 GC use, %27.116.710.023.10.678 MMP-3, ng/ml66.8 (51.8, 103)52.5 (40.0, 56.7)82.8 (57.8, 186)157.5 (90.8, 250)0.001 DAS28ESR3.43 ± 0.873.48 ± 1.323.36 ± 1.083.80 ± 1.270.661 mHAQ0.31 (0, 0.50)0.19 (0.03, 0.44)0.38 (0, 0.84)0.50 (0.25, 0.88)0.383 BMI, kg/m223.4 ± 3.621.6 ± 2.419.2 ± 1.619.5 ± 2.6<0.001 SMI, kg/m26.8 ± 0.86.2 ± 0.65.8 ± 0.55.7 ± 0.6<0.001 fat percentage, %30.4 ± 8.429.1 ± 9.123.9 ± 4.025.1 ± 8.30.046 estimated bone mass, kg2.2 (2.0, 2.4)1.9 (1.8, 2.1)2.0 (1.7, 2.1)1.7 (1.7, 1.9)0.012 BMR, kcal1100 (1031, 1197)1029 (918, 1070)1012 (917, 1057)934 (894, 1006)0.005Change during 4 years ΔDAS28ESR-0.34 ± 0.97-0.52 ± 0.98-0.60 ± 1.46-0.56 ± 1.140.834 ΔmHAQ0 (-0.25, 0.16)0.19 (0, 0.56)-0.06 (-0.44, 0.94)0 (-0.38, 0.38)0.357 ΔSMI, kg/m20.0 ± 0.3-0.6 ± 0.30.3 ± 0.4-0.0 ± 0.3<0.001 fall, %43.883.330.023.10.079 fracture, %14.683.320.023.10.002Data are shown as mean ± standard deviation (SD) or median (25th, 75th percentile).GC: glucocorticoids, BMI: body mass index, SMI: skeletal muscle mass index, BMR: body metabolization rate.Conclusion:Overall, 7.8% of RA patients developed sarcopenia during the 4-year follow-up period, and they developed fractures more frequently. Evaluation of sarcopenia is important for risk assessment of fractures.References:[1]Y Yamada, M Tada, K Mandai et al. Glucocorticoid use is an independent risk factor for developing sarcopenia in patients with rheumatoid arthritis: from the CHIKARA study. Clin Rheumatol 2020 Jun;39(6):1757-1764.Disclosure of Interests:Yutaro Yamada: None declared, Masahiro Tada: None declared, Koji Mandai: None declared, Noriaki Hidaka: None declared, Hiroaki Nakamura Grant/research support from: Astellas and Asahi Kasei
Collapse
|
27
|
Yoshimura H, Koike T, Mamoto K, Sugioka Y, Okano T, Tada M, Inui K, Nakamura H. POS0532 AveRAGE PREDNISOLONE DOSE OF ONLY 1 MG PER DAY WAS RISK FACTOR FOR CLINICAL FRACTURES IN PATIENTS WITH RHEUMATOID ARTHRITIS - NINE-YEAR FINDINGS OF THE TOMORROW STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1868] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Previous cohort studies showed that the use of prednisolone (PSL) was a risk factor for clinical fractures in patients with rheumatoid arthritis (RA). However, there are few reports on relationship between PSL dose and clinical fractures.Objectives:The present study aimed to determine the effect of PSL dose on the incidence of clinical fractures in the RA patients treated with PSL.Methods:We evaluated anthropoetric parameters, bone mineral density (BMD), disease activity score 28-erythrocyte sedimentation rate (DAS28-ESR), RA medication (methotrexate (MTX) dose, use of biologic disease modified anti-rheumatic-drugs (bDMARDs), and PSL dose) and the incidence of clinical fractures during nine years in RA patients who participant the TOMORROW study (UMIN000003876), which is a 10-years prospective cohort study. Data on clinical fracture was self-reported on the questionnaires. In this analysis, the data of RA patients treated with PSL at least once during nine-year period were evaluated. We analyzed the average dose of PSL until the incidence of the clinical fractures. The risk factor for clinical fractures were analyzed by using Cox proportional hazard model with adjustment for age, sex, body mass index (BMI), and smoking history.Results:We analyzed the data of 67 RA patients treated with PSL. Among them, median age was 61.8 year, 56 patients (83.6%) were female, 47 patients (70.1%) were never smoker and median disease duration was 12.1 year. The number of patients treated with PSL at baseline was 48 (69.1%). During 9 years, 23 clinical fractures were observed in 67 patients, and the incidence of clinical fracture was 0.046/person-year. In 19 patients, who were not treated with PSL at baseline but treated with PSL at least once during 9 years, 5 clinical fractures were observed. In 67 RA patients, Cox proportional hazard analysis revealed that baseline disease activities, BMD at thoracic vertebrae and medication were not significant risk factors for clinical fractures. However, average PSL dose of more than only 1 mg/day was a significant risk factor for the incidence of clinical fracture (hazard ratio (HR): 2.80; p=0.03) (Table 1).Table 1.Adjusted hazard ratio for clinical fractures in patients with rheumatoid arthritis treated with PSL.* Adjusted Hazard ratio95% Confidence intervalP valueCRP (mg/dL)1.290.88-1.910.19RF (IU/mL)0.990.99-1.000.07ACPA (U/mL)0.990.98-1.000.18DAS28-ESR0.990.71-1.390.97BMD at thoracic vertebrae (mg/cm2)0.020.00-1.000.05bDMARDs use0.550.23-1.320.18Bisphosphonate use2.330.95-5.710.07average dose of MTX (mg/week)1.020.92-1.120.74average score of DAS28-ESR1.150.76-1.750.52average dose of PSL more than 1mg/day2.81.09-7.240.03*Hazard ratio was adjusted for age, sex, body mass index (BMI), and smoking history. RF, Rheumatoid factor; ACPA, Anti-cyclic citrullinated peptide antibody; DAS28-ESR, disease activity score 28-erythrocyte sedimentation rate; BMD, Bone mineral density; bDMARDs, biologic disease modified anti-rheumatic-drugs; MTX, methotrexate; PSL, prednisolone.Conclusion:In RA patients treated with PSL, average PSL dose of only 1mg/day significantly increased the risk for the incidence of clinical fractures. Even for established RA patients, continuous use or initiation of low PSL dose was apparently significant risk factor for clinical fractures.Disclosure of Interests:Hitoshi Yoshimura: None declared, Tatsuya Koike Grant/research support from: Takeda Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical, Eisai, Abbott Japan, Teijin Pharma, Banyu Pharmaceutical and Ono Pharmaceutical, Kenji Mamoto: None declared, Yuko Sugioka: None declared, Tadashi Okano: None declared, Masahiro Tada: None declared, Kentaro Inui Grant/research support from: Janssen Pharmaceutical K.K. and Astellas Pharma Inc, Hiroaki Nakamura: None declared
Collapse
|
28
|
Mandai K, Tada M, Yamada Y, Koike T, Okano T, Hidaka N, Nakamura H. POS0517 A LONGITUDINAL STUDY OF SARCOPENIA, LOCOMOTIVE SYNDROME, AND FRAILTY IN PATIENTS WITH RHEUMATOID ARTHRITIS: FROM THE CHIKARA STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Rheumatoid arthritis (RA) patients have a high frequency of sarcopenia, and they commonly have reduced physical function. We previously reported that the prevalence of sarcopenia was 28%, that of frailty was 18.9%, and that of pre-frailty was 38.9% in RA patients1,2, and 13.2% of RA patients developed sarcopenia within a year 3.Objectives:To investigate the risk factors for new onset of sarcopenia, locomotive syndrome, and frailty in patients with RA and the course of each disease.Methods:Two-year follow-up data from the rural group of the prospective, observational CHIKARA study were used. Sarcopenia was diagnosed using the criteria of the Asian Working Group for Sarcopenia 2014, locomotive syndrome was diagnosed using locomotive 5, and frailty was diagnosed using the basic checklist. New onset of the disease over the 2-year follow-up period was studied, excluding cases that had the disease at baseline. Improvement was defined as cases with disease at baseline that no longer met the diagnostic criteria after 2 years. Differences in the characteristics of each disease were tested using the Chi-squared test and the paired t-test.Results:The 81 patients with RA (82.7% female) had mean age 66.9±11.5 years, mean DAS28-ESR 2.9±1.2, methotrexate use in 81.5% (with a dose of 9.9±2.7 mg/week), and glucocorticoid (GC) use in 22.2% (with a dose of 3.1±1.7 mg/week). The baseline prevalence was 44.4% for sarcopenia, 35.8% for locomotive syndrome, and 25.9% for frailty, and the new onset rate was 4.4% for sarcopenia, 15.4% for locomotive syndrome, and 13.3% for frailty. Of the patients with each disease at baseline, 36.1% had sarcopenia, 20.7% had locomotive syndrome, and 33.3% had frailty, and of those with each disease at 2 years, 36.1% had sarcopenia, 20.7% had locomotive syndrome, and 33.3% had frailty. The new onset sarcopenia and locomotive syndrome groups had significantly higher rates of GC use (p=0.036, p=0.007, paired t-test) and significantly higher doses (p=0.01, p=0.001, paired t-test) than the groups without new onset sarcopenia and locomotive syndrome. High baseline disease activity was an independent predictor of new onset of locomotive syndrome on multivariate logistic regression analysis (OR=3.21, p=0.015).Conclusion:The new onset rates at 2 years were 4.4% for sarcopenia, 15.4% for locomotive syndrome, and 13.3% for frailty. In the new onset sarcopenia and locomotive syndrome groups, both GC use and dosage were significantly higher.References:[1]Tada M, et al. Matrix metalloprotease 3 is associated with sarcopenia in rheumatoid arthritis - results from the CHIKARA study. Int J Rheum Dis. 2018 Nov;21(11):1962-1969.[2]Tada M, et al. Correlation between frailty and disease activity in patients with rheumatoid arthritis: Data from the CHIKARA study. Geriatr Gerontol Int. 2019 Dec;19(12):1220-1225.[3]Yamada Y, et al. Glucocorticoid use is an independent risk factor for developing sarcopenia in patients with rheumatoid arthritis: from the CHIKARA study. Clin Rheumatol. 2020 Jun;39(6):1757-1764.Disclosure of Interests:None declared
Collapse
|
29
|
Tada M, Yamada Y, Mandai K, Hidaka N. POS0514 IMPORTANCE OF BODY MASS MEASUREMENT AND THE GRIP STRENGTH TEST TO PREDICT FALLS IN PATIENTS WITH RHEUMATOID ARTHRITIS. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.940] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:We previously reported that the prevalence of sarcopenia was 28% in patients with rheumatoid arthritis (RA) in a cohort study 1. RA patients have a high risk of falls and fractures 2. However, the predictors of falls and fractures in RA patients are not known.Objectives:Whether evaluation of muscle mass and function at baseline could predict falls and fractures during four-year follow-up was investigated.Methods:The four-year follow-up data from a prospective, observational study (CHIKARA study: Correlation researcH of sarcopenIa, sKeletal muscle and disease Activity in Rheumatoid Arthritis) were used. Muscle mass was measured by a body impedance analyzer, and leg muscle mass was calculated. The leg muscle score (max: 100, min: 0) reflected the ratio of leg muscle mass to overall weight. Grip strength as an indicator of muscle function was evaluated using a digital, hand-held, isokinetic dynamometer. The correlations between muscle mass or function and falls or fractures were analyzed by survival rates and Cox hazard ratios. Leg muscle mass and grip strength were investigated by receiver operating characteristic (ROC) curve analysis for correlations with falls or fractures.Results:A total of 100 RA patients (female: 78%, mean age: 66.1 years) were enrolled; 35 patients had falls, and 19 patients had fractures during the four-year follow-up. The leg muscle score, grip strength, age, and fractures at baseline were significantly correlated with falls. The cut-off values of the leg muscle score and grip strength were calculated to be 84.5 points (sensitivity: 0.79, specificity: 0.43) and 15.9 kg (sensitivity: 0.56, specificity: 0.70), respectively, by ROC curve analysis. The patients were divided into four groups by their leg muscle scores and grip strength; the numbers of falls and fractures are shown in Table 1 for each group. The fall-free survival rate was significantly lower in the group with low leg muscle score and low grip strength (35.3%) than in the other groups (P=0.002) (Figure 1). The hazard ratio for the both low group was significantly increased, 3.6-fold (95%CI: 1.1-11.5), compared to that in the both high group.Table 1.Numbers of falls and fractures by category of leg muscle score and grip strengthLG + GS+(n=34)LG - GS+(n=12)LG + GS-(n=37)LG - GS-(n=17)P value*Falls, N6515110.010Fractures, N34660.072LG+: leg muscle score >84.5 points, GS+: grip strength >15.9kg, LG-: leg muscle score ≤84.5 points, GS+: grip strength ≤15.9kg*: compared in four groups by Kruskal-Walls test.Figure 1.Fall-free survival rate in the four groupsConclusion:RA patients with both low leg muscle score and low grip strength at baseline were at high risk for falls during the four-year follow-up period. Evaluation of muscle mass and function can predict falls in RA patients.References:[1]Tada, M., Yamada, Y., Mandai, K. & Hidaka, N. Matrix metalloprotease 3 is associated with sarcopenia in rheumatoid arthritis - results from the CHIKARA study. Int J Rheum Dis21, 1962-1969, doi:10.1111/1756-185X.13335 (2018).[2]van Staa, T. P., Geusens, P., Bijlsma, J. W., Leufkens, H. G. & Cooper, C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum54, 3104-3112, doi:10.1002/art.22117 (2006).Disclosure of Interests:None declared
Collapse
|
30
|
Tada M, Yamada Y, Mandai K, Hidaka N. OP0319 OSTEOSARCOPENIA INCREASES THE RISK OF FALLS IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS OF A FOUR-YEAR LONGITUDINAL STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Osteosarcopenia is defined as osteoporosis combined with sarcopenia. Both osteoporosis and sarcopenia are risk factors for falls and fractures in healthy individuals1. The relationships of falls and fractures to osteosarcopenia in rheumatoid arthritis (RA) patients are unknown.Objectives:The synergistic effect of osteoporosis and sarcopenia and the impact of osteosarcopenia on falls and fractures in RA patients were investigated using four years of data from a longitudinal study.Methods:The data from a prospective, observational study (CHIKARA study: UMIN000023744) were examined. The patients were divided into four groups according to their baseline status: no sarcopenia and osteoporosis (SP-OP-); only sarcopenia (SP+OP-); only osteoporosis (SP-OP+); and both sarcopenia and osteoporosis (SP+OP+). Sarcopenia was diagnosed by the criteria of the Asia Working Group on Sarcopenia 20142. Patients with osteoporosis were defined as those having a therapeutic intervention for osteoporosis. The survival rate and Cox hazard ratio were analyzed using falls and fractures as endpoints, adjusted by age, sex, and body mass index.Results:A total of 100 RA patients (female 78%, mean age 66.1 years) were enrolled. The number of SP-OP-, SP+OP-, SP-OP+, and SP+OP+ patients was 45, 17, 27, and 11, respectively. Their baseline characteristics are shown in Table 1. A total of 35 patients had falls, and 19 patients had fractures during the four-year follow-up. The fall-free survival rate in the SP-OP-, SP+OP-, SP-OP+, and SP+OP+ groups was 75.6%, 64.7%, 51.9%, and 36.4%, respectively; that of the SP+OP+ group was significantly lower than that of the other groups (P=0.021) (Figure 1). The fracture-free survival rate in the SP-OP-, SP+OP-, SP-OP+, and SP+OP+ groups was 86.7%, 82.4%, 81.5%, and 54.5%, respectively. That of the SP+OP+ group was relatively lower than that of the other groups (P=0.121). The hazard ratio of falls was significantly increased in the SP+OP+ group by 3.32-fold (95%CI: 1.01-10.9) compared to that in the SP-OP- group, whereas that in the SP+OP- and SP-OP+ groups was 2.58-fold (95%CI: 0.75-8.8) and 2.29-fold (95%CI: 0.94-5.6) higher, respectively. There were no significant differences compared to the SP-OP- group. The hazard ratio of fractures in the SP+OP+ group was increased 2.73-fold (95%CI: 0.61-12.2) compared to that in the SP-OP- group.Table 1.Baseline characteristics of the four groupsSA-OP-SA+OP-SA-OP+SA+OP+P value*Female, %73.358.888.91000.027Age, years63 (49, 72)69 (60, 79)73 (64, 75)73 (65, 81)0.008Disease duration, years4.4 (1.0, 8.4)4.0 (1.3, 8.9)7.6 (1.5, 14.5)10.5 (3.2, 26.5)0.035DAS28-ESR3.14 (2.66, 3.70)3.55 (3.01, 4.65)3.93 (3.28, 4.63)3.53 (2.48, 3.89)0.01mHAQ0.25 (0, 0.375)0.375 (0.125, 0.875)0.375 (0.125, 0.875)0.5 (0.125, 0.875)0.065MTX, mg/week, rate (%)8.4 ± 2.9 (86.7)8.7 ± 3.5 (70.6)8.3 ± 2.8 (92.6)6.8 ± 1.0 (90.9)0.388Glucocorticoid, mg/day, rate (%)3.7 ± 1.9 (20.0)6.3 ± 1.8 (11.8)4.0 ± 1.7 (44.4)3.8 ± 1.8 (18.2)0.400Body mass index, kg/m223.4 ± 3.819.2 ± 2.321.7 ± 2.419.2 ± 2.0<0.001Data are shown as mean ± standard deviation (SD) or median (25th, 75th percentile).*: compared in four groups by Kruskal-Walls test.Figure 1.Fall-free survival rates of the four groups.Conclusion:The survival rates with the endpoints of falls and fractures in RA patients with osteosarcopenia were lower during the four-year follow-up. In particular, the risk of falls increased with the synergistic effect of osteoporosis and sarcopenia in RA patients.References:[1]Dennison, E. M. et al. Fracture risk following intermission of osteoporosis therapy. Osteoporos Int30, 1733-1743, doi:10.1007/s00198-019-05002-w (2019).[2]Chen, L. K. et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc15, 95-101, doi:10.1016/j.jamda.2013.11.025 (2014).Disclosure of Interests:None declared.
Collapse
|
31
|
Mamoto K, Koike T, Yamada Y, Okano T, Sugioka Y, Tada M, Inui K, Nakamura H. POS0466 RHEUMATOID ARTHRITIS PER SE IS NOT RISK FACTOR FOR CLINICAL FRACTURES: NINE-YEAR FINDINGS OF THE TOMORROW STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.2331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Patients with rheumatoid arthritis (RA) who have sarcopenia and stiff or painful joints might be at increased risk of falls and fractures.Objectives:The present study aimed to prospectively identify the incidence of clinical fractures and associated risk factors in patients with RA in a cohort study named the TOMORROW (UMIN000003876) that started in 2010.Methods:We evaluated anthropometric parameters, bone mineral density (BMD), disease activity, RA medication at baseline and observed the incidence of clinical fractures during nine years in 202 patients with RA (mean age, 58.6 y; medication with biological agents, 54.9%) and 202 age- and sex-matched non-RA volunteers (mean age, 57.4 y). We compared the incidence of clinical fractures between patients with RA and controls for nine years, and analyzed the risk factors for fractures using Cox proportional hazard model.Results:The incidence of clinical fractures in RA patients was significantly higher compared to controls (27.5 vs 18.3%, p=0.04). However, Cox proportional hazard model, adjusted by age, sex, smoking and body mass index, revealed that low BMD at thoracic vertebrae (< 0.7 g/cm2) significantly associated to the incidence of clinical fractures (hazard ratio [HR], 1.86, p=0.02), but not RA morbidity (HR 1.47, p=0.10) (Table 1). Among patients with RA, low BMD at the thoracic vertebrae (< 0.7 g/cm2) was the most prominent risk factor for clinical fractures (HR, 2.66, p=0.02) (Table 1). Although the use of glucocorticoid (GC) at baseline (HR, 1.68, p=0.09) was not a significant risk factor for fractures, a mean GC dose (≥ 2 mg/day) at entry increased risk for clinical fractures in the patients (HR, 1.91, p=0.04) (Table 1).Conclusion:RA per se was not a risk factor for clinical fractures in this cohort. Low BMD at the thoracic vertebrae and the use of GC with even low dose at entry were apparently significant risk factors for the incidence of clinical fractures among patients with RA.Disclosure of Interests:Kenji Mamoto: None declared, Tatsuya Koike Grant/research support from: Takeda Pharmaceutical, Mitsubishi Tanabe Pharma Corporation,Chugai Pharmaceutical, Eisai, Abbott Japan, Teijin Pharma, Banyu Pharmaceutical and Ono Pharmaceutical, Yutaro Yamada: None declared, Tadashi Okano: None declared, Yuko Sugioka: None declared, Masahiro Tada: None declared, Kentaro Inui Speakers bureau: Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma, Janssen Pharmaceutical K.K., Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Abbvie GK, Pfizer Inc., Eisai Co.,Ltd., Chugai Pharmaceutical Co., Ltd., Grant/research support from: Janssen Pharmaceutical K.K., Astellas Pharma Inc., Sanofi K.K., Abbvie GK, Takeda Pharmaceutical Co. Ltd., QOL RD Co. Ltd., Mitsubishi Tanabe Pharma, Ono Pharmaceutical Co. Ltd., Eisai Co.,Ltd., Hiroaki Nakamura: None declared
Collapse
|
32
|
Wan XK, Samjeské G, Matsui H, Chen C, Muratsugu S, Tada M. Ultrafine Pt-Ni nanoparticles in hollow porous carbon spheres for remarkable oxygen reduction reaction catalysis. Dalton Trans 2021; 50:6811-6822. [PMID: 33890597 DOI: 10.1039/d1dt00647a] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Ultrafine bimetallic Pt-Ni nanoparticles, which catalyze the oxygen reduction reaction (ORR) efficiently, were successfully prepared in hollow porous carbon spheres (HPCSs) under the assistance of organic molecules. 2,2'-Dipyridylamine (dpa) was found to be most effective in preparing homogeneous small Pt-Ni nanoparticles (2.0 ± 0.4 nm) without the phase separation of Pt and Ni during synthesis, and the assistance of the organic molecules was investigated for the alloy nanoparticle formation. The Pt-Ni nanoparticle/HPCS catalyst synthesized in the presence of dpa exhibited remarkable electrochemical performance in the ORR showing a high mass activity of 3.25 ± 0.14 A mg-1Pt at 0.9 VRHE (13.5-fold higher relative to a commercial Pt/C catalyst), a large electrochemical surface area of 105 ± 8 m2 g-1Pt, and high durability. After 60 000 cycles of accelerated durability testing, the mass activity was still 12.3 times higher than that of the commercial Pt/C catalyst.
Collapse
Affiliation(s)
- Xian-Kai Wan
- Research Center for Materials Science, Nagoya University, Furo-cho, Chikusa, Nagoya, Aichi 464-8602, Japan.
| | - Gabor Samjeské
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa, Nagoya, Aichi 464-8602, Japan.
| | - Hirosuke Matsui
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa, Nagoya, Aichi 464-8602, Japan.
| | - Chaoqi Chen
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa, Nagoya, Aichi 464-8602, Japan.
| | - Satoshi Muratsugu
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa, Nagoya, Aichi 464-8602, Japan.
| | - Mizuki Tada
- Research Center for Materials Science, Nagoya University, Furo-cho, Chikusa, Nagoya, Aichi 464-8602, Japan. and Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa, Nagoya, Aichi 464-8602, Japan.
| |
Collapse
|
33
|
Tada M, Sumi T, Tanaka Y, Hirai S, Yamaguchi M, Miyajima M, Takahashi H, Watanabe A, Sakuma Y. P61.02 MCL1 Inhibition Enhances the Therapeutic Effect of MEK Inhibitors in KRAS-Mutant Lung Adenocarcinoma Cells. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.974] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
34
|
Chaveanghong S, Nakamura T, Takagi Y, Cagnon B, Uruga T, Tada M, Iwasawa Y, Yokoyama T. Sulfur poisoning of Pt and PtCo anode and cathode catalysts in polymer electrolyte fuel cells studied by operando near ambient pressure hard X-ray photoelectron spectroscopy. Phys Chem Chem Phys 2021; 23:3866-3873. [PMID: 33538733 DOI: 10.1039/d0cp06020h] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
We have investigated the S adsorption behaviours on Pt (average particle diameter of ∼2.6 nm) and Pt3Co (∼3.0 nm) anode and cathode electrode catalysts in polymer electrolyte fuel cells (PEFCs) under working conditions for the fresh state just after the aging process and also the degraded state after accelerated degradation tests (ADT), by studying near ambient pressure hard X-ray photoelectron spectroscopy (HAXPES). S 1s HAXPES of both the anode and cathode electrodes shows not only the principal S species from the sulfonic acid group (-SO3H) in the Nafion electrolyte but also other characteristic S species such as zero-valent S (S0) adsorbed on the carbon support and anionic S (S2-) adsorbed on the Pt electrode. The S2- species on Pt should be ascribed to S contamination poisoning the Pt catalyst electrode. The S2- species on the cathode can be oxidatively removed by applying a high cathode-anode bias voltage (≥0.8 V) to form SO32-, while at the anode the S2- species cannot be eliminated because of reductive environment in hydrogen gas. The important finding is the difference in S adsorption behaviours between the Pt/C and Pt3Co/C electrodes after ADT. After ADT, the Pt/C anode electrode exhibits much larger S2- adsorption than the Pt3Co/C anode electrode. This indicates that the Pt3Co/C anode is more desirable than the Pt/C one from the viewpoint of S poisoning. The reason for more tolerance of the Pt3Co/C anode catalyst against S poisoning after ADT can be ascribed to the more negative charge of the surface Pt atoms in the Pt3Co/C catalyst than those in the Pt/C one, thus yielding a weaker interaction between the surface Pt and the anionic S species as S2-, SO32-, and SO42-. A similar behaviour was observed also in the cathode catalyst. The present findings will nevertheless provide important information to design novel Pt-based PEFC electrodes with higher performance and longer durability.
Collapse
Affiliation(s)
- Suwilai Chaveanghong
- Department of Materials Molecular Science, Institute for Molecular Science, Okazaki, Aichi 444-8585, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Matsui H, Ishiguro N, Suzuki Y, Wakamatsu K, Yamada C, Sato K, Maejima N, Uruga T, Tada M. Reversible structural transformation and redox properties of Cr-loaded iron oxide dendrites studied by in situ XANES spectroscopy. Phys Chem Chem Phys 2020; 22:28093-28099. [PMID: 33289731 DOI: 10.1039/d0cp04416d] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Cr-Loaded iron oxide with a dendritic crystalline structure was synthesized and the reversible crystalline phase transition during redox cycling of the iron oxide was investigated. X-ray diffraction and transmission electron microscopy analyses revealed that Cr was well dispersed and loaded in the iron oxide dendrite crystals, whose lattice constant was dependent on the Cr loading. Temperature-programmed oxidation and reduction experiments revealed the reversible redox properties of the Cr-loaded iron oxide dendrites, whose redox temperature was found to be lower than that of Cr-free iron oxide dendrites. In situ Fe K-edge and Cr K-edge X-ray absorption near-edge structure (XANES) analysis indicated that Cr loading extended the redox reaction window for conversion between Fe3O4 and γ-Fe2O3 owing to compressive lattice strain in the iron oxide spinel structures.
Collapse
Affiliation(s)
- Hirosuke Matsui
- Department of Chemistry, Graduate School of Science & Institute for Advanced Science & Integrated Research Consortium on Chemical Science (IRCCS) & the R-ing (Reaction Infography) World Research Unit (B-1), Nagoya University, Furo-cho, Chikusa, Nagoya, Aichi 464-8602, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Ohki Y, Ishihara K, Yaoi M, Tada M, Sameera WMC, Cramer RE. A dinuclear Mo 2H 8 complex supported by bulky C 5H 2tBu 3 ligands. Chem Commun (Camb) 2020; 56:8035-8038. [PMID: 32691780 DOI: 10.1039/d0cc03274c] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Hydride-bridged transition metal complexes have been found to serve as suitable precursors for the activation of small molecules without the use of reducing agents. In this study, we synthesized a dinuclear Mo2H8 complex supported by bulky C5H2tBu3 (Cp‡) ligands, Cp‡2Mo2H8 (1), from the reaction of Cp‡MoCl4 with KC8 under H2. The hydrides of complex 1 can be replaced with benzene at 60 °C to afford a μ-benzene complex Cp‡2Mo2H2(μ-C6H6) (2).
Collapse
Affiliation(s)
- Yasuhiro Ohki
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8602, Japan.
| | - Kodai Ishihara
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8602, Japan.
| | - Moeko Yaoi
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8602, Japan.
| | - Mizuki Tada
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8602, Japan. and Integrated Research Consortium on Chemical Sciences (IRCCS), Nagoya University, Japan
| | - W M C Sameera
- Institute of Low Temperature Science, Hokkaido University, Sapporo, Japan
| | - Roger E Cramer
- Department of Chemistry, University of Hawaii, Manoa, 2545 McCarthy Mall, Honolulu, Hawaii 96822-2275, USA
| |
Collapse
|
37
|
Ishihara K, Araki Y, Tada M, Takayama T, Sakai Y, Sameera WMC, Ohki Y. Synthesis of Dinuclear Mo-Fe Hydride Complexes and Catalytic Silylation of N 2. Chemistry 2020; 26:9537-9546. [PMID: 32180271 DOI: 10.1002/chem.202000104] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2020] [Revised: 02/24/2020] [Indexed: 11/08/2022]
Abstract
Two transition-metal atoms bridged by hydrides may represent a useful structural motif for N2 activation by molecular complexes and the enzyme active site. In this study, dinuclear MoIV -FeII complexes with bridging hydrides, CpR Mo(PMe3 )(H)(μ-H)3 FeCp* (2 a; CpR =Cp*=C5 Me5 , 2 b; CpR =C5 Me4 H), were synthesized via deprotonation of CpR Mo(PMe3 )H5 (1 a; CpR =Cp*, 1 b; CpR =C5 Me4 H) by Cp*FeN(SiMe3 )2 , and they were characterized by spectroscopy and crystallography. These Mo-Fe complexes reveal the shortest Mo-Fe distances ever reported (2.4005(3) Å for 2 a and 2.3952(3) Å for 2 b), and the Mo-Fe interactions were analyzed by computational studies. Removal of the terminal Mo-H hydride in 2 a-2 b by [Ph3 C]+ in THF led to the formation of cationic THF adducts [CpR Mo(PMe3 )(THF)(μ-H)3 FeCp*]+ (3 a; CpR =Cp*, 3 b; CpR =C5 Me4 H). Further reaction of 3 a with LiPPh2 gave rise to a phosphido-bridged complex Cp*Mo(PMe3 )(μ-H)(μ-PPh2 )FeCp* (4). A series of Mo-Fe complexes were subjected to catalytic silylation of N2 in the presence of Na and Me3 SiCl, furnishing up to 129±20 equiv of N(SiMe3 )3 per molecule of 2 b. Mechanism of the catalytic cycle was analyzed by DFT calculations.
Collapse
Affiliation(s)
- Kodai Ishihara
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8602, Japan
| | - Yuna Araki
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8602, Japan
| | - Mizuki Tada
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8602, Japan.,Integrated Research Consortium on Chemical Sciences (IRCCS), Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8602, Japan
| | - Tsutomu Takayama
- Department of Chemistry, Daido University, Takiharu-cho, Minami-ku, Nagoya, 457-8530, Japan
| | - Yoichi Sakai
- Department of Chemistry, Daido University, Takiharu-cho, Minami-ku, Nagoya, 457-8530, Japan
| | - W M C Sameera
- Institute of Low Temperature Science, Hokkaido University, Sapporo, 060-0819, Japan
| | - Yasuhiro Ohki
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8602, Japan
| |
Collapse
|
38
|
Moock D, Wiesenfeldt MP, Freitag M, Muratsugu S, Ikemoto S, Knitsch R, Schneidewind J, Baumann W, Schäfer AH, Timmer A, Tada M, Hansen MR, Glorius F. Mechanistic Understanding of the Heterogeneous, Rhodium-Cyclic (Alkyl)(Amino)Carbene-Catalyzed (Fluoro-)Arene Hydrogenation. ACS Catal 2020; 10:6309-6317. [PMID: 32551183 PMCID: PMC7295364 DOI: 10.1021/acscatal.0c01074] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2020] [Revised: 05/04/2020] [Indexed: 12/31/2022]
Abstract
![]()
Recently, chemoselective
methods for the hydrogenation of fluorinated,
silylated, and borylated arenes have been developed providing direct
access to previously unattainable, valuable products. Herein, a comprehensive
study on the employed rhodium-cyclic (alkyl)(amino)carbene (CAAC)
catalyst precursor is disclosed. Mechanistic experiments, kinetic
studies, and surface-spectroscopic methods revealed supported rhodium(0)
nanoparticles (NP) as the active catalytic species. Further studies
suggest that CAAC-derived modifiers play a key role in determining
the chemoselectivity of the hydrogenation of fluorinated arenes, thus
offering an avenue for further tuning of the catalytic properties.
Collapse
Affiliation(s)
- Daniel Moock
- Organisch-Chemisches Institut, Westfälische Wilhelms-Universität Münster, Corrensstrasse 40, 48149 Münster, Germany
| | - Mario P. Wiesenfeldt
- Organisch-Chemisches Institut, Westfälische Wilhelms-Universität Münster, Corrensstrasse 40, 48149 Münster, Germany
| | - Matthias Freitag
- Organisch-Chemisches Institut, Westfälische Wilhelms-Universität Münster, Corrensstrasse 40, 48149 Münster, Germany
| | - Satoshi Muratsugu
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8602, Aichi, Japan
| | - Satoru Ikemoto
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8602, Aichi, Japan
| | - Robert Knitsch
- Institut für Physikalische Chemie, Westfälische Wilhelms-Universität Münster, Corrensstrasse 28/30, 48149 Münster, Germany
| | - Jacob Schneidewind
- Leibniz-Institut für Katalyse e. V., Albert-Einstein-Strasse 29a, 18059 Rostock, Germany
| | - Wolfgang Baumann
- Leibniz-Institut für Katalyse e. V., Albert-Einstein-Strasse 29a, 18059 Rostock, Germany
| | | | - Alexander Timmer
- nanoAnalytics GmbH, Heisenbergstrasse 11, 48149 Münster, Germany
| | - Mizuki Tada
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8602, Aichi, Japan
- Research Center for Materials Science (RCMS) and Integrated Research Consortium on Chemical Science (IRCCS), Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8603, Aichi, Japan
| | - Michael Ryan Hansen
- Institut für Physikalische Chemie, Westfälische Wilhelms-Universität Münster, Corrensstrasse 28/30, 48149 Münster, Germany
| | - Frank Glorius
- Organisch-Chemisches Institut, Westfälische Wilhelms-Universität Münster, Corrensstrasse 40, 48149 Münster, Germany
| |
Collapse
|
39
|
Tada M, Yamada Y, Mandai K, Hidaka N. AB0266 ANALYSIS OF STRESS AND FATIGUE IN PATIENTS WITH RHEUMATOID ARTHRITIS USING A DIGITIZING DEVICE. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.3022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Stress and fatigue are evaluated subjectively by patients using a visual analog scale (VAS) and questionnaires such as the SF-36 and the FACIT Fatigue Scale. Such evaluations are based on patients’ self-reported outcomes. It is difficult to evaluate stress and fatigue objectively. A digitizing device was used to quantify stress objectively.Objectives:To evaluate the correlations of a digitizing device and a VAS or a questionnaire about stress and fatigue, and the relationships with disease activity of patients with rheumatoid arthritis (RA).Methods:Data from a prospective observational study (CHIKARA study: Correlation researcH of sarcopenIa, sKeletal muscle and disease Activity in Rheumatoid Arthritis) were used. The study protocol was reported previously1. A total of 84 RA patients entered the study and were evaluated using a stress digitizing device (Smart Pulse, MEDICORE Co. LTD). This device evaluates stress based on heart rate variability theory2. The objective physical stress score (O-physical ST), mental stress score (O-mental ST), and total stress score (O-total ST) were calculated, ranging from 0 to 100 (higher score indicating greater stress). A questionnaire for stress, the Perceived Stress Scale3(PSS) 10 Japanese version (minimum 0, maximum 40), and VAS evaluations of stress (stress-VAS) and fatigue (fatigue-VAS) were carried out. The correlations between subjective and objective methods were analyzed. The relationships between stress, fatigue, and disease activity of RA patients were examined.Results:The patients’ mean age was 68.6 years (women n=66, men n=18), disease duration was 8.8 years, DAS28ESR was 3.24, and modified Health Assessment Questionnaire (mHAQ) was 0.5. The average PSS10 was 26.1, which was higher than in healthy individuals (20.3). The fatigue-VAS was higher than the stress-VAS (41.3 vs 34.5 mm). The O-physical ST score was similar to the O-mental ST score (39.5 vs 37.4). Correlations are shown in Table. The O-physical ST was positively correlated with the fatigue-VAS (R=0.243 p=0.026), and the O-mental ST was also positively correlated with the stress-VAS (R=0.267 p=0.014). However, there was no correlation between the PSS10 and objective stress parameters. The DAS28-ESR was correlated with the fatigue-VAS (R=0.223 p=0.041) and the O-total ST (R=0.329 p=0.002). The stress scale (O-total ST) was worse with moderate and high disease activity than in remission (Figure).Conclusion:The stress score obtained by an objective digitizing device was correlated with stress- and fatigue-VAS scores. However, there was no correlation with the PSS10 questionnaire. It was found that the fatigue-VAS score and the objective total stress score were high with worse disease control.References:[1]Tada, M., Yamada, Y., Mandai, K. & Hidaka, N. Matrix metalloprotease 3 is associated with sarcopenia in rheumatoid arthritis - results from the CHIKARA study.Int J Rheum Dis21, 1962-1969, doi:10.1111/1756-185X.13335 (2018).[2]Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology.Circulation93, 1043-1065 (1996).[3]Cohen, S., Kamarck, T. & Mermelstein, R. A global measure of perceived stress.J Health Soc Behav24, 385-396 (1983).Table.Correlation coefficients of subjective and objective evaluations of stress and fatigue in patients with RAPSS10Stress-VASfatigue-VASO-physical STO-mental STO-total STPSS100.580**0.404**0.0660.0550.004Stress-VAS0.673**0.0070.267*0.023Fatigue-VAS0.243*0.0590.160O-physical ST-0.224*0.708**O-mental ST-0.017O-total ST*: p<0.05, **: p,0.01, Spearman rank correlation coefficientDisclosure of Interests:None declared
Collapse
|
40
|
Mamoto K, Inui K, Okano T, Sugioka Y, Tada M, Koike T, Nakamura H. SAT0044 ADIPOCYTOKINE FLUCTUATES WITH INFLAMMATORY MARKERS OR DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS FROM FIVE-YEAR DATA OF TOMORROW STUDY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.4030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Leptin and adiponectin have been thought to be adipocytokines that promote or suppress inflammation, respectively.Objectives:The aim of this study was to investigate the relationship between adipocytokine and inflammatory markers or disease activity in patients with rheumatoid arthritis (RA) by using 5-year data of TOMORROW study which is a cohort study and started from 2010.Methods:We evaluated inflammatory markers, disease activity score (DAS)-CRP, medication and levels of adipocytokines in 202 patients with RA (mean age, 58.6 y; medication with biological agents, 54.9%) and 202 age- and sex-matched healthy volunteers (controls; mean age, 57.4 y). We eventually compared leptin or adiponectin concentrations in 183 RA patients and 190 controls from 2010 (BL) to 2015 (5Y) and investigated the relationship between adipocytokines and CRP or DAS in patients by using Spearman correlation analysis.Results:The levels of leptin and adiponectin in patients were significantly higher than controls at all time points. Adiponectin level of patients significantly increased from BL to 5Y compared to controls (Table 1). In patients, adiponectin showed significant negative correlation with CRP at both of BL and 5Y (BL:R=-0.174, 5Y:R=-0.240; p<0.05), however, not with DAS at BL and 5Y. Leptin positively correlated with CRP at 5Y(R=0.207; p<0.05), but not with CRP at BL or DAS at any time. Adiponectin levels at BL and 5Y were significantly higher in biologics users at BL and significantly increased from BL to 5Y compared to patients without biologics. No association between leptin levels and the use of biologics (Table 2).Conclusion:The level of adiponectin in RA patients with continuous treatments for 5 years increased, and the trend was more pronounced in biologics users. These results might indicate that adiponectin is a cytokine involved in anti-inflammatory effects.Disclosure of Interests:Kenji Mamoto: None declared, Kentaro Inui Grant/research support from: Janssen Pharmaceutical K.K., Astellas Pharma Inc., Sanofi K.K., Abbvie GK, Takeda Pharmaceutical Co. Ltd., QOL RD Co. Ltd., Mitsubishi Tanabe Pharma, Ono Pharmaceutical Co. Ltd., Eisai Co.,Ltd.,, Speakers bureau: Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma, Janssen Pharmaceutical K.K., Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Abbvie GK, Pfizer Inc., Eisai Co.,Ltd., Chugai Pharmaceutical Co., Ltd., Tadashi Okano Grant/research support from: AbbVie, Eisai, Mitsubishi Tanabe Pharma Corporation and Nipponkayaku, Speakers bureau: AbbVie, Asahikasei, Astellas Pharma Inc, Ayumi Pharmaceutical, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiich Sankyo, Eisai, Janssen, Lilly, Mitsubishi Tanabe Pharma Corporation, Novartis Pharma, Ono Pharmaceutical, Pfizer, Sanofi, Takeda Pharmaceutical, Teijin Pharma and UCB, Yuko Sugioka: None declared, Masahiro Tada: None declared, Tatsuya Koike Grant/research support from: AbbVie, Astellas Pharma Inc, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Janssen, Lilly, Mitsubishi Tanabe Pharma Corporation, MSD, Ono Pharmaceutical, Pfizer, Roche, Takeda Pharmaceutical, Teijin Pharma, and UCB, Speakers bureau: AbbVie, Astellas Pharma Inc, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Janssen, Lilly, Mitsubishi Tanabe Pharma Corporation, MSD, Ono Pharmaceutical, Pfizer, Roche, Takeda Pharmaceutical, Teijin Pharma, and UCB, Hiroaki Nakamura Grant/research support from: Astellas Pharma Inc. and Asahi Kasei Pharma Co.
Collapse
|
41
|
Anno S, Sugioka Y, Mamoto K, Okano T, Tada M, Inui K, Koike T, Nakamura H. FRI0051 RHEUMATOID ARTHRITIS PATIENTS WITH HIGH DISEASE ACTIVITY AND TREATED WITH HIGH DOSE GLUCOCORTICOID FREQUENTLY FALL: NINE YEARS OF THE TOMORROW STUDY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.2413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Falling is a multicausal phenomenon resulting from complex interactions between intrinsic and extrinsic or environmental factors. Patients with rheumatoid arthritis (RA) who have muscle weakness and stiff or painful joints might be at increased risk of falling. However, little is known about the exact properties of risk factors for falling in patients with RA. Recently, the disease activity of RA has been more satisfactorily controlled by the ‘‘treat-to-target’’ strategy, including the use of biologics. Given this new era, it is important to accurately estimate the incidence of falling in patients with RA and to elucidate contributing risk factors.Objectives:The objective of this study was to evaluate the incidence of falling and associated risk factors in 208 patients with RA and in age- and sex-matched 205 controls (Co) who participated in the TOMORROW (TOtalManagementOfRisk factors inRheumatoid arthritis patients to lOWer morbidity and mortality) study, a 10-year cohort study that started in 2010 in Japan. This research was conducted using TOMORROW study data for 9 years.Methods:We evaluated the incidence of falling by self-administered questionnaire every year and confirmed them by medical records. We also collected information about general health status, body composition including bone mineral density, lean body mass, fat mass and laboratory data. We compared the frequency of the incidence of falling in RA patients and Co for 9 years and analyzed risk factors for falling.Results:A total of 157 patients with RA (mean age: 57.1 ± 12.5 years, female: 84.7%, mean disease duration 13.9 ± 12.0 years) and 169 Co (mean age: 57.6 ± 12.5 years, female: 84.0%) completed 9 years observation. The rate of individuals who fell did not differ between two groups (RA: 66.9%, Co: 59.2%, p=0.19). However, number of falls was higher in RA than Co (0.35 vs 0.21/person-year, p=0.03). Multivariate logistic regression analysis adjusted for age, sex and BMI, revealed that RA was not a risk factor for the incidence of falling (OR: 1.36, 95%CI: 0.8-2.32, p=0.26) and the history of falling was a risk factor for the incidence of falling (OR: 3.27, 95%CI: 1.78-7.0, p<0.001). Multivariate linear regression analysis adjusted for age, sex and BMI, revealed that mHAQ (β=0.17, p=0.04), mean DAS28-CRP over 9 years (β=0.19, p=0.02) and mean dosage of glucocorticoid over 9 years (β=0.18, p=0.03) were the risk factors for number of falls (table 1).Table 1.Multivariate linear regression analysis of risk factors associated with number of falls sustained by patients RA.RAN=157Number of fallsβpAt the entryAnti-CCP antibody (U/mL)0.0160.835RF (IU/ml)0.0200.803History of falling0.1030.201DAS28-CRP0.0780.333mHAQ0.1690.039Dose of GC (mg/day)0.0280.7239 yearsAverage DAS28-CRP0.1850.024Average dose of GC (mg/day)0.1790.025RA, rheumatoid arthritis; CCP, cyclic citrullinated peptide; RF, Rheumatoid factor; DAS28-CRP, disease activity score 28 with C-reactive protein; mHAQ, modified Health Assessment Questionnaire; GC, glucocorticoid.Conclusion:There was no difference in the incidence of falling between RA and Co. However, number of falls was significantly higher in RA group. High disease activity and higher dosage of glucocorticoid were the risk factors for number of falls among RA patients.References:[1]C Armstrong et al, Ann Rheum Dis 2005;64:1602–1604[2]M Hayashibara et al, Osteoporos Int 2010;21:1825–1833Acknowledgments:We wish to thank Atsuko Kamiyama, Tomoko Nakatsuka and all participants in this study.Disclosure of Interests:Shohei Anno: None declared, Yuko Sugioka: None declared, Kenji Mamoto: None declared, Tadashi Okano Grant/research support from: AbbVie, Eisai, Mitsubishi Tanabe Pharma Corporation and Nipponkayaku, Speakers bureau: AbbVie, Asahikasei, Astellas Pharma Inc, Ayumi Pharmaceutical, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiich Sankyo, Eisai, Janssen, Lilly, Mitsubishi Tanabe Pharma Corporation, Novartis Pharma, Ono Pharmaceutical, Pfizer, Sanofi, Takeda Pharmaceutical, Teijin Pharma and UCB, Masahiro Tada: None declared, Kentaro Inui Grant/research support from: Janssen Pharmaceutical K.K., Astellas Pharma Inc., Sanofi K.K., Abbvie GK, Takeda Pharmaceutical Co. Ltd., QOL RD Co. Ltd., Mitsubishi Tanabe Pharma, Ono Pharmaceutical Co. Ltd., Eisai Co.,Ltd.,, Speakers bureau: Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma, Janssen Pharmaceutical K.K., Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Abbvie GK, Pfizer Inc., Eisai Co.,Ltd., Chugai Pharmaceutical Co., Ltd., Tatsuya Koike Grant/research support from: AbbVie, Astellas Pharma Inc, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Janssen, Lilly, Mitsubishi Tanabe Pharma Corporation, MSD, Ono Pharmaceutical, Pfizer, Roche, Takeda Pharmaceutical, Teijin Pharma, and UCB, Speakers bureau: AbbVie, Astellas Pharma Inc, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Janssen, Lilly, Mitsubishi Tanabe Pharma Corporation, MSD, Ono Pharmaceutical, Pfizer, Roche, Takeda Pharmaceutical, Teijin Pharma, and UCB, Hiroaki Nakamura Grant/research support from: Astellas Pharma Inc. and Asahi Kasei Pharma Co.
Collapse
|
42
|
Matsumoto Y, Sugioka Y, Tada M, Okano T, Mamoto K, Inui K, Habu D, Koike T. FRI0609-HPR NUTRIENTS INTAKE CONDITION RELATES TO MAINTENANCE LOW DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING 6 YEARS: TOMORROW STUDY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.4058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:We have previously reported that nutritional intake status might relate to disease activity (1). Nutritional survey on prospective cohort study in rheumatoid arthritis (RA) patients and information about relationship between nutritional intake status and disease activity was very limited.Objectives:This study aimed to obtain data from a cohort study for new nutritional therapy in RA patients.Methods:We used TOMORROW cohort study data which conducted from years of 2010 to 2020. Two hundred and eight RA patients, and 205 non-RA sex and age matched controls were investigated, and we analyzed data from 2011 to 2017. Nutritional intake status was compared between who maintain lower disease activity during 2011 to 2017 (LDA group) and being higher disease activity even once in 2011 to 2017 (non-LDA group). Disease activity was evaluated by DAS28-ESR in every year and nutritional intake status was surveyed by brief self-administered diet history questionnaire (BDHQ) in 2011 and 2017.Results:In RA patients, the change value from 2011 to 2017 of iron (odds ratio; 2.37), thiamin (OR; 2.96) and folic acid (OR; 3.16) intake which adjusted by energy intake, age, rheumatoid factor and medication status were extracted as independent factors for maintain LDA by multivariate logistic regression. These nutrients intake in RA patients was significantly lower than control both in 2011 and 2017. In RA patients, iron and folic acid intake in LDA group was significantly lower than non-LDA group in 2011. Folic acid intake was increased in LDA group and decreased in non-LDA group over time, and these nutrients showed significant differences in change value between LDA group and non-LDA group (p<0.05).Conclusion:The overtime change value in iron, thiamin and folic acid related to maintain six years low disease activity in RA patients.References:[1] Matsumoto Y, Sugioka Y, Tada M, Okano T, Mamoto K, Inui K, et al. Monounsaturated fatty acids might be key factors in the Mediterranean diet that suppress rheumatoid arthritis disease activity: The TOMORROW study. Clinical Nutrition 37:675-680, 2018Disclosure of Interests:Yoshinari Matsumoto Grant/research support from: Yamada Research Grant (grant No.249), Yuko Sugioka: None declared, Masahiro Tada: None declared, Tadashi Okano Grant/research support from: AbbVie, Eisai, Mitsubishi Tanabe Pharma Corporation and Nipponkayaku, Speakers bureau: AbbVie, Asahikasei, Astellas Pharma Inc, Ayumi Pharmaceutical, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiich Sankyo, Eisai, Janssen, Lilly, Mitsubishi Tanabe Pharma Corporation, Novartis Pharma, Ono Pharmaceutical, Pfizer, Sanofi, Takeda Pharmaceutical, Teijin Pharma and UCB, Kenji Mamoto: None declared, Kentaro Inui Grant/research support from: Janssen Pharmaceutical K.K., Astellas Pharma Inc., Sanofi K.K., Abbvie GK, Takeda Pharmaceutical Co. Ltd., QOL RD Co. Ltd., Mitsubishi Tanabe Pharma, Ono Pharmaceutical Co. Ltd., Eisai Co.,Ltd.,, Speakers bureau: Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma, Janssen Pharmaceutical K.K., Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Abbvie GK, Pfizer Inc., Eisai Co.,Ltd., Chugai Pharmaceutical Co., Ltd., Daiki Habu: None declared, Tatsuya Koike Grant/research support from: AbbVie, Astellas Pharma Inc, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Janssen, Lilly, Mitsubishi Tanabe Pharma Corporation, MSD, Ono Pharmaceutical, Pfizer, Roche, Takeda Pharmaceutical, Teijin Pharma, and UCB, Speakers bureau: AbbVie, Astellas Pharma Inc, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Janssen, Lilly, Mitsubishi Tanabe Pharma Corporation, MSD, Ono Pharmaceutical, Pfizer, Roche, Takeda Pharmaceutical, Teijin Pharma, and UCB
Collapse
|
43
|
Tada M, Yamada Y, Mandai K, Hidaka N. AB0265 REDUCTION OF APPENDICULAR SKELETAL MASS INDEX IS A PREDICTOR OF FRACTURE IN PATIENTS WITH RHEUMATOID ARTHRITIS BASED ON THE THREE-YEAR FOLLOW-UP DATA OF THE CHIKARA STUDY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.2064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Patients with rheumatoid arthritis (RA) have lower muscle mass1and a higher risk of fragility fracture2compared with healthy individuals. The predictors for fractures among baseline data and the chronological changes of disease activity, body composition, and muscle mass are unknown.Objectives:The predictors for fractures were investigated over a 3-year period in a longitudinal study.Methods:The 3-year follow-up data from a prospective observational study (CHIKARA study: Correlation researcH of sarcopenIa, sKeletal muscle and disease Activity in Rheumatoid Arthritis) were used. The patients’ fractures were counted, and correlations between fractures and disease activity, body composition, and sarcopenia were investigated. Muscle mass, body fat mass, total body water, bone mass, and basal metabolic rate were measured using a body composition analyzer. The fracture-free survival rate was calculated. The relationships between fractures and each parameter at baseline and the changes over the 3-year period (Δ) were investigated by univariate and multivariate analyses.Results:A total of 100 patients (78 female, average age 68 years) were enrolled in this study; 12 patients (10 female and 2 male) had fractures during the 3-year follow-up, and the fracture-free survival rate was 86.9%. The Δmodified Health Assessment Questionnaire (mHAQ), Δweight, Δmuscle mass, Δestimated bone mass, Δbasal metabolic rate, and Δappendicular skeletal muscle index (ASMI) were predictors for fractures. On the other hand, body composition, disease activity, and sarcopenia at baseline were not correlated with fractures (Table 1). The ΔASMI was an independent predictor for fractures on multivariate analysis (odds ratio:0.015, P=0.026). The estimated cut-off value of the ΔASMI was 0.14 kg/m2on receiver operating characteristic curve analysis (Figure). When the ΔASMI decrease was greater than or equal to 0.14 kg/m2for three years, the odds ratio of fractures was significantly increased 9.8-fold, compared to a ΔASMI decrease less than 0.14 kg/m2(P=0.001).Table 1.Predictors for fractures in patients with RAUnivariateR valueP valueBaselineAge, year0.1720.087DAS28-ESR-0.0830.411mHAQ0.0770.447Weight, kg0.0210.837Muscle mass, kg-0.00350.728Estimated bone mass, kg-0.0200.845Sarcopenia-0.0930.356Change of 3-year periodΔDAS28-ESR0.1870.088ΔmHAQ0.2240.040ΔWeight, kg-0.2240.045ΔMuscle mass, kg-0.2530.023ΔEstimated bone mass, kg-0.2360.034ΔBasal metabolic rate, kcal/day-0.2480.025ΔAppendicular skeletal muscle index, kg/m2-0.3520.001Conclusion:The fracture-free survival rate was 86.9% in this 3-year longitudinal study. It was difficult to predict future fractures from the baseline data. Reduction of the ASMI was an independent predictor for fractures. Alleviating muscle mass loss may prevent fractures.References:[1]Inui K., Koike T., Tada M., et al. Sarcopenia is apparent in patients with rheumatoid arthritis, especially those with biologics -TOMORROW study-.EULAR2015 abstract (AB0359).[2]van Staa TP, Geusens P, Bijlsma JW, et al. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis.Arthritis Rheum.2006; 54: 3104–12.Disclosure of Interests:None declared
Collapse
|
44
|
Inui K, Sugioka Y, Okano T, Tada M, Mamoto K, Orita K, Nakamura H. THU0138 AGEING IN RA PATIENTS DETERIORATED MODIFIED HEALTH ASSESSMENT QUESTIONNAIRE (MHAQ) OVER A 7-YEAR PERIOD INDEPENDENTLY FROM DISEASE ACTIVITY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.2775] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/18/2023]
Abstract
Background:Recent advances of treatment for rheumatoid arthritis (RA) realizes us to set the treatment goal as remission. As the results, health assessment questionnaire (HAQ) has been also becoming better in these years. On the other hand, progress in ageing has been a major issue in Japan, including the patients with RA. which is thought as one of the factors affecting HAQ.Objectives:To evaluate the impact of ageing on HAQ in RA patients.Methods:The data of 208 RA patients used in this study was collected over a 7-year period from 2010 to 2017 as part of a prospective cohort study (TOMORROW Study: UMIN000003876) that included RA patients and age- and sex-matched volunteers recruited through mass media as controls. The data of RA patients included anthropometric, blood test data, disease activity score28-CRP (DAS28) and modified HAQ (mHAQ), together with baseline (BL) characteristics. The course of mHAQ for 7 years were analyzed by repeated measure ANOVA, and association between the changes of mHAQ at year-7 from BL (ΔmHAQ) and BL factors were analyzed by multiple regression analysis.Results:Two hundred and eight RA patients (153 women; mean age 58.1 years) were enrolled in the present study. Modified HAQ decreased significantly over the 7-year study period in RA patients. When the patients were stratified into 3 groups (lower than 2.7, between 2.7 and 4.1, over 4.1) by DAS28 at BL, mHAQ of the patients with high disease activity (DAS28: over 4.1) at BL was significantly worse than other groups (p=0.018; repeated measure ANOVA). There was no interaction between time and 3 groups (p=0.118; repeated measure ANOVA). Multiple regression analysis with ΔmHAQ as the outcome variable and ACPA, age, BMI, CRP, DAS28, MMP-3 at BL as independent variables revealed that age (p=0.034) and DAS28 (p=0.042) were independently related with ΔmHAQ.Conclusion:Ageing in RA patients impacted worsening of mHAQ over a 7-year period independently from disease activity. On assessing mHAQ in elderly RA patients, we must consider the age as well as the disease activity.Disclosure of Interests:Kentaro Inui Grant/research support from: Janssen Pharmaceutical K.K., Astellas Pharma Inc., Sanofi K.K., Abbvie GK, Takeda Pharmaceutical Co. Ltd., QOL RD Co. Ltd., Mitsubishi Tanabe Pharma, Ono Pharmaceutical Co. Ltd., Eisai Co.,Ltd.,, Speakers bureau: Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma, Janssen Pharmaceutical K.K., Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Abbvie GK, Pfizer Inc., Eisai Co.,Ltd., Chugai Pharmaceutical Co., Ltd., Yuko Sugioka: None declared, Tadashi Okano Grant/research support from: AbbVie, Eisai, Mitsubishi Tanabe Pharma Corporation and Nipponkayaku, Speakers bureau: AbbVie, Asahikasei, Astellas Pharma Inc, Ayumi Pharmaceutical, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiich Sankyo, Eisai, Janssen, Lilly, Mitsubishi Tanabe Pharma Corporation, Novartis Pharma, Ono Pharmaceutical, Pfizer, Sanofi, Takeda Pharmaceutical, Teijin Pharma and UCB, Masahiro Tada: None declared, Kenji Mamoto: None declared, kazuki Orita: None declared, Hiroaki Nakamura Grant/research support from: Astellas Pharma Inc. and Asahi Kasei Pharma Co.
Collapse
|
45
|
Kimura Y, Tomura A, Fakkao M, Nakamura T, Ishiguro N, Sekizawa O, Nitta K, Uruga T, Okumura T, Tada M, Uchimoto Y, Amezawa K. 3D Operando Imaging and Quantification of Inhomogeneous Electrochemical Reactions in Composite Battery Electrodes. J Phys Chem Lett 2020; 11:3629-3636. [PMID: 32315194 DOI: 10.1021/acs.jpclett.0c00876] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
The performances of electrochemical systems such as solid-state batteries (SSBs) can be severely hindered by the three-dimensional (3D) and mesoscopically inhomogeneous electrochemical reactions that take place in the electrodes. However, the majority of existing methods for analyzing such inhomogeneous reactions are restricted to one- or two-dimensional observations. Herein, we performed 3D operando imaging of the mesoscopically inhomogeneous electrochemical reaction in a composite SSB electrode using hard X-ray computed-tomography with X-ray absorption near edge structure spectroscopy (CT-XANES). The 3D inhomogeneous reaction evolution during (dis)charge was successfully visualized for the first time. Furthermore, our 3D quantitative analysis unambiguously revealed the origin of the inhomogeneous reaction in the investigated electrode. Our results suggested that slow ion transport through active material particles can considerably restrict SSB performances. Our technique therefore provides new insights into the electrochemical reactions taking place in electrodes and enables us to maximize the performance of electrochemical systems.
Collapse
Affiliation(s)
- Yuta Kimura
- Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Katahira, Aoba, Sendai, Miyagi 980-8579, Japan
| | - Aina Tomura
- Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Katahira, Aoba, Sendai, Miyagi 980-8579, Japan
| | - Mahunnop Fakkao
- Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Katahira, Aoba, Sendai, Miyagi 980-8579, Japan
| | - Takashi Nakamura
- Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Katahira, Aoba, Sendai, Miyagi 980-8579, Japan
| | - Nozomu Ishiguro
- Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Katahira, Aoba, Sendai, Miyagi 980-8579, Japan
| | - Oki Sekizawa
- Japan Synchrotron Radiation Research Institute, SPring-8, Koto, Sayo, Hyogo 679-5198, Japan
| | - Kiyofumi Nitta
- Japan Synchrotron Radiation Research Institute, SPring-8, Koto, Sayo, Hyogo 679-5198, Japan
| | - Tomoya Uruga
- Japan Synchrotron Radiation Research Institute, SPring-8, Koto, Sayo, Hyogo 679-5198, Japan
| | - Toyoki Okumura
- National Institute of Advanced Industrial Science and Technology, Midorigaoka, Ikeda, Osaka 563-8577, Japan
| | - Mizuki Tada
- Graduate School of Science/Institute for Advanced Science, Nagoya University, Furo, Chikusa, Nagoya, Aichi 464-8602, Japan
| | - Yoshiharu Uchimoto
- Graduate School of Human and Environmental Studies, Kyoto University, Yoshida-nihonmatsu, Sakyo, Kyoto 606-8501, Japan
| | - Koji Amezawa
- Institute of Multidisciplinary Research for Advanced Materials, Tohoku University, Katahira, Aoba, Sendai, Miyagi 980-8579, Japan
| |
Collapse
|
46
|
Samjeské G, Kaneko T, Gunji T, Higashi K, Uruga T, Tada M, Iwasawa Y. Feed gas exchange (startup/shutdown) effects on Pt/C cathode electrocatalysis and surface Pt-oxide behavior in polymer electrolyte fuel cells as revealed using in situ real-time XAFS and high-resolution STEM measurements. Phys Chem Chem Phys 2020; 22:9424-9437. [PMID: 32314748 DOI: 10.1039/c9cp06895c] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The synchronizing measurements of both cyclic voltammograms (CVs) and real-time quick XAFSs (QXAFSs) for Pt/C cathode electrocatalysts in a membrane electrode assembly (MEA) of polymer electrolyte fuel cells (PEFCs) treated by anode-gas exchange (AGEX) and cathode-gas exchange (CGEX) cycles (startup/shutdown conditions of FC vehicles) were performed for the first time to understand the opposite effects of the AGEX and CGEX treatments on the Pt/C performance and durability and also the contradiction between the electrochemical active surface area (ECSA) decrease and the performance increase by CGEX treatment. While the AGEX treatment decreased both the ECSA and performance of MEA Pt/C due to carbon corrosion, it was found that the CGEX treatment decreased the ECSA but increased the Pt/C performance significantly due to high-index (331) facet formation (high-resolution STEM) and hence the suppression of strongly bound Pt-oxide formation at cathode Pt nanoparticle surfaces. Transient QXAFS time-profile analysis for the MEA Pt/C also revealed a direct relationship between the electrochemical performance or durability and transient kinetics of the Pt/C cathode.
Collapse
Affiliation(s)
- Gabor Samjeské
- Department of Chemistry, Graduate School of Science, Nagoya University, Chikusa, Nagoya, Aichi 464-8602, Japan
| | | | | | | | | | | | | |
Collapse
|
47
|
Abe K, Akutsu R, Ali A, Alt C, Andreopoulos C, Anthony L, Antonova M, Aoki S, Ariga A, Asada Y, Ashida Y, Atkin ET, Awataguchi Y, Ban S, Barbi M, Barker GJ, Barr G, Barrow D, Barry C, Batkiewicz-Kwasniak M, Beloshapkin A, Bench F, Berardi V, Berkman S, Berns L, Bhadra S, Bienstock S, Blondel A, Bolognesi S, Bourguille B, Boyd SB, Brailsford D, Bravar A, Bravo Berguño D, Bronner C, Bubak A, Buizza Avanzini M, Calcutt J, Campbell T, Cao S, Cartwright SL, Catanesi MG, Cervera A, Chappell A, Checchia C, Cherdack D, Chikuma N, Christodoulou G, Coleman J, Collazuol G, Cook L, Coplowe D, Cudd A, Dabrowska A, De Rosa G, Dealtry T, Denner PF, Dennis SR, Densham C, Di Lodovico F, Dokania N, Dolan S, Doyle TA, Drapier O, Dumarchez J, Dunne P, Eklund L, Emery-Schrenk S, Ereditato A, Fernandez P, Feusels T, Finch AJ, Fiorentini GA, Fiorillo G, Francois C, Friend M, Fujii Y, Fujita R, Fukuda D, Fukuda R, Fukuda Y, Fusshoeller K, Gameil K, Giganti C, Golan T, Gonin M, Gorin A, Guigue M, Hadley DR, Haigh JT, Hamacher-Baumann P, Hartz M, Hasegawa T, Hastings NC, Hayashino T, Hayato Y, Hiramoto A, Hogan M, Holeczek J, Hong Van NT, Iacob F, Ichikawa AK, Ikeda M, Ishida T, Ishii T, Ishitsuka M, Iwamoto K, Izmaylov A, Jakkapu M, Jamieson B, Jenkins SJ, Jesús-Valls C, Jiang M, Johnson S, Jonsson P, Jung CK, Kabirnezhad M, Kaboth AC, Kajita T, Kakuno H, Kameda J, Karlen D, Kasetti SP, Kataoka Y, Katori T, Kato Y, Kearns E, Khabibullin M, Khotjantsev A, Kikawa T, Kim H, Kim J, King S, Kisiel J, Knight A, Knox A, Kobayashi T, Koch L, Koga T, Konaka A, Kormos LL, Koshio Y, Kostin A, Kowalik K, Kubo H, Kudenko Y, Kukita N, Kuribayashi S, Kurjata R, Kutter T, Kuze M, Labarga L, Lagoda J, Lamoureux M, Laveder M, Lawe M, Licciardi M, Lindner T, Litchfield RP, Liu SL, Li X, Longhin A, Ludovici L, Lu X, Lux T, Machado LN, Magaletti L, Mahn K, Malek M, Manly S, Maret L, Marino AD, Marti-Magro L, Martin JF, Maruyama T, Matsubara T, Matsushita K, Matveev V, Mavrokoridis K, Mazzucato E, McCarthy M, McCauley N, McFarland KS, McGrew C, Mefodiev A, Metelko C, Mezzetto M, Minamino A, Mineev O, Mine S, Miura M, Molina Bueno L, Moriyama S, Morrison J, Mueller TA, Munteanu L, Murphy S, Nagai Y, Nakadaira T, Nakahata M, Nakajima Y, Nakamura A, Nakamura KG, Nakamura K, Nakayama S, Nakaya T, Nakayoshi K, Nantais C, Ngoc TV, Niewczas K, Nishikawa K, Nishimura Y, Nonnenmacher TS, Nova F, Novella P, Nowak J, Nugent JC, O'Keeffe HM, O'Sullivan L, Odagawa T, Okumura K, Okusawa T, Oser SM, Owen RA, Oyama Y, Palladino V, Palomino JL, Paolone V, Parker WC, Pasternak J, Paudyal P, Pavin M, Payne D, Penn GC, Pickering L, Pidcott C, Pintaudi G, Pinzon Guerra ES, Pistillo C, Popov B, Porwit K, Posiadala-Zezula M, Pritchard A, Quilain B, Radermacher T, Radicioni E, Radics B, Ratoff PN, Reinherz-Aronis E, Riccio C, Rondio E, Roth S, Rubbia A, Ruggeri AC, Ruggles CA, Rychter A, Sakashita K, Sánchez F, Schloesser CM, Scholberg K, Schwehr J, Scott M, Seiya Y, Sekiguchi T, Sekiya H, Sgalaberna D, Shah R, Shaikhiev A, Shaker F, Shaykina A, Shiozawa M, Shorrock W, Shvartsman A, Smirnov A, Smy M, Sobczyk JT, Sobel H, Soler FJP, Sonoda Y, Steinmann J, Suvorov S, Suzuki A, Suzuki SY, Suzuki Y, Sztuc AA, Tada M, Tajima M, Takeda A, Takeuchi Y, Tanaka HK, Tanaka HA, Tanaka S, Thompson LF, Toki W, Touramanis C, Towstego T, Tsui KM, Tsukamoto T, Tzanov M, Uchida Y, Uno W, Vagins M, Valder S, Vallari Z, Vargas D, Vasseur G, Vilela C, Vinning WGS, Vladisavljevic T, Volkov VV, Wachala T, Walker J, Walsh JG, Wang Y, Wark D, Wascko MO, Weber A, Wendell R, Wilking MJ, Wilkinson C, Wilson JR, Wilson RJ, Wood K, Wret C, Yamada Y, Yamamoto K, Yanagisawa C, Yang G, Yano T, Yasutome K, Yen S, Yershov N, Yokoyama M, Yoshida T, Yu M, Zalewska A, Zalipska J, Zaremba K, Zarnecki G, Ziembicki M, Zimmerman ED, Zito M, Zsoldos S, Zykova A. Search for Electron Antineutrino Appearance in a Long-Baseline Muon Antineutrino Beam. Phys Rev Lett 2020; 124:161802. [PMID: 32383902 DOI: 10.1103/physrevlett.124.161802] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/19/2019] [Revised: 02/26/2020] [Accepted: 03/25/2020] [Indexed: 06/11/2023]
Abstract
Electron antineutrino appearance is measured by the T2K experiment in an accelerator-produced antineutrino beam, using additional neutrino beam operation to constrain parameters of the Pontecorvo-Maki-Nakagawa-Sakata (PMNS) mixing matrix. T2K observes 15 candidate electron antineutrino events with a background expectation of 9.3 events. Including information from the kinematic distribution of observed events, the hypothesis of no electron antineutrino appearance is disfavored with a significance of 2.40σ and no discrepancy between data and PMNS predictions is found. A complementary analysis that introduces an additional free parameter which allows non-PMNS values of electron neutrino and antineutrino appearance also finds no discrepancy between data and PMNS predictions.
Collapse
Affiliation(s)
- K Abe
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - R Akutsu
- University of Tokyo, Institute for Cosmic Ray Research, Research Center for Cosmic Neutrinos, Kashiwa, Japan
| | - A Ali
- Kyoto University, Department of Physics, Kyoto, Japan
| | - C Alt
- ETH Zurich, Institute for Particle Physics and Astrophysics, Zurich, Switzerland
| | - C Andreopoulos
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - L Anthony
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - M Antonova
- IFIC (CSIC & University of Valencia), Valencia, Spain
| | - S Aoki
- Kobe University, Kobe, Japan
| | - A Ariga
- University of Bern, Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), Bern, Switzerland
| | - Y Asada
- Yokohama National University, Faculty of Engineering, Yokohama, Japan
| | - Y Ashida
- Kyoto University, Department of Physics, Kyoto, Japan
| | - E T Atkin
- Imperial College London, Department of Physics, London, United Kingdom
| | - Y Awataguchi
- Tokyo Metropolitan University, Department of Physics, Tokyo, Japan
| | - S Ban
- Kyoto University, Department of Physics, Kyoto, Japan
| | - M Barbi
- University of Regina, Department of Physics, Regina, Saskatchewan, Canada
| | - G J Barker
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | - G Barr
- Oxford University, Department of Physics, Oxford, United Kingdom
| | - D Barrow
- Oxford University, Department of Physics, Oxford, United Kingdom
| | - C Barry
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | | | - A Beloshapkin
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - F Bench
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - V Berardi
- INFN Sezione di Bari and Università e Politecnico di Bari, Dipartimento Interuniversitario di Fisica, Bari, Italy
| | - S Berkman
- University of British Columbia, Department of Physics and Astronomy, Vancouver, British Columbia, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - L Berns
- Tokyo Institute of Technology, Department of Physics, Tokyo, Japan
| | - S Bhadra
- York University, Department of Physics and Astronomy, Toronto, Ontario, Canada
| | - S Bienstock
- Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Paris, France
| | - A Blondel
- University of Geneva, Section de Physique, DPNC, Geneva, Switzerland
- Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Paris, France
| | | | - B Bourguille
- Institut de Fisica d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra (Barcelona) Spain
| | - S B Boyd
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | - D Brailsford
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - A Bravar
- University of Geneva, Section de Physique, DPNC, Geneva, Switzerland
| | - D Bravo Berguño
- University Autonoma Madrid, Department of Theoretical Physics, Madrid, Spain
| | - C Bronner
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - A Bubak
- University of Silesia, Institute of Physics, Katowice, Poland
| | - M Buizza Avanzini
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - J Calcutt
- Michigan State University, Department of Physics and Astronomy, East Lansing, Michigan, USA
| | - T Campbell
- University of Colorado at Boulder, Department of Physics, Boulder, Colorado, USA
| | - S Cao
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - S L Cartwright
- University of Sheffield, Department of Physics and Astronomy, Sheffield, United Kingdom
| | - M G Catanesi
- INFN Sezione di Bari and Università e Politecnico di Bari, Dipartimento Interuniversitario di Fisica, Bari, Italy
| | - A Cervera
- IFIC (CSIC & University of Valencia), Valencia, Spain
| | - A Chappell
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | - C Checchia
- INFN Sezione di Padova and Università di Padova, Dipartimento di Fisica, Padova, Italy
| | - D Cherdack
- University of Houston, Department of Physics, Houston, Texas, USA
| | - N Chikuma
- University of Tokyo, Department of Physics, Tokyo, Japan
| | - G Christodoulou
- CERN European Organization for Nuclear Research, CH-1211 Genève 23, Switzerland
| | - J Coleman
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - G Collazuol
- INFN Sezione di Padova and Università di Padova, Dipartimento di Fisica, Padova, Italy
| | - L Cook
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- Oxford University, Department of Physics, Oxford, United Kingdom
| | - D Coplowe
- Oxford University, Department of Physics, Oxford, United Kingdom
| | - A Cudd
- Michigan State University, Department of Physics and Astronomy, East Lansing, Michigan, USA
| | - A Dabrowska
- H. Niewodniczanski Institute of Nuclear Physics PAN, Cracow, Poland
| | - G De Rosa
- INFN Sezione di Napoli and Università di Napoli, Dipartimento di Fisica, Napoli, Italy
| | - T Dealtry
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - P F Denner
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | - S R Dennis
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - C Densham
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - F Di Lodovico
- King's College London, Department of Physics, Strand, London WC2R 2LS, United Kingdom
| | - N Dokania
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - S Dolan
- CERN European Organization for Nuclear Research, CH-1211 Genève 23, Switzerland
| | - T A Doyle
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - O Drapier
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - J Dumarchez
- Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Paris, France
| | - P Dunne
- Imperial College London, Department of Physics, London, United Kingdom
| | - L Eklund
- University of Glasgow, School of Physics and Astronomy, Glasgow, United Kingdom
| | | | - A Ereditato
- University of Bern, Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), Bern, Switzerland
| | - P Fernandez
- IFIC (CSIC & University of Valencia), Valencia, Spain
| | - T Feusels
- University of British Columbia, Department of Physics and Astronomy, Vancouver, British Columbia, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - A J Finch
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - G A Fiorentini
- York University, Department of Physics and Astronomy, Toronto, Ontario, Canada
| | - G Fiorillo
- INFN Sezione di Napoli and Università di Napoli, Dipartimento di Fisica, Napoli, Italy
| | - C Francois
- University of Bern, Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), Bern, Switzerland
| | - M Friend
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - Y Fujii
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - R Fujita
- University of Tokyo, Department of Physics, Tokyo, Japan
| | - D Fukuda
- Okayama University, Department of Physics, Okayama, Japan
| | - R Fukuda
- Tokyo University of Science, Faculty of Science and Technology, Department of Physics, Noda, Chiba, Japan
| | - Y Fukuda
- Miyagi University of Education, Department of Physics, Sendai, Japan
| | - K Fusshoeller
- ETH Zurich, Institute for Particle Physics and Astrophysics, Zurich, Switzerland
| | - K Gameil
- University of British Columbia, Department of Physics and Astronomy, Vancouver, British Columbia, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - C Giganti
- Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Paris, France
| | - T Golan
- Wroclaw University, Faculty of Physics and Astronomy, Wroclaw, Poland
| | - M Gonin
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - A Gorin
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M Guigue
- Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Paris, France
| | - D R Hadley
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | - J T Haigh
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | | | - M Hartz
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- TRIUMF, Vancouver, British Columbia, Canada
| | - T Hasegawa
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - N C Hastings
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - T Hayashino
- Kyoto University, Department of Physics, Kyoto, Japan
| | - Y Hayato
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - A Hiramoto
- Kyoto University, Department of Physics, Kyoto, Japan
| | - M Hogan
- Colorado State University, Department of Physics, Fort Collins, Colorado, USA
| | - J Holeczek
- University of Silesia, Institute of Physics, Katowice, Poland
| | - N T Hong Van
- Institute For Interdisciplinary Research in Science and Education (IFIRSE), ICISE, Quy Nhon, Vietnam
- International Centre of Physics, Institute of Physics (IOP), Vietnam Academy of Science and Technology (VAST), 10 Dao Tan, Ba Dinh, Hanoi, Vietnam
| | - F Iacob
- INFN Sezione di Padova and Università di Padova, Dipartimento di Fisica, Padova, Italy
| | - A K Ichikawa
- Kyoto University, Department of Physics, Kyoto, Japan
| | - M Ikeda
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - T Ishida
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - T Ishii
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - M Ishitsuka
- Tokyo University of Science, Faculty of Science and Technology, Department of Physics, Noda, Chiba, Japan
| | - K Iwamoto
- University of Tokyo, Department of Physics, Tokyo, Japan
| | - A Izmaylov
- IFIC (CSIC & University of Valencia), Valencia, Spain
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M Jakkapu
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - B Jamieson
- University of Winnipeg, Department of Physics, Winnipeg, Manitoba, Canada
| | - S J Jenkins
- University of Sheffield, Department of Physics and Astronomy, Sheffield, United Kingdom
| | - C Jesús-Valls
- Institut de Fisica d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra (Barcelona) Spain
| | - M Jiang
- Kyoto University, Department of Physics, Kyoto, Japan
| | - S Johnson
- University of Colorado at Boulder, Department of Physics, Boulder, Colorado, USA
| | - P Jonsson
- Imperial College London, Department of Physics, London, United Kingdom
| | - C K Jung
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - M Kabirnezhad
- Oxford University, Department of Physics, Oxford, United Kingdom
| | - A C Kaboth
- Royal Holloway University of London, Department of Physics, Egham, Surrey, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - T Kajita
- University of Tokyo, Institute for Cosmic Ray Research, Research Center for Cosmic Neutrinos, Kashiwa, Japan
| | - H Kakuno
- Tokyo Metropolitan University, Department of Physics, Tokyo, Japan
| | - J Kameda
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - D Karlen
- TRIUMF, Vancouver, British Columbia, Canada
- University of Victoria, Department of Physics and Astronomy, Victoria, British Columbia, Canada
| | - S P Kasetti
- Louisiana State University, Department of Physics and Astronomy, Baton Rouge, Louisiana, USA
| | - Y Kataoka
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - T Katori
- King's College London, Department of Physics, Strand, London WC2R 2LS, United Kingdom
| | - Y Kato
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - E Kearns
- Boston University, Department of Physics, Boston, Massachusetts, USA
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - M Khabibullin
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - A Khotjantsev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - T Kikawa
- Kyoto University, Department of Physics, Kyoto, Japan
| | - H Kim
- Osaka City University, Department of Physics, Osaka, Japan
| | - J Kim
- University of British Columbia, Department of Physics and Astronomy, Vancouver, British Columbia, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - S King
- Queen Mary University of London, School of Physics and Astronomy, London, United Kingdom
| | - J Kisiel
- University of Silesia, Institute of Physics, Katowice, Poland
| | - A Knight
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | - A Knox
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - T Kobayashi
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - L Koch
- Oxford University, Department of Physics, Oxford, United Kingdom
| | - T Koga
- University of Tokyo, Department of Physics, Tokyo, Japan
| | - A Konaka
- TRIUMF, Vancouver, British Columbia, Canada
| | - L L Kormos
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - Y Koshio
- Okayama University, Department of Physics, Okayama, Japan
| | - A Kostin
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - K Kowalik
- National Centre for Nuclear Research, Warsaw, Poland
| | - H Kubo
- Kyoto University, Department of Physics, Kyoto, Japan
| | - Y Kudenko
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - N Kukita
- Osaka City University, Department of Physics, Osaka, Japan
| | - S Kuribayashi
- Kyoto University, Department of Physics, Kyoto, Japan
| | - R Kurjata
- Warsaw University of Technology, Institute of Radioelectronics and Multimedia Technology, Warsaw, Poland
| | - T Kutter
- Louisiana State University, Department of Physics and Astronomy, Baton Rouge, Louisiana, USA
| | - M Kuze
- Tokyo Institute of Technology, Department of Physics, Tokyo, Japan
| | - L Labarga
- University Autonoma Madrid, Department of Theoretical Physics, Madrid, Spain
| | - J Lagoda
- National Centre for Nuclear Research, Warsaw, Poland
| | - M Lamoureux
- INFN Sezione di Padova and Università di Padova, Dipartimento di Fisica, Padova, Italy
| | - M Laveder
- INFN Sezione di Padova and Università di Padova, Dipartimento di Fisica, Padova, Italy
| | - M Lawe
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - M Licciardi
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - T Lindner
- TRIUMF, Vancouver, British Columbia, Canada
| | - R P Litchfield
- University of Glasgow, School of Physics and Astronomy, Glasgow, United Kingdom
| | - S L Liu
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - X Li
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - A Longhin
- INFN Sezione di Padova and Università di Padova, Dipartimento di Fisica, Padova, Italy
| | - L Ludovici
- INFN Sezione di Roma and Università di Roma "La Sapienza", Roma, Italy
| | - X Lu
- Oxford University, Department of Physics, Oxford, United Kingdom
| | - T Lux
- Institut de Fisica d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra (Barcelona) Spain
| | - L N Machado
- INFN Sezione di Napoli and Università di Napoli, Dipartimento di Fisica, Napoli, Italy
| | - L Magaletti
- INFN Sezione di Bari and Università e Politecnico di Bari, Dipartimento Interuniversitario di Fisica, Bari, Italy
| | - K Mahn
- Michigan State University, Department of Physics and Astronomy, East Lansing, Michigan, USA
| | - M Malek
- University of Sheffield, Department of Physics and Astronomy, Sheffield, United Kingdom
| | - S Manly
- University of Rochester, Department of Physics and Astronomy, Rochester, New York, USA
| | - L Maret
- University of Geneva, Section de Physique, DPNC, Geneva, Switzerland
| | - A D Marino
- University of Colorado at Boulder, Department of Physics, Boulder, Colorado, USA
| | - L Marti-Magro
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - J F Martin
- University of Toronto, Department of Physics, Toronto, Ontario, Canada
| | - T Maruyama
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - T Matsubara
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - K Matsushita
- University of Tokyo, Department of Physics, Tokyo, Japan
| | - V Matveev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - K Mavrokoridis
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | | | - M McCarthy
- York University, Department of Physics and Astronomy, Toronto, Ontario, Canada
| | - N McCauley
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - K S McFarland
- University of Rochester, Department of Physics and Astronomy, Rochester, New York, USA
| | - C McGrew
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - A Mefodiev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - C Metelko
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - M Mezzetto
- INFN Sezione di Padova and Università di Padova, Dipartimento di Fisica, Padova, Italy
| | - A Minamino
- Yokohama National University, Faculty of Engineering, Yokohama, Japan
| | - O Mineev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - S Mine
- University of California, Irvine, Department of Physics and Astronomy, Irvine, California, USA
| | - M Miura
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - L Molina Bueno
- ETH Zurich, Institute for Particle Physics and Astrophysics, Zurich, Switzerland
| | - S Moriyama
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - J Morrison
- Michigan State University, Department of Physics and Astronomy, East Lansing, Michigan, USA
| | - Th A Mueller
- Ecole Polytechnique, IN2P3-CNRS, Laboratoire Leprince-Ringuet, Palaiseau, France
| | - L Munteanu
- IRFU, CEA Saclay, Gif-sur-Yvette, France
| | - S Murphy
- ETH Zurich, Institute for Particle Physics and Astrophysics, Zurich, Switzerland
| | - Y Nagai
- University of Colorado at Boulder, Department of Physics, Boulder, Colorado, USA
| | - T Nakadaira
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - M Nakahata
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - Y Nakajima
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - A Nakamura
- Okayama University, Department of Physics, Okayama, Japan
| | - K G Nakamura
- Kyoto University, Department of Physics, Kyoto, Japan
| | - K Nakamura
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - S Nakayama
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - T Nakaya
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- Kyoto University, Department of Physics, Kyoto, Japan
| | - K Nakayoshi
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - C Nantais
- University of Toronto, Department of Physics, Toronto, Ontario, Canada
| | - T V Ngoc
- Institute For Interdisciplinary Research in Science and Education (IFIRSE), ICISE, Quy Nhon, Vietnam
| | - K Niewczas
- Wroclaw University, Faculty of Physics and Astronomy, Wroclaw, Poland
| | - K Nishikawa
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - Y Nishimura
- Keio University, Department of Physics, Kanagawa, Japan
| | - T S Nonnenmacher
- Imperial College London, Department of Physics, London, United Kingdom
| | - F Nova
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - P Novella
- IFIC (CSIC & University of Valencia), Valencia, Spain
| | - J Nowak
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - J C Nugent
- University of Glasgow, School of Physics and Astronomy, Glasgow, United Kingdom
| | - H M O'Keeffe
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - L O'Sullivan
- University of Sheffield, Department of Physics and Astronomy, Sheffield, United Kingdom
| | - T Odagawa
- Kyoto University, Department of Physics, Kyoto, Japan
| | - K Okumura
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- University of Tokyo, Institute for Cosmic Ray Research, Research Center for Cosmic Neutrinos, Kashiwa, Japan
| | - T Okusawa
- Osaka City University, Department of Physics, Osaka, Japan
| | - S M Oser
- University of British Columbia, Department of Physics and Astronomy, Vancouver, British Columbia, Canada
- TRIUMF, Vancouver, British Columbia, Canada
| | - R A Owen
- Queen Mary University of London, School of Physics and Astronomy, London, United Kingdom
| | - Y Oyama
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - V Palladino
- INFN Sezione di Napoli and Università di Napoli, Dipartimento di Fisica, Napoli, Italy
| | - J L Palomino
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - V Paolone
- University of Pittsburgh, Department of Physics and Astronomy, Pittsburgh, Pennsylvania, USA
| | - W C Parker
- Royal Holloway University of London, Department of Physics, Egham, Surrey, United Kingdom
| | - J Pasternak
- Imperial College London, Department of Physics, London, United Kingdom
| | - P Paudyal
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - M Pavin
- TRIUMF, Vancouver, British Columbia, Canada
| | - D Payne
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - G C Penn
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - L Pickering
- Michigan State University, Department of Physics and Astronomy, East Lansing, Michigan, USA
| | - C Pidcott
- University of Sheffield, Department of Physics and Astronomy, Sheffield, United Kingdom
| | - G Pintaudi
- Yokohama National University, Faculty of Engineering, Yokohama, Japan
| | - E S Pinzon Guerra
- York University, Department of Physics and Astronomy, Toronto, Ontario, Canada
| | - C Pistillo
- University of Bern, Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), Bern, Switzerland
| | - B Popov
- Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Paris, France
| | - K Porwit
- University of Silesia, Institute of Physics, Katowice, Poland
| | | | - A Pritchard
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - B Quilain
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - T Radermacher
- RWTH Aachen University, III. Physikalisches Institut, Aachen, Germany
| | - E Radicioni
- INFN Sezione di Bari and Università e Politecnico di Bari, Dipartimento Interuniversitario di Fisica, Bari, Italy
| | - B Radics
- ETH Zurich, Institute for Particle Physics and Astrophysics, Zurich, Switzerland
| | - P N Ratoff
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - E Reinherz-Aronis
- Colorado State University, Department of Physics, Fort Collins, Colorado, USA
| | - C Riccio
- INFN Sezione di Napoli and Università di Napoli, Dipartimento di Fisica, Napoli, Italy
| | - E Rondio
- National Centre for Nuclear Research, Warsaw, Poland
| | - S Roth
- RWTH Aachen University, III. Physikalisches Institut, Aachen, Germany
| | - A Rubbia
- ETH Zurich, Institute for Particle Physics and Astrophysics, Zurich, Switzerland
| | - A C Ruggeri
- INFN Sezione di Napoli and Università di Napoli, Dipartimento di Fisica, Napoli, Italy
| | - C A Ruggles
- University of Glasgow, School of Physics and Astronomy, Glasgow, United Kingdom
| | - A Rychter
- Warsaw University of Technology, Institute of Radioelectronics and Multimedia Technology, Warsaw, Poland
| | - K Sakashita
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - F Sánchez
- University of Geneva, Section de Physique, DPNC, Geneva, Switzerland
| | - C M Schloesser
- ETH Zurich, Institute for Particle Physics and Astrophysics, Zurich, Switzerland
| | - K Scholberg
- Duke University, Department of Physics, Durham, North Carolina, USA
| | - J Schwehr
- Colorado State University, Department of Physics, Fort Collins, Colorado, USA
| | - M Scott
- Imperial College London, Department of Physics, London, United Kingdom
| | - Y Seiya
- Osaka City University, Department of Physics, Osaka, Japan
| | - T Sekiguchi
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - H Sekiya
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - D Sgalaberna
- CERN European Organization for Nuclear Research, CH-1211 Genève 23, Switzerland
| | - R Shah
- Oxford University, Department of Physics, Oxford, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - A Shaikhiev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - F Shaker
- University of Winnipeg, Department of Physics, Winnipeg, Manitoba, Canada
| | - A Shaykina
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M Shiozawa
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - W Shorrock
- Imperial College London, Department of Physics, London, United Kingdom
| | - A Shvartsman
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - A Smirnov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M Smy
- University of California, Irvine, Department of Physics and Astronomy, Irvine, California, USA
| | - J T Sobczyk
- Wroclaw University, Faculty of Physics and Astronomy, Wroclaw, Poland
| | - H Sobel
- University of California, Irvine, Department of Physics and Astronomy, Irvine, California, USA
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - F J P Soler
- University of Glasgow, School of Physics and Astronomy, Glasgow, United Kingdom
| | - Y Sonoda
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - J Steinmann
- RWTH Aachen University, III. Physikalisches Institut, Aachen, Germany
| | - S Suvorov
- IRFU, CEA Saclay, Gif-sur-Yvette, France
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | | | - S Y Suzuki
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - Y Suzuki
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - A A Sztuc
- Imperial College London, Department of Physics, London, United Kingdom
| | - M Tada
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - M Tajima
- Kyoto University, Department of Physics, Kyoto, Japan
| | - A Takeda
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - Y Takeuchi
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- Kobe University, Kobe, Japan
| | - H K Tanaka
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - H A Tanaka
- SLAC National Accelerator Laboratory, Stanford University, Menlo Park, California, USA
- University of Toronto, Department of Physics, Toronto, Ontario, Canada
| | - S Tanaka
- Osaka City University, Department of Physics, Osaka, Japan
| | - L F Thompson
- University of Sheffield, Department of Physics and Astronomy, Sheffield, United Kingdom
| | - W Toki
- Colorado State University, Department of Physics, Fort Collins, Colorado, USA
| | - C Touramanis
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - T Towstego
- University of Toronto, Department of Physics, Toronto, Ontario, Canada
| | - K M Tsui
- University of Liverpool, Department of Physics, Liverpool, United Kingdom
| | - T Tsukamoto
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - M Tzanov
- Louisiana State University, Department of Physics and Astronomy, Baton Rouge, Louisiana, USA
| | - Y Uchida
- Imperial College London, Department of Physics, London, United Kingdom
| | - W Uno
- Kyoto University, Department of Physics, Kyoto, Japan
| | - M Vagins
- University of California, Irvine, Department of Physics and Astronomy, Irvine, California, USA
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
| | - S Valder
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | - Z Vallari
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - D Vargas
- Institut de Fisica d'Altes Energies (IFAE), The Barcelona Institute of Science and Technology, Campus UAB, Bellaterra (Barcelona) Spain
| | - G Vasseur
- IRFU, CEA Saclay, Gif-sur-Yvette, France
| | - C Vilela
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - W G S Vinning
- University of Warwick, Department of Physics, Coventry, United Kingdom
| | - T Vladisavljevic
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, University of Tokyo, Kashiwa, Chiba, Japan
- Oxford University, Department of Physics, Oxford, United Kingdom
| | - V V Volkov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - T Wachala
- H. Niewodniczanski Institute of Nuclear Physics PAN, Cracow, Poland
| | - J Walker
- University of Winnipeg, Department of Physics, Winnipeg, Manitoba, Canada
| | - J G Walsh
- Lancaster University, Physics Department, Lancaster, United Kingdom
| | - Y Wang
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - D Wark
- Oxford University, Department of Physics, Oxford, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - M O Wascko
- Imperial College London, Department of Physics, London, United Kingdom
| | - A Weber
- Oxford University, Department of Physics, Oxford, United Kingdom
- STFC, Rutherford Appleton Laboratory, Harwell Oxford, and Daresbury Laboratory, Warrington, United Kingdom
| | - R Wendell
- Kyoto University, Department of Physics, Kyoto, Japan
| | - M J Wilking
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - C Wilkinson
- University of Bern, Albert Einstein Center for Fundamental Physics, Laboratory for High Energy Physics (LHEP), Bern, Switzerland
| | - J R Wilson
- King's College London, Department of Physics, Strand, London WC2R 2LS, United Kingdom
| | - R J Wilson
- Colorado State University, Department of Physics, Fort Collins, Colorado, USA
| | - K Wood
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - C Wret
- University of Rochester, Department of Physics and Astronomy, Rochester, New York, USA
| | - Y Yamada
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki, Japan
| | - K Yamamoto
- Osaka City University, Department of Physics, Osaka, Japan
| | - C Yanagisawa
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - G Yang
- State University of New York at Stony Brook, Department of Physics and Astronomy, Stony Brook, New York, USA
| | - T Yano
- University of Tokyo, Institute for Cosmic Ray Research, Kamioka Observatory, Kamioka, Japan
| | - K Yasutome
- Kyoto University, Department of Physics, Kyoto, Japan
| | - S Yen
- TRIUMF, Vancouver, British Columbia, Canada
| | - N Yershov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| | - M Yokoyama
- University of Tokyo, Department of Physics, Tokyo, Japan
| | - T Yoshida
- Tokyo Institute of Technology, Department of Physics, Tokyo, Japan
| | - M Yu
- York University, Department of Physics and Astronomy, Toronto, Ontario, Canada
| | - A Zalewska
- H. Niewodniczanski Institute of Nuclear Physics PAN, Cracow, Poland
| | - J Zalipska
- National Centre for Nuclear Research, Warsaw, Poland
| | - K Zaremba
- Warsaw University of Technology, Institute of Radioelectronics and Multimedia Technology, Warsaw, Poland
| | - G Zarnecki
- National Centre for Nuclear Research, Warsaw, Poland
| | - M Ziembicki
- Warsaw University of Technology, Institute of Radioelectronics and Multimedia Technology, Warsaw, Poland
| | - E D Zimmerman
- University of Colorado at Boulder, Department of Physics, Boulder, Colorado, USA
| | - M Zito
- Sorbonne Université, Université Paris Diderot, CNRS/IN2P3, Laboratoire de Physique Nucléaire et de Hautes Energies (LPNHE), Paris, France
| | - S Zsoldos
- Queen Mary University of London, School of Physics and Astronomy, London, United Kingdom
| | - A Zykova
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, Russia
| |
Collapse
|
48
|
Abe K, Akutsu R, Ali A, Alt C, Andreopoulos C, Anthony L, Antonova M, Aoki S, Ariga A, Arihara T, Asada Y, Ashida Y, Atkin ET, Awataguchi Y, Ban S, Barbi M, Barker GJ, Barr G, Barrow D, Barry C, Batkiewicz-Kwasniak M, Beloshapkin A, Bench F, Berardi V, Berkman S, Berns L, Bhadra S, Bienstock S, Blondel A, Bolognesi S, Bourguille B, Boyd SB, Brailsford D, Bravar A, Berguño DB, Bronner C, Bubak A, Avanzini MB, Calcutt J, Campbell T, Cao S, Cartwright SL, Catanesi MG, Cervera A, Chappell A, Checchia C, Cherdack D, Chikuma N, Cicerchia M, Christodoulou G, Coleman J, Collazuol G, Cook L, Coplowe D, Cudd A, Dabrowska A, De Rosa G, Dealtry T, Denner PF, Dennis SR, Densham C, Di Lodovico F, Dokania N, Dolan S, Doyle TA, Drapier O, Dumarchez J, Dunne P, Eguchi A, Eklund L, Emery-Schrenk S, Ereditato A, Fernandez P, Feusels T, Finch AJ, Fiorentini GA, Fiorillo G, Francois C, Friend M, Fujii Y, Fujita R, Fukuda D, Fukuda R, Fukuda Y, Fusshoeller K, Gameil K, Giganti C, Golan T, Gonin M, Gorin A, Guigue M, Hadley DR, Haigh JT, Hamacher-Baumann P, Hartz M, Hasegawa T, Hassani S, Hastings NC, Hayashino T, Hayato Y, Hiramoto A, Hogan M, Holeczek J, Hong Van NT, Iacob F, Ichikawa AK, Ikeda M, Ishida T, Ishii T, Ishitsuka M, Iwamoto K, Izmaylov A, Jakkapu M, Jamieson B, Jenkins SJ, Jesús-Valls C, Jiang M, Johnson S, Jonsson P, Jung CK, Junjie X, Jurj PB, Kabirnezhad M, Kaboth AC, Kajita T, Kakuno H, Kameda J, Karlen D, Kasetti SP, Kataoka Y, Katori T, Kato Y, Kearns E, Khabibullin M, Khotjantsev A, Kikawa T, Kikutani H, Kim H, Kim J, King S, Kisiel J, Knight A, Knox A, Kobayashi T, Koch L, Koga T, Konaka A, Kormos LL, Koshio Y, Kostin A, Kowalik K, Kubo H, Kudenko Y, Kukita N, Kuribayashi S, Kurjata R, Kutter T, Kuze M, Labarga L, Lagoda J, Lamoureux M, Laveder M, Lawe M, Licciardi M, Lindner T, Litchfield RP, Liu SL, Li X, Longhin A, Ludovici L, Lu X, Lux T, Machado LN, Magaletti L, Mahn K, Malek M, Manly S, Maret L, Marino AD, Marti-Magro L, Martin JF, Maruyama T, Matsubara T, Matsushita K, Matveev V, Mavrokoridis K, Mazzucato E, McCarthy M, McCauley N, McElwee J, McFarland KS, McGrew C, Mefodiev A, Metelko C, Mezzetto M, Minamino A, Mineev O, Mine S, Miura M, Bueno LM, Moriyama S, Morrison J, Mueller TA, Munteanu L, Murphy S, Nagai Y, Nakadaira T, Nakahata M, Nakajima Y, Nakamura A, Nakamura KG, Nakamura K, Nakayama S, Nakaya T, Nakayoshi K, Nantais C, Naseby CER, Ngoc TV, Niewczas K, Nishikawa K, Nishimura Y, Noah E, Nonnenmacher TS, Nova F, Novella P, Nowak J, Nugent JC, O’Keeffe HM, O’Sullivan L, Odagawa T, Okumura K, Okusawa T, Oser SM, Owen RA, Oyama Y, Palladino V, Palomino JL, Paolone V, Pari M, Parker WC, Parsa S, Pasternak J, Paudyal P, Pavin M, Payne D, Penn GC, Pickering L, Pidcott C, Pintaudi G, Guerra ESP, Pistillo C, Popov B, Porwit K, Posiadala-Zezula M, Pritchard A, Quilain B, Radermacher T, Radicioni E, Radics B, Ratoff PN, Reinherz-Aronis E, Riccio C, Rondio E, Roth S, Rubbia A, Ruggeri AC, Ruggles CA, Rychter A, Sakashita K, Sánchez F, Santucci G, Schloesser CM, Scholberg K, Schwehr J, Scott M, Seiya Y, Sekiguchi T, Sekiya H, Sgalaberna D, Shah R, Shaikhiev A, Shaker F, Shaykina A, Shiozawa M, Shorrock W, Shvartsman A, Smirnov A, Smy M, Sobczyk JT, Sobel H, Soler FJP, Sonoda Y, Steinmann J, Suvorov S, Suzuki A, Suzuki SY, Suzuki Y, Sztuc AA, Tada M, Tajima M, Takeda A, Takeuchi Y, Tanaka HK, Tanaka HA, Tanaka S, Thompson LF, Toki W, Touramanis C, Towstego T, Tsui KM, Tsukamoto T, Tzanov M, Uchida Y, Uno W, Vagins M, Valder S, Vallari Z, Vargas D, Vasseur G, Vilela C, Vinning WGS, Vladisavljevic T, Volkov VV, Wachala T, Walker J, Walsh JG, Wang Y, Wark D, Wascko MO, Weber A, Wendell R, Wilking MJ, Wilkinson C, Wilson JR, Wilson RJ, Wood K, Wret C, Yamada Y, Yamamoto K, Yanagisawa C, Yang G, Yano T, Yasutome K, Yen S, Yershov N, Yokoyama M, Yoshida T, Yu M, Zalewska A, Zalipska J, Zaremba K, Zarnecki G, Ziembicki M, Zimmerman ED, Zito M, Zsoldos S, Zykova A. Constraint on the matter–antimatter symmetry-violating phase in neutrino oscillations. Nature 2020; 580:339-344. [DOI: 10.1038/s41586-020-2177-0] [Citation(s) in RCA: 188] [Impact Index Per Article: 47.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2019] [Accepted: 03/03/2020] [Indexed: 11/09/2022]
|
49
|
Akiyama S, Ikemoto S, Muratsugu S, Tada M, Yamashita M. Copper Complexes Bearing a Dianionic Diborane(4) Ligand: Synthesis and Evaluation of the Donor Property. Organometallics 2020. [DOI: 10.1021/acs.organomet.0c00027] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Seiji Akiyama
- Department of Molecular and Macromolecular Chemistry, Graduate School of Engineering, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8603 Aichi, Japan
| | - Satoru Ikemoto
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8603 Aichi, Japan
| | - Satoshi Muratsugu
- Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8603 Aichi, Japan
| | - Mizuki Tada
- Department of Chemistry, Graduate School of Science, Integrated Research Consortium on Chemical Science (IRCCS), Institute for Advanced Science (IAS), Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8603 Aichi, Japan
| | - Makoto Yamashita
- Department of Molecular and Macromolecular Chemistry, Graduate School of Engineering, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8603 Aichi, Japan
| |
Collapse
|
50
|
Higashi K, Takao S, Samjeské G, Matsui H, Tada M, Uruga T, Iwasawa Y. Visualization and understanding of the degradation behaviors of a PEFC Pt/C cathode electrocatalyst using a multi-analysis system combining time-resolved quick XAFS, three-dimensional XAFS-CT, and same-view nano-XAFS/STEM-EDS techniques. Phys Chem Chem Phys 2020; 22:18919-18931. [DOI: 10.1039/d0cp01356k] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
We developed a multi-analysis system that can measure in situ time-resolved quick XAFS and in situ three-dimensional XAFS-CT in the same area of a cathode electrocatalyst layer in a membrane-electrode assembly of a polymer electrolyte fuel cell.
Collapse
Affiliation(s)
- Kotaro Higashi
- Innovation Research Center for Fuel Cells
- The University of Electro-Communications
- Tokyo 182-8585
- Japan
| | - Shinobu Takao
- Innovation Research Center for Fuel Cells
- The University of Electro-Communications
- Tokyo 182-8585
- Japan
| | - Gabor Samjeské
- Innovation Research Center for Fuel Cells
- The University of Electro-Communications
- Tokyo 182-8585
- Japan
- Department of Chemistry
| | - Hirosuke Matsui
- Department of Chemistry
- Graduate School of Science
- Nagoya University
- Nagoya
- Japan
| | - Mizuki Tada
- Department of Chemistry
- Graduate School of Science
- Nagoya University
- Nagoya
- Japan
| | - Tomoya Uruga
- Innovation Research Center for Fuel Cells
- The University of Electro-Communications
- Tokyo 182-8585
- Japan
- JASRI/SPring-8
| | - Yasuhiro Iwasawa
- Innovation Research Center for Fuel Cells
- The University of Electro-Communications
- Tokyo 182-8585
- Japan
- Graduate School of Informatics and Engineering
| |
Collapse
|